Method for producing neural crest cells

The suspension culture method using ALK and GSK-3β inhibitors in xeno-free conditions efficiently induces neural crest cells within 4 days, overcoming the time constraints of existing methods and enabling diverse differentiation capabilities.

WO2024242069A1PCT designated stage expired Publication Date: 2024-11-28KYOTO UNIV
View PDF 35 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/018417
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-19
Filing Date
2024-05-17
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current methods for inducing neural crest cells from pluripotent stem cells are time-consuming, typically requiring at least 7 days, and when conducted under xeno-free conditions, they take even longer, posing a need for a more efficient and shorter protocol.

Method used

A method involving suspension culture of pluripotent stem cells in a medium containing an ALK inhibitor and bone morphogenetic protein, followed by a floating culture with a GSK-3β inhibitor, which includes shaking culture to enhance efficiency and shorten the process to just 4 days, while maintaining xeno-free conditions.

Benefits of technology

This method allows for the stable and high-efficiency induction of neural crest cells that can differentiate into various cell types, including peripheral nerve cells, melanoblasts, and mesenchymal stem cells, with the added capability of producing first pharyngeal arch ectodermal mesenchymal cells, significantly reducing development costs and time.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024018417_28112024_PF_FP_ABST
    Figure JP2024018417_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention provides a method for producing neural crest cells from pluripotent stem cells, the method comprising: (1) a step for suspension-culturing the pluripotent stem cells in a culture medium containing an ALK inhibitor and a bone morphogenetic protein; and (2) a step for suspension-culturing the cells in a culture medium containing the ALK inhibitor and a GSK-3β inhibitor.
Need to check novelty before this filing date? Find Prior Art

Description

Method for producing neural crest cells

[0001] The present invention relates to a method for producing neural crest cells. More specifically, the present invention relates to a method for producing neural crest cells, which comprises a step of suspension culture of cells derived from pluripotent stem cells under specific conditions, and uses of the neural crest cells obtained by the method.

[0002] Neural crest cells (NCCs) are cells that arise between the neuroectoderm and epidermal ectoderm during early development when the neural tube is formed from the neural plate. These cells have the multipotency and self-proliferation capacity to differentiate into many cell types, including neurons, glial cells, mesenchymal stromal cells, bone cells, chondrocytes, corneal cells, and pigment cells. These multipotency and self-proliferation capacities demonstrate the usefulness of NCCs as cell medicines for regenerative medicine, and there is a need for technologies to efficiently induce NCCs.

[0003] Non-Patent Document 1 describes that NCCs can be induced by performing neural priming for three days on human pluripotent stem cells seeded on Matrigel, followed by a neural crest (NC) induction step for five days. Non-Patent Document 2 describes that NCCs can be induced by performing adhesion culture of human pluripotent stem cells for seven days in a medium containing BMP4 and SB431542, and that ectodermal chondrogenic cells (ECCs) can be induced by culturing the NCCs induced in this manner for 23 days in a medium containing CHIR99021, SB431542, SAG, EGF, FGF2, and DMH1.

[0004] The present inventors previously reported a method for inducing NCCs that have lost their ability to differentiate into neurons by culturing pluripotent stem cells in a xeno-free medium containing SB431542 and CHIR99021 for 10 days as adherent cells, and then culturing the NCCs in a medium containing SB431542, EGF, and bFGF (Non-Patent Document 3). Meanwhile, the present inventors have also succeeded in expanding NCCs that have retained their pluripotency by culturing NCCs induced to differentiate from pluripotent stem cells in a medium containing a GSK-3β inhibitor at a concentration equivalent to the effect of CHIR99021 at a concentration of over 1 μM (Patent Document 1).

[0005] International Publication No. 2019 / 107485

[0006] Kreitzer FR et al., Am J Stem Cells, 2(2):119-131 (2013)Shen L. et al., NPJ Regen Med, 7(1):69 (2022)Kamiya D. et al., NPJ Regen Med, 7(1):47 (2022)

[0007] However, in the above-mentioned conventional methods, it takes at least seven days to induce differentiation of pluripotent stem cells into neural crest cells, and under xeno-free conditions, it takes 10 days to induce neural crest cells. Therefore, an object of the present invention is to provide a method for inducing neural crest cells from pluripotent stem cells in a shorter period of time, preferably under xeno-free conditions.

[0008] While researching methods for inducing bone organoids from pluripotent stem cells, the inventors focused on suspension culture. Therefore, they sought a method for inducing neural crest cells (NCCs) from pluripotent stem cells using suspension culture, rather than the conventional adherent culture method, during the first step of the process. After extensive research, they found that short-term suspension culture of pluripotent stem cells in a medium containing an ALK inhibitor and bone morphogenetic protein to form round cell clusters, followed by subsequent culture in a medium containing an ALK inhibitor and GSK-3β inhibitor, enabled stable and highly efficient induction of NCCs under xeno-free conditions. Surprisingly, NCCs were successfully induced in just four days (five days including the pluripotent stem cell cluster formation step) in the medium containing the ALK inhibitor and bone morphogenetic protein. Furthermore, by performing shaking culture during the culture period, they were able to improve NCC induction efficiency and shorten the culture period.

[0009] The present inventors investigated the differentiation potential of NCCs obtained by the above-mentioned suspension culture. As a result, they found that, like conventional NCCs, they could be induced to differentiate into peripheral neurons, melanoblasts, and mesenchymal stem cells, and that these differentiation inductions were highly efficient. Furthermore, NCCs obtained by suspension culture could be induced to differentiate into first pharyngeal arch ectodermal mesenchymal (PA1-EM) cells. However, there have been no reports of successful in vitro differentiation of NCCs into PA1-EM cells, which was quite surprising. PA1-EM cells could also be induced to develop into bone organoids, and these bone organoids could be transplanted into living organisms to efficiently repair bone defects. Based on these findings, the present inventors conducted further research and completed the present invention.

[0010] That is, the present invention provides the following: [1] A method for producing neural crest cells from pluripotent stem cells, comprising: (1) a step of suspension culturing the pluripotent stem cells in a medium containing an ALK inhibitor and a bone morphogenetic protein, and (2) a step of suspension culturing the pluripotent stem cells in a medium containing an ALK inhibitor and a GSK-3β inhibitor. [2-1] The method described in [1], wherein the step (2) comprises a step of performing shaking culture and / or spinner culture. [2-2] The method described in [1] or [2-1], wherein the step (1) comprises a step of performing shaking culture and / or spinner culture. [3-1] The method described in any one of [1] to [2-2], wherein the culture period in the step (1) is 6 hours to 5 days. [3-2] The method described in any one of [1] to [3-1], wherein the culture period in the step (1) is 6 hours to 3 days. [3-3] The method described in any one of [1] to [3-2], wherein the culture period in the step (1) is 1 day to 3 days. [4-1] The method according to any one of [1] to [3-3], wherein the culture period in step (2) is 1 to 6 days. [4-2] The method according to any one of [1] to [4-1], wherein the culture period in step (2) is 1 to 4 days. [4-3] The method according to any one of [1] to [4-2], wherein the culture period in step (2) is 1 to 3 days. [4-4] The method according to any one of [1] to [4-3], wherein the culture period in steps (1) and (2) is 2 to 5 days. [4-5] The method according to any one of [1] to [4-4], wherein the culture period in step (1) is 1 day and the culture period in step (2) is 3 days. [5] The method according to any one of [1] to [4-5], comprising a step of suspension-culturing pluripotent stem cells in a medium containing a ROCK inhibitor prior to step (1). [6-1] The method according to any one of [1] to [5], wherein at least one of the bone morphogenetic proteins used in step (1) is selected from the group consisting of BMP4, BMP2, and BMP7. [6-2] The method according to any one of [1] to [6-1], wherein at least one of the ALK inhibitors used in step (2) is SB431542 or A-83-01.[6-3] The method according to any one of [1] to [6-2], wherein the pluripotent stem cells are derived from a patient with a disease (e.g., osteogenesis imperfecta). [7] The method according to any one of [1] to [6-3], wherein at least one of steps (1) and (2) is a step of culturing cells under xeno-free conditions and / or feeder-free conditions. [8-1] The method according to any one of [1] to [7], wherein the pluripotent stem cells are induced pluripotent stem cells. [8-2] The method according to any one of [1] to [8-1], wherein the pluripotent stem cells are derived from a human. [8-3] The method according to [8-2], wherein the pluripotent stem cells are derived from a patient with a disease (e.g., osteogenesis imperfecta). [9] Neural crest cells obtained by the method according to any one of [1] to [8-3].

[10] Neural crest cells having all of the following characteristics (A) to (C): (A) Derived from a pluripotent stem cell; (B) Expressing one or more genes selected from CD271, SOX10, TFAP2A, and PAX3; (C) Having the ability to differentiate into first pharyngeal arch ectomesenchymal cells. [11-1] The neural crest cell according to

[10] , which has at least one of the following characteristics (D) to (F): (D) Having the ability to differentiate into melanoblasts; (E) Having the ability to differentiate into neurons; (F) Having the ability to differentiate into mesenchymal stem cells. [11-2] The cell according to

[10] or [11-1], wherein the pluripotent stem cell is an induced pluripotent stem cell. [11-3] The cell according to any one of

[10] to [11-2], wherein the pluripotent stem cell is derived from a human. [11-4] The cell according to [11-3], wherein the pluripotent stem cell is derived from a patient with a disease (e.g., osteogenesis imperfecta).

[12] A method for producing differentiated cells or organoids, comprising a step of inducing differentiation of the neural crest cells according to any one of [9] to [11-4].

[13] The method according to

[12] , wherein the differentiated cells are selected from the group consisting of mesenchymal cells, neurons, and melanoblasts.

[14] The method according to

[13] , wherein the mesenchymal cells are selected from the group consisting of mesenchymal stem cells, first pharyngeal arch ectodermal mesenchymal cells, bone precursor cells, osteoblasts, osteocytes, chondrocytes, myoblasts, odontogenic mesenchymal cells, and smooth muscle cells.

[15] The method according to

[12] , wherein the organoids are bone organoids.[16-1] The method according to

[15] , wherein the bone organoids are jawbone organoids. [16-2] The method according to

[15] or [16-1], wherein the bone organoids exhibit a phenotype of a bone disease (e.g., osteogenesis imperfecta). [17-1] The method according to

[12] , wherein the differentiation-inducing step comprises culturing neural crest cells in a medium containing endothelin and fibroblast growth factor, and the differentiated cells obtained by the culture are first pharyngeal arch ectomesenchymal cells. [17-2] The method according to [17-1], wherein at least one of the endothelins is endothelin-1. [17-3] The method according to [17-1] or [17-2], wherein at least one of the fibroblast growth factors is FGF-8. [18-1] The method according to any one of [17-1] to [17-3], wherein the medium further contains a bone morphogenetic protein. [18-2] The method according to [18-1], wherein at least one of the bone morphogenetic proteins is BMP4.

[19] A differentiated cell or organoid obtained by the method according to any one of

[12] to [18-2]. [20-1] A first pharyngeal arch ectodermal mesenchymal cell having all of the following characteristics (a) to (c): (a) derived from neural crest cells that do not express HOX; (b) expressing DLX5, PRRX1, and TWIST1; and (c) responding to epithelial signals and capable of inducing patterning. [20-2] The cell according to [20-1], wherein the neural crest cells that do not express HOX are derived from pluripotent stem cells. [20-3] The cell according to [20-1] or [20-2], wherein the pluripotent stem cells are induced pluripotent stem cells. [20-4] The cell according to any one of [20-1] to [20-3], wherein the pluripotent stem cells are derived from humans. [20-5] The cell according to [20-4], wherein the pluripotent stem cells are derived from a patient with a disease (e.g., osteogenesis imperfecta).

[21] A transplantation therapy agent comprising the differentiated cells or organoids according to any one of

[19] to [20-5].

[22] A method for screening for therapeutic or preventive agents for diseases, comprising culturing the differentiated cells or organoids according to any one of

[19] to [20-5] in the presence or absence of a test substance.

[23] The transplantation therapy agent according to

[21] for treating or preventing tissue damage or disease.

[24] A method for treating or preventing tissue damage or disease, comprising administering or transplanting an effective amount of the differentiated cells or organoids according to any one of

[19] to [20-5] to a subject.

[25] The differentiated cells or organoids according to any one of

[19] to [20-5] for use in treating or preventing tissue damage or disease.

[26] Use of the differentiated cells or organoids according to any one of

[19] to [20-5] in the manufacture of a drug for treating or preventing tissue damage or disease.

[0011] According to the present invention, neural crest cells (NCCs) can be produced from pluripotent stem cells in a short period of time with high efficiency. Because NCCs can be produced with high efficiency, cell sorting is no longer necessary, which contributes to reducing development costs and ultimately the cost of clinical application. Furthermore, not only can differentiated cells such as neurons, melanoblasts, and mesenchymal stem cells be produced with high efficiency from the NCCs obtained by the present invention, but it also makes it possible to produce first pharyngeal arch ectomesenchymal cells, which have not previously been reported, making a significant contribution to medical care, particularly regenerative medicine in the field of oral surgery.

[0012] Schematic diagram of the method for inducing NCC clusters from iPS cells and micrographs of cell clusters on days 1 (D1), 2 (D2), and 5 (D5) after the start of culture. (A) Micrograph of cell clusters induced under 3D conditions from the 1231A3 iPS cell line. Uniform cell clusters with a diameter of approximately 500 μm were induced. (B) Cell clusters were dispersed into single cells using Accutase and analyzed by flow cytometry for the rate of strongly CD271-positive cells. Strongly CD271-positive cells were induced with high efficiency. (C) Histological image of fluorescent immunostaining of cell clusters. The majority of cells within the cell clusters consisted of CD271- and SOX10-positive NCCs. Changes in CD271 and SOX10 expression over time from iPS cell seeding to the formation of NCC clusters. On the fourth day of induction (the second day after the start of culture in medium containing SB431542 (hereafter, sometimes abbreviated as "SB") and CHIR99021 (hereafter, sometimes abbreviated as "CHIR")), SOX10- and CD271-positive NCCs began to appear. NCC-associated gene expression was compared by reverse transcription quantitative PCR (RT-qPCR) between NCCs induced under conventional 2D (adherent culture) conditions (Non-Patent Document 3) (an outline of the induction method is shown at the top of the figure) and 3D-induced NCC clusters (an outline of the induction method is shown in the center of the figure). All NCC-associated genes (NGFR, SOX10, TFAP2A, and PAX3) were expressed at similar levels, while the pluripotent cell marker POU5F1 (Oct4) disappeared. The expression levels of NCC-related genes (TFAP2A and PAX3) and neural plate border marker genes (DLX5 and MSX2) were compared by RT-qPCR in cell clusters on days 0 (D0) through 5 (D5) after the start of cell culture, as well as in cell clusters (D5 271H and 2D 271H) sorted by flow cytometry for strongly CD271-positive cells. At D3, neural plate border markers were elevated, and D5 cells expressed NCC-related genes at levels similar to those of D5 271H and 2D 271H cells.The expression levels of NCC-associated genes (NGFR, SOX10) and the pluripotent cell marker Oct4 were compared by RT-qPCR in cell clumps on days 0 (D0) through 5 (D5) after the start of cell culture, as well as in cell clumps (D5 271H and 2D 271H) sorted by flow cytometry for strongly CD271-positive cells. D5 cells were shown to express NCC-associated genes at approximately the same levels as D5 271H cells, and also to express NCC-associated genes at approximately the same levels as 2D 271H cells. Flow cytometry was used to examine the change in the percentage of strongly CD271-positive cells when BMP4 was replaced with BMP2 or BMP7, or when SB431542 was replaced with another TGF-beta / Smad inhibitor, A-83-01 (BMP4, BMP2, BMP7: 10 ng / ml; SB431542: 10 μM; A-83-01: 1.0 μM). Under all conditions, strongly CD271-positive NCCs were induced with high efficiency. We also examined whether NCCs could be induced under 3D conditions from iPS cell lines other than the 1231A3 line (Ff-I 14s04 line, Ff-I 14s04 HLA-KO line, and an iPS cell line derived from an osteogenesis imperfecta patient). (A) Micrographs of induced cell clusters. Cell clusters were successfully obtained from all cell lines. (B) Flow cytometry analysis of the percentage of strongly CD271-positive cells. Both cell lines were able to induce highly CD271-positive cells. (C) Histological image of the cell clusters by immunofluorescence staining. The majority of cells within the cell clusters consisted of CD271- and SOX10-positive NCCs. The conventional method (2D NCC induction method) was performed under the same conditions as the 3D NCC induction method, except for the difference between adherent and suspension culture. The results showed that the 2D NCC induction method induced almost no CD271-highly expressing cells (top). Furthermore, it was shown that the efficiency of NCC induction was improved by shaking culture in the 3D NCC induction method (bottom). To explore the optimal duration of SB and BMP4 treatment, the duration of the treatment step (hereinafter referred to as the "SB and BMP treatment step") was varied, and the percentage of strongly CD271-positive cells was measured by flow cytometry (the shaking culture period was fixed).(A) When SB and BMP4 were applied for 1 day, NCCs were induced with high efficiency. (B) When SB and BMP4 were not applied, a clear decrease in the percentage of strongly CD271-positive cells was observed. When SB and BMP4 were applied for a longer time, a decrease in the percentage of strongly CD271-positive cells was observed. Fluorescent immunostaining for CD271 (NCCs), PAX6 (neurectoderm), and E-Cadherin (epithelial cells) was performed for each condition in Figure 10. (A) When SB and BMP4 were applied for 1 day, strongly CD271-positive NCCs were induced with high efficiency, but PAX6 and E-Cadherin-positive cells were not induced. (B) When SB and BMP4 were not applied, PAX6-positive neuroectoderm was induced. (C) When SB and BMP4 were applied for a longer time, E-Cadherin-positive epithelial cells were induced around the cell clusters. Figure 12 shows an outline of NCC induction using various SB and BMP4 treatment times. Shaking culture was performed from the beginning of the NCC induction process. Flow cytometry was used to measure the percentage of strongly CD271-positive cells for each condition in Figure 12. Flow cytometry analysis on day 5 after 6 hours (SB BMP4 6h) or 12 hours (SB BMP4 12h) of SB and BMP4 treatment demonstrated a lower NCC induction efficiency compared to 1 day (SB BMP4 D1). Flow cytometry analysis on day 5 after 2 days (SB BMP4 D2) or 3 days (SB BMP4 D3) of SB and BMP4 treatment demonstrated a high NCC induction efficiency. On the other hand, when flow cytometry was performed on day 5 without the application of SB and BMP4, the NCC induction effect was shown to be low. Figure 12 shows the results of measuring the rate of strongly CD271-positive cells under each condition by flow cytometry.When SB and BMP4 treatments were performed for 6 hours (SB BMP4 6h), 12 hours (SB BMP4 12h), 1 day (SB BMP4 D1), 2 days (SB BMP4 D2), 3 days (SB BMP4 D3), 4 days (SB BMP4 D4), or 7 days (SB BMP4 D6), flow cytometry analysis on day 7 demonstrated a decrease in CD271 expression across the entire cell population compared to day 5. NGFR expression levels were measured by RT-qPCR for each condition (Figure 12). RT-qPCR results also demonstrated a decrease in NGFR (CD271) expression after day 5 of culture. Regarding the duration of SB and BMP4 treatment, this was the preferred method for NCC induction efficiency. The percentage of strongly CD271-positive cells was measured by flow cytometry with extended SB and CHIR treatment times. As the overall culture period was extended, the percentage of strongly CD271-positive cells decreased in a time-dependent manner. Figure 12 shows an outline of each induction method when shaking culture was performed from the beginning of the SB431542 and BMP4 treatment period. Flow cytometry was used to measure the percentage of strongly CD271-positive cells for each condition. When shaking culture was performed from the start of the SB and BMP4 treatment period, NCCs were induced by day 5 in both 6-hour (SB BMP4 6h) and 12-hour (SB BMP4 12h) SB and BMP4 treatments. The 12-hour treatment showed a similarly efficient induction of NCCs as the 1-day treatment (SB BMP4 D1). Figure 12 shows immunohistochemical results for the expression patterns of CD271 (NCC marker) and E-Cadherin (epithelial cell marker) for each condition. When SB and BMP4 treatment was performed for 1 or 2 days, epithelial cells were observed surrounding the cell clusters on day 5. The percentage of strongly CD271-positive cells was measured by flow cytometry under each condition in Figure 12. It was shown that extending the NCC induction process to 7 or 10 days resulted in a decrease in the percentage of strongly CD271-positive cells. This is a schematic diagram of the preferred method in terms of NCC induction efficiency when shaking culture is performed from the start of the SB and BMP4 treatment process.Schematic diagram of the differentiation induction of NCCs obtained using the 3D NCC induction method into various cell types. Schematic diagram of the method for inducing peripheral neurons from NCCs obtained using the 3D NCC induction method (A) and melanoblasts (B). Peripheral neurons and melanoblasts were induced from NCC clusters, and differentiation was confirmed by fluorescent immunostaining. (A) Peripheral neurons were induced from NCC clusters. Peripherin-positive peripheral neurons were induced with high efficiency. (B) Melanoblasts were induced from NCC clusters. MITF-positive melanoblasts were induced with high efficiency. Schematic diagram of the method for inducing mesenchymal stem cells from NCCs obtained using the 3D NCC induction method. NCC clusters were dispersed using Accutase and plated on culture plates for MSC induction. MSC markers CD105, CD90, CD73, and CD44 all showed high expression. Schematic diagram of the characteristics of first pharyngeal arch ectomesenchyme (PA1-EM) cells. HOX gene expression was confirmed by RT-qPCR in NCC clusters obtained by the 3D NCC induction method. As a positive control, HOX gene expression was induced in NCC clusters stimulated with retinoic acid (RA). (A) Method for inducing HOX gene-positive NCC clusters. 1.0 μM RA was added from day 4 of induction. (B) Expression of NCC-related genes (NGFR, SOX10) was confirmed by RT-qPCR. RA stimulation did not alter the expression levels of NCC-related genes. (C) Expression of HOX genes (HOXA2, HOXA3) was confirmed by RT-qPCR. RA-stimulated NCC clusters showed high HOX gene expression, whereas unstimulated NCC clusters showed no HOX gene expression. Schematic diagram of the method for inducing PA1-EM cells from NCCs obtained using the 3D NCC induction method. PA1-EM cells were induced from NCC clusters, and the induction of PA1-EM cells was confirmed by fluorescent immunostaining for TWIST1 and DLX5. (A) Microscopic images of an NCC cluster and the induced PA1-EM cell cluster. The size of the cluster increased due to proliferation of internal cells. (B) Fluorescent immunostaining images for SOX10 and TWIST1.Induction of PA1-EM cells resulted in a clear increase in SOX10 expression, confirming differentiation into TWIST1-positive ectomesenchyme. (C) Fluorescent immunostaining image of DLX5. The induced ectomesenchyme highly expressed DLX5, recapitulating the genetic characteristics of PA1-EM. PA1-EM cells were induced from iPS cell lines from patients with osteogenesis imperfecta, and induction of PA1-EM cells was confirmed by fluorescent staining for DLX5. HOX (-) NCC ("-" and "). - " indicates negative. The same applies below.) and HOX (+) NCC ("+" and " +" indicates positive. The same applies below.) Schematic diagram of the induction method (top). Expression of HOXB2 and DLX5 was confirmed by RT-qPCR in PA1-EM cells obtained using each induction method. No increase in DLX5 expression was observed in cells induced with HOX(+) NCCs (bottom). Schematic diagram of the induction method for PA1-EM cells from NCCs obtained using the 2D NCC induction method. The resulting cells showed significantly low PRRX1 and DLX5 expression. Schematic diagram of the induction method used to verify the optimal combination of Fgf8, Edn-1, and BMP4 for PA1-EM cell induction. RT-qPCR analysis of the expression levels of DLX, PRRX1, and TWIST1 for each condition in Figure 36. Edn-1 is essential for DLX5 expression, and the expression levels of DLX5, PRRX1, and TWIST1 indicate that the addition of Fgf8, Edn-1, and BMP4 to the culture medium is optimal for PA1-EM cell induction. Schematic diagram of the method for inducing PA1-EM cells into proximal-oral side (molar tooth-forming region) cells (top) and distal-aboral side (jaw bone ossification origin region) cells (bottom). By reacting the induced DLX5- and TWIST1-positive PA1-EM cells with epithelial signals from the first pharyngeal arch, we investigated whether we could recapitulate the patterning of the first pharyngeal arch and induce characteristic gene patterns in each region. (A) Arrangement of epithelial signals in the first pharyngeal arch and the genetic patterns induced in the proximal-oral side and distal-aboral side. (B) Induction in the proximal-oral side resulted in high expression of PAX9 and LHX8. (C) Induction in the distal-aboral side resulted in high expression of GSC and MSX2. Schematic diagram of the method for inducing distal-aboral side cells into jaw bone-like tissue. Osteoprogenitor cells were induced by osteogenic differentiation of PA1-EM cell clusters induced into distal-aboral side cells. (A) Increased expression of osteoprogenitor cell markers SP7, RUNX2, and DLX5 was confirmed. (B) At this induction stage, increased expression of the early osteoblast marker ALPL and the immature osteocyte marker E11 / gp38 was not confirmed. Following the induction shown in Figure 41, two-stage osteogenic differentiation induction was performed. Further increased expression of osteoprogenitor cell markers SP7, RUNX2, and DLX5 was confirmed. Following the induction shown in Figure 41, two-stage osteogenic differentiation induction was performed.A clear increase in the expression of the osteoblast marker ALPL and the osteocyte markers E11 / gp38, DMP1, PHEX, and SOST was confirmed. Histological images of the jawbone-like tissue obtained by the osteogenic differentiation induction described above. (A) Alizarin red-stained image of an undecalcified section. Mineral deposition stained with Alizarin red was confirmed. (B) HE-stained image of a decalcified section. Within the cell clusters, jawbone-like tissue was confirmed, consisting of eosinophilic bone matrix surrounding osteoblast-like cells and osteocyte-like cells embedded within the bone matrix. (C) F-actin immunostained image of osteocyte-like cells embedded within the bone matrix. Osteocyte-like cells formed a three-dimensional network with surrounding cells within the bone matrix. The human mandibular bone-like tissue (Figure 44) was transplanted into a 1.6mm bone defect created in the ramus of the right mandibular angle of the mandible in immunodeficient NSG mice. Micro-CT imaging was performed immediately after transplantation and at 1, 2, 3, and 4 weeks to examine the regenerative effects of the mandibular bone-like tissue. In the transplanted mandibular bone-like tissue, mineral deposition confirmed the defect's closure as early as 3 weeks after transplantation. Efficient induction of HOX-negative NCCs from 3D-cultured iPSCs. a: Schematic showing regional specification of cranial neural crest cells (NCCs) along the anterior-posterior axis of the embryo. PA1-3, pharyngeal arches 1-3. b: Strategy for differentiation of iPSCs into NCCs in a three-dimensional (3D) culture system. d0-5, days 0-5. Y, Y-27632; SB, SB431542 (TGF-β inhibitor); CHIR, CHIR99021 (GSK-3β inhibitor). c) Brightfield images of 1231A3 aggregates on days 1, 2, and 5 of optimized culture. Scale bar: 100 μm. d) Immunofluorescence staining for SOX10, CD271, and TFAP2A in serial sections of day 5 aggregates. Nuclei were stained with DAPI. The dashed box is enlarged to the right. n = 34 from 11 biologically independent experiments. Scale bar: 100 μm. e) Flow cytometry analysis of NCC marker (CD271) expression in day 5 aggregates (dark gray). Isotype controls are displayed in light gray. Results are presented as mean ± standard error from six biologically independent experiments. f) Immunofluorescence staining for TFAP2A, E-cadherin (ECAD, white), PAX6, and OCT3 / 4 in day 5 aggregates. Nuclei were stained with DAPI.n = 3 from three biologically independent experiments. Scale bar, 100 μm. g; Gene expression analysis of NCC markers (SOX10, NGFR, TFAP2A, RHOB, PAX3) and pluripotent stem cell marker (POU5F1) by real-time quantitative PCR (RT-qPCR) analysis. Gene expression levels were quantified using GAPDH as reference controls, and CD271 in iPSCs (d0), day 5 aggregates (d5), and sorted day 5 aggregates. high+ NCC (d5 271H) and CD271 sorted from a conventional two-dimensional (2D) protocol high+ Gene expression levels compared between NCCs (2D 271H). Data were normalized to d0 values. Values ​​are presented as mean ± standard error. n = 6 from three biologically independent experiments. h, i: Immunofluorescent staining for peripherin (PRPH) and class III β-tubulin (TUBB3) in aggregates after peripheral neuron induction (h), and for MITF in aggregates after melanoblast induction (i). Nuclei were stained with DAPI. The dashed box is enlarged on the right. The enlarged image represents a Z-stack projection of 15 confocal optical sections (step size, 0.5 μm) (h). n = 6 from three biologically independent experiments. Scale bar, 100 μm. j, k: Gene expression analysis of NCC markers (NGFR, SOX10) (j) and HOX genes (HOXA1, HOXA2, HOXB2, HOXA3) (k) by RT-qPCR. Gene expression levels were quantified using GAPDH as a reference control and were compared between iPSCs (d0), day 5 aggregates (d5), and day 5 aggregates treated with retinoic acid (RA) (RA +Comparisons were made between iPSCs (day 0 and day 5). Data were normalized to the iPSC (day 0) values. Values ​​are presented as mean ± standard error. n = 6 from three biologically independent experiments. g, j, k: *P < 0.05, **P < 0.01, ***P < 0.001 by one-way ANOVA. ND, not determined. ns, not significant. c–f, h, i: Representative data are shown. Effect of BMP4 treatment duration on NCC induction efficiency in 3D cultures. a, d: Overview of an experiment testing the effect of BMP4 treatment duration on NCC induction efficiency. Aggregates were treated without (a) or with BMP4 for 2 days (d). SB, SB431542; CHIR, CHIR99021. b, e: Flow cytometry analysis of NCC marker (CD271) expression in day 5 aggregates (dark gray). The isotype control is shown in light gray. In the absence of BMP4 (-), CD271 high+ The cell population was reduced (b). c, f: Bright-field images and immunofluorescence staining of PAX6, ECAD (white), and CD271 in the aggregates on day 5. Nuclei were stained with DAPI. In the absence of BMP4 (-), CD271 high+ Not only NCC but also the undesirable PAX6 + Neuroectoderm was also induced (c). In contrast, under the BMP4 (2 days) condition, E-cadherin (ECAD) was not expressed on the surface of the aggregates. +Cells were induced (f). n = 6 from three biologically independent experiments. Scale bar, 100 μm. b, c, e, f: Representative data shown. Highly efficient induction of NCCs from various iPSC lines. A: Tricolor immunofluorescence staining for SOX10, CD271, and PAX6 in aggregates generated from various iPSC lines (Ff-14s04, Ff-14s04 with knockout of human leukocyte antigen (HLA)-A, B, and CIITA genes (HLA-KO Ff-I 14s04), Ff-I 01s04, iPSCs derived from an osteogenesis imperfecta (OI) patient (OI-iPSCs), and OI-iPSCs with rescued mutations (resOI-iPSCs)). Nuclei were stained with DAPI. n = 3 from three biologically independent experiments. Representative data shown. Scale bar, 100 μm. b) Flow cytometry analysis of NCC marker (CD271) in day 5 aggregates. Results are shown as mean ± standard error (six biologically independent experiments). Stepwise differentiation of iPSCs to NCCs via the ectodermal lineage. a) 1231A3 iPSCs (d0), day 1–5 aggregates, and CD271 sorted from day 5 aggregates. high+ NCC (d5 271H) and CD271 sorted from a conventional two-dimensional (2D) protocol high+RNA-seq analysis of NCC (2D 271H) (Non-Patent Document 3). The heatmap shows gene expression levels of pluripotent stem cell (PSC) markers, ectodermal lineage markers (neurectoderm (NE), neural plate border (NPB), neural crest cell (NCC), and epidermal ectoderm (SE)), primitive streak (PS) markers, presomitic mesoderm (PSM) markers, lateral plate mesoderm (LPM) markers, and endoderm (END) markers. The log2 (Transcripts Per Million (TPM) + 1) value was used to evaluate gene expression. b; Immunofluorescence staining for SOX10 and CD271 in clumps on days 1 to 5. Nuclei were stained with DAPI. n = 3 from three biologically independent experiments. Representative data are shown. Scale bar, 100 μm. Induction of NCC clumps into MSCs. a; Differentiation strategy for mesenchymal stem / stromal cells (MSCs). b) Brightfield image of cells in MSC induction (PN2). Scale bar, 200 μm. c) Flow cytometry analysis of MSC-associated surface markers in cells in MSC induction (PN2). MSC induction (PN2) (dark gray) and isotype control (light gray). MSC induction (PN2) cells were positive for CD105, CD90, CD73, CD44, and CD29, and negative for CD45, CD34, and HLA-DR (three biologically independent experiments). d) MSC differentiation characteristics. Differentiation into osteogenic, chondrogenic, and adipogenic lineages was confirmed by Alizarin Red, Alcian Blue, and Oil Red O staining, respectively (two biologically independent experiments). Scale bar, 100 μm. b-d) Representative data are shown. Induction of HOX-positive NCC clusters from iPSCs. a) Schematic model of HOX-positive NCC colonizing the posterior PA. b) Differentiation strategy for HOX-positive NCC. c) Aggregates on day 5 of RA treatment (RA + Tricolor immunofluorescence staining for SOX10, CD271, and PAX6 in d5). Nuclei were stained with DAPI. n = 6 from three biologically independent experiments. Representative data are shown. Scale bar, 100 μm. RA + At d5, many cells expressed CD271 + SOX10 +d: 1231A3 iPSCs (d0), 5-day-old aggregates not treated with RA (d5), and CD271 cells sorted from 5-day-old aggregates. high+ NCC (d5 271H), and RA +Heatmap showing the expression levels of regional markers—forebrain (FB), midbrain (MB), midbrain-hindbrain boundary (MHB), hindbrain (HB), and spinal cord (SC)—in RNA-seq analysis on day 5. Directional differentiation of HOX-negative NCC clusters into mdEM. a) Schematic model showing regional specification of NCC-derived pharyngeal arch ectomesenchyme along the embryonic proximal-distal (PD) axis. mdEM, mandibular prominence ectomesenchyme. b) RT-qPCR gene expression analysis of common PA1 ectomesenchyme markers (DLX1, DLX2), mdEM markers (DLX5, DLX3, GSC), and distal region marker (HAND2). Gene expression levels were quantified using GAPDH as a reference control and compared between 1231A3 iPSCs (d0), day 5 NCC clusters (d5), and clusters treated with a combination of FGF8, endothelin-1 (EDN1), and BMP4 for 4 days (d9). Data were normalized to the d0 value. Values ​​are presented as mean ± standard error. n = 6 from three biologically independent experiments. c; Differentiation strategy from NCC clusters to mdEM. d; Brightfield images and immunofluorescence staining for SOX10 and TWIST1 at d5 (upper panel) and d5 treated with FEDB (a combination of FGF8, EDN1, and BMP4) for 4 days (d5+FEDB) (lower panel). Nuclei were stained with DAPI. n = 6 from three biologically independent experiments. Scale bar, 100 μm. e; Phalloidin staining of clusters at d5 and d5+FEDB. Nuclei were stained with DAPI. n = 6 from three biologically independent experiments. Scale bar, 50 μm. f; Tricolor immunofluorescence staining for DLX2, DLX5, and HAND2 in d5+FEDB. Nuclei were stained with DAPI. The lower panel shows an enlargement of the white dashed box in the upper panel. n = 15 from eight biologically independent experiments. White dotted circle, area with weak DLX5 and negative HAND2. White dotted line, HAND2-negative area. Scale bar, 100 μm. g; Schematic model showing the regional designation of embryonic PA1 and derived mdEM along the PD axis.h: Schematic model showing the strategy for investigating the influence of EDN1 signaling on the branching of mandibular prominence ectomesenchyme (mxEM) and mdEM. i: Immunofluorescent staining for SOX10 and TWIST1 on day 5 (d5+FQ) after 7 days of treatment with FGF8 and BQ-123. Nuclei were stained with DAPI. n = 3 from three biologically independent experiments. Scale bar, 100 μm. j, k: Gene expression analysis of mdEM marker (DLX5) (j) and mxEM markers (POU3F3, CYP26A1) (k) by RT-qPCR. Gene expression levels were quantified using GAPDH as a reference control and compared between d0, d5, d5+FEDB, and d5+FQ. Data were normalized to the values ​​on d0 (j) or d5 (k). Values ​​are presented as mean ± standard error. n = 6 from three biologically independent experiments. l: Schematic model showing the strategy to investigate the importance of early AP identity in mdEM differentiation. m: RA treated with FEDB for 4 days. + Immunofluorescence staining for SOX10 and TWIST1 on d5 (RA + Nuclei were stained with DAPI. n = 3 from three biologically independent experiments. Scale bar, 100 μm. n = 3; gene expression analysis of mdEM marker (DLX5) and HOX genes (HOXB2, HOXB4). Gene expression levels were quantified using GAPDH as a reference control, and the expression levels were significantly different between d5, d5+FEDB, and RA. + d5, and RA +Comparisons were made between d5+FEDB. Data were normalized to the d5 value. Values ​​are presented as mean ± standard error. n = 6 from three biologically independent experiments. b, j, k, n: *P < 0.05, ***P < 0.001 by one-way ANOVA. ns, not significant. d–f, i, m: Representative data are shown. Gene expression analysis of NCC marker (SOX10) and early pharyngeal arch mesenchymal markers (TWIST1, PRRX1) by RT-qPCR. Gene expression levels were quantified using GAPDH as a reference control and compared between 1231A3 iPSCs (d0), day 5 NCC clusters (d5), and d5 clusters treated with a combination of FGF8, endothelin-1 (EDN1), and BMP4 for 4 days (d9). Data were normalized to the iPSC (d0) value of 1.0. Values ​​are presented as mean ± standard error. n = 6 from three biologically independent experiments. ***P < 0.001 by one-way ANOVA. Selective induction of NCC clusters to mdEM. a–c; RNA-seq analysis of 1231A3 iPSCs (d0), NCC clusters (d5), and mdEM (d9). Markers for pluripotent stem cells (PSCs), neural crest cells (NCCs), pan-ectomesenchyme (EM), mandibular ectomesenchyme (mdEM), and maxillary ectomesenchyme (mxEM); melanocyte, glial, sensory, and autonomic neuron markers (b); heatmap showing gene expression levels of HOX genes (c). Log2 (Transcripts Per Million (TPM) + 1) values ​​were used to evaluate gene expression. n = 3 from three biologically independent experiments. mdEM recapitulates the regional patterning of the distal cap and proximal-oral domain in the mandibular process. a, b: Schematic of the major pharyngeal epithelial signals in the mandibular process (a) and the regional patterning of mdEM (b). The dotted line corresponds to the coronal section. c: Strategy for inducing the distal cap and proximal-oral domain from mdEM. LDN, LDN193189.d, e, f: Brightfield images and immunofluorescence staining for DLX5 (d), HAND1 and GATA3 (e), HAND2 (e), FOXF1, and PITX1 (f) in 1231A3 mdEM (d9, upper panel) and aggregates after induction into the distal cap (d13, middle panel) or proximal oral domain (d13, lower panel). Nuclei were stained with DAPI. n = 6 from three biologically independent experiments. Scale bar, 100 μm. In d, the dashed box is enlarged to the right. g: Gene expression analysis by RT-qPCR for distal cap marker (HAND1), distal region markers (HAND2, GATA3, DKK1), and proximal oral domain-associated genes (FOXF1, PITX1, GBX2, BARX1). Gene expression levels were quantified using GAPDH as a reference control and compared between d5, d9, and d13 (distal cap or proximal oral domain) aggregates. Data were normalized to d5 values. Values ​​are presented as mean ± standard error. n = 6 from three biologically independent experiments. *P < 0.05, ***P < 0.001 by one-way ANOVA. ns, not significant. d–f: Representative data are shown. Study of the optimized protocol for distal cap and proximal oral (molar) domain induction. a: Gene expression analysis of the distal cap marker (HAND1) and other distal region markers (HAND2, GATA3, DKK1) by RT-qPCR. Gene expression levels were quantified using GAPDH as a reference control and compared between 1231A3 NCC aggregates (d5), mdEM (d9), and mdEM (d13) cultured for 4 days with various combinations of FGF8 (20 and 100 ng / ml) or FGF2 (20 ng / ml), EDN1 (50 nM), and BMP4 (2.5 and 25 ng / ml). Data were normalized to the values ​​for iPSCs (d0). Values ​​are presented as mean ± standard error. n = 3 from three biologically independent experiments. b; Cell viability analysis of mdEM cultured with FGF8 or FGF2 (20 ng / ml), EDN1 (50 nM), and BMP4 (25 ng / ml) from days 5 to 9.Live and dead cells were distinguished using the LIVE / DEAD Viability / Cytotoxicity kit. Apoptotic cells were detected by TUNEL staining. Nuclei were stained with DAPI. n = 3 from three biologically independent experiments. Representative data are shown. Scale bar, 100 μm. c; Gene expression analysis of proximal buccal (molar) domain-associated markers (FOXF1, GLI1, PITX1, GBX2, BARX1, PAX9, LHX6). Gene expression levels were quantified using GAPDH as a reference control and compared between NCC clusters (d5), mdEM (d9), and mdEM (d13) cultured for 4 days with various combinations of FGF8 (100 ng / ml), SAG (400 nM), BQ-123 (BQ) (10 μM), LDN193189 (LDN) (500 nM), EDN1 (50 nM), and BMP4 (2.5 ng / ml). Data were normalized to iPSC (d0) values. Values ​​are presented as mean ± standard error. n = 3 from three biologically independent experiments. a, c; *P < 0.05, **P < 0.01, ***P < 0.001 by one-way ANOVA. ns, not significant. mdEM recapitulates regional patterning of the mandibular process. RNA-seq analysis of 1231A3 iPSC-derived NCC aggregates (d5), mdEM (d9), distal cap (d13), and proximal oral domain (d13). Heatmap visualizing gene expression levels of ectodermal mesenchyme (EM), mdEM, aboral domain, distal domain, oral domain, proximal domain, and dental mesenchyme markers. n = 3 from three biologically independent experiments. Z-scores are used to evaluate gene expression levels. Dental mesenchyme induction from mdEM of the proximal oral domain. a; Brightfield image and immunofluorescence staining for TFAP2B and LHX6, TFAP2A, and PAX9 in aggregates 17 days after dental mesenchyme induction. Nuclei were stained with DAPI. The dashed box is enlarged to the right. n = 3 from three biologically independent experiments. Representative data are shown. Scale bar, 100 μm. b, RNA-seq analysis of NCC clusters (d5) and tooth mesenchyme (d17).Gene-Set Enrichment Analysis (GSEA). Shows the top 15 enriched (activated and repressed) pathways based on biological process GO terms. Pre-ranked gene list is -log. 10The mean p-value was calculated by multiplying the mean p-value by the direction of the fold-change. n = 3 from three biologically independent experiments. NES, normalized enrichment score. Creation and characterization of jawbone-like organoids. a) Stepwise induction strategy from mdEM to jawbone-like organoids. β-gly, β-glycerophosphate disodium salt hydrate; AA, ascorbic acid 2-phosphate sesquimagnesium salt hydrate; DEX, dexamethasone. b) Image of a d38 cluster derived from 1231A3. Scale bar, 1.0 mm. c) Monitoring alkaline phosphatase (ALP) activity and calcium content in the cluster during osteogenic induction. Values ​​are presented as mean ± standard error. n = 6 from three biologically independent experiments. d) Alizarin red and von Kossa staining of serial sections of a d38 cluster. The dashed box is enlarged on the right (Alizarin Red, n = 12; von Kossa, n = 6 from three biologically independent experiments). Scale bar, 100 μm. e: Gene expression analysis of mature osteocyte markers (SOST) by RT-qPCR. Gene expression levels were quantified using 18s rRNA as a reference control and compared between clusters during osteogenic induction. Data were normalized to values ​​on day 9. Values ​​are presented as mean ± standard error. n = 6 from three biologically independent experiments. f: Hematoxylin and eosin (HE) and Azan staining of serial sections of d38 clusters (decalcified specimens). n = 52 from 12 biologically independent experiments. Scale bar, 100 μm. g: Tricolor immunofluorescence staining of COLI, OCN, and OPN in d38 tissue (decalcified specimens). Nuclei were stained with DAPI. n = 9 from three biologically independent experiments. Scale bar, 100 μm. h–k: Immunofluorescent staining of SP7 and ALPL (h), PDPN (i), PHEX (j), and SOST (k) in decalcified tissues at day 38. Nuclei and F-actin were stained with DAPI and phalloidin, respectively. Images (ik) represent Z-stack projections of 40 confocal optical sections (step size, 0.5 μm).h, n = 6; i, n = 12; j, n = 6; k, n = 6 (from four biologically independent experiments). Scale bar, 25 μm. l: Schematic model of the generated jawbone-like organoid. m: Image of the kidney of an NSG mouse 4 weeks after jawbone-like organoid transplantation. n: 3D reconstructed micro-computed tomography (microCT) image of the kidney region 4 weeks after transplantation. The dashed circle indicates ectopic calcified tissue. Scale bar, 1.0 mm. n = 6. o: HE staining and Azan staining (decalcified specimen) of serial sections of transplanted tissue. n = 6. Scale bar, 100 μm. p: Immunofluorescent staining for human vimentin in transplanted tissue (decalcified specimen). Nuclei and F-actin were stained with DAPI and phalloidin, respectively. Images represent Z-stack projections of 40 confocal optical sections (step size, 0.5 μm). n = 6. Scale bar, 25 μm. c, e: *P < 0.05, ***P < 0.001 by one-way ANOVA. ns, not significant. b, d, fk, mp: Representative data shown. Directional differentiation of mdEMs to the osteogenic lineage. a: Gene expression analysis of bone matrix proteins (COLIA1, OPN, IBSP), osteoblast markers (SP7, RUNX2, ALP, DLX5), early osteocyte markers (CAPG, PDPN, DMP1, PHEX), and mature osteocyte markers (MEPE, TNFSF11, MMP13) by RT-qPCR. Gene expression levels were quantified using 18s rRNA as a reference control and compared between 1231A3 iPSC-derived mdEMs (day 9) and each time point of osteogenic induction. Data were normalized to day 9 values. Values ​​represent the mean ± standard error. n = 6 from three biologically independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 by one-way ANOVA. ns, not significant. b-d; RNA-seq analysis of 1231A3 NCC clusters (d5), mdEM (d9), and day 38 clusters (d38). Heatmap visualizing gene expression levels of bone matrix proteins, osteoblasts, early osteocytes, and mature osteocytes (b); chondrogenic markers (c); and HOX genes (d). Gene expression levels were evaluated using log2(TPM + 1) values. n = 2 from three biologically independent experiments.mdEM gradually produce bone matrix and differentiate into osteogenic cells. a) Immunofluorescent staining for COLI in 1231A3 iPSC-derived mdEM (day 9) and at each time point of osteogenic induction. Nuclei were stained with DAPI. n = 3 from three biologically independent experiments. Scale bar, 100 μm. b) Safranin O / Fast Green staining and immunofluorescent staining for COLX in mdEM and day 38 clusters. Nuclei were stained with DAPI. Post-chondrogenic induction aggregates served as positive controls for Safranin O and COLX expression. c, d) Immunofluorescent staining for SP7 (c), PDPN, and PHEX (d) in mdEM and at each time point of osteogenic induction. F-actin was stained with phalloidin (d). Nuclei were stained with DAPI. n = 3 from three biologically independent experiments. a–d) Representative data are shown. Scale bar. 100 μm (a-c), 25 μm (d). Generation of mdEM and jawbone-like organoids from multiple iPSC lines via mdEM. a-c; HE staining and tricolor immunofluorescence staining for DLX2, DLX5, and HAND2 in mdEM and jawbone-like organoids generated from Ff-I 14s04 iPSCs (a), HLA-KO Ff-I 14s04 iPSCs (b), and Ff-I 01s04 (c) iPSCs. Nuclei were stained with DAPI. n = 3 from three biologically independent experiments. The dashed box is enlarged on the right. Representative data are shown. Scale bar, 100 μm. Jawbone-like organoids form bone tissue composed of human bone matrix proteins. a) Von Kossa staining, HE staining, Azan staining, and Safranin O / Fast Green staining, as well as immunofluorescence staining for CD31 in bone-like tissue formed under the kidney capsule of NSG mice (n = 6). Nuclei were stained with DAPI. Scale bar, 50 μm (CD31), 200 μm (others). b) Three-color immunofluorescence staining for human bone matrix proteins (human COLI, OCN, and OPN) in bone-like tissue. Nuclei were stained with DAPI. n = 6. a, b) Representative data are shown. Scale bar, 200 μm. Transplantation of jawbone-like organoids promotes jawbone formation.a) Schematic diagram of jawbone-like organoid (day 38) transplantation into a mandibular defect in an NSG mouse. b) Images showing a mandibular defect without a transplant or with three jawbone-like organoids. The dotted line indicates the border of the mandible. c) Single-section and 3D reconstructed micro-CT images of the mandibular defect 4 weeks after transplantation. n = 8. Scale bar, 1.0 mm. d) Quantification of the volume of newly formed mineralized tissue in the defect 4 weeks after transplantation. n = 8. ***P < 0.001 by two-tailed Student's t-test. e) HE staining (e), Azan staining (e), and tricolor immunofluorescence staining for human COLI, OCN, OPN (f), and human vimentin (g) in serial sections (decalcified specimens) of the transplanted tissue 4 weeks after transplantation. Nuclei were stained with DAPI (f, g). n = 8. The dashed boxes are enlarged on the right (e, g). The black arrow indicates the edge of the defect (e). The white and light gray arrows indicate donor human cells and host mouse cells, respectively (g). Scale bars, 200 μm (e, f), 100 μm (g). h: Immunofluorescent staining for human vimentin in the transplanted tissue (decalcified specimen). Nuclei and F-actin were stained with DAPI and phalloidin, respectively. n = 6. Images represent Z-stack projections of 40 confocal optical sections (step size, 0.5 μm). Scale bar, 50 μm. i: Tartrate-resistant acid phosphatase (TRAP) staining in the transplanted tissue. n = 6. Scale bar, 100 μm. b, c, e-i: Representative data are shown. Jaw regeneration by transplanted mandible-like organoids. Individual microCT scan images of a mandible without a transplant (left panel) and a mandible with transplanted mandible-like organoids (right panel). n = 8 per group. Characterization of mdEM and bone tissue derived from OI-iPSCs formed under the kidney capsule of NSG mice. a) Three-color immunofluorescence staining for DLX2, DLX5, and HAND2 in mdEM (day 9) derived from OI-iPSCs and resOI-iPSCs. Scale bar, 100 μm. b) Von Kossa and Safranin O / Fast Green staining of bone tissue derived from OI-iPSCs and resOI-iPSCs formed under the kidney capsule of NSG mice, as well as immunofluorescence staining for human COLI and human OPN. Nuclei were stained with DAPI. n = 3.Scale bar, 200 μm. a, b: Representative data shown. Recapitulation of the osteogenesis imperfecta (OI) disease phenotype. a: Immunofluorescent staining for COLI and collagen hybridizing peptide (CHP) in OI-iPSC- and resOI-iPSC-derived aggregates after 3 days of osteogenic induction. Nuclei were stained with DAPI. n = 6 from three biologically independent experiments. Scale bar, 25 μm. b: HE and Azan staining of serial sections of decalcified OI- and resOI-mandible-like organoids at day 38. n = 6 from three biologically independent experiments. Scale bar, 100 μm. c: Phalloidin staining of decalcified OI- and resOI-organoids. Nuclei were stained with DAPI. Images represent Z-stack projections of 40 confocal optical sections (step size, 0.5 μm). The dashed box is enlarged on the right. n = 6 from three biologically independent experiments. Scale bar, 25 μm. d) 3D reconstructed microCT image of ectopic calcified tissue in the kidney region of NSG mice 4 weeks after OI-organoid or resOI-organoid transplantation. e) HE and Azan staining of the transplanted tissue (decalcified specimen). n = 6 from three biologically independent experiments. Scale bar, 100 μm. f) Quantification of the volume and tissue mineral density (TMD) of the calcified tissue in the OI-organoid and resOI-organoid transplantation groups. g) Quantification of osteocytes and Azan red-stained areas. h) TUNEL staining of the transplanted tissue (decalcified specimen) in the OI-organoid and resOI-organoid transplantation groups. n = 6. The dashed box is enlarged below. Scale bar, 50 μm. i) Immunofluorescence staining for human vimentin in the decalcified explant tissue. Nuclei and F-actin were stained with DAPI and phalloidin, respectively. Images represent Z-stack projections of 40 confocal optical sections (step size, 0.5 μm). n = 6. Scale bar, 25 μm. j) Quantification of TUNEL-positive apoptotic cells. k) Quantitative analysis of osteocyte dendrite number. f, g, j, k) *P < 0.05, **P < 0.01, ***P < 0.001 by two-tailed Student's t-test.a-e, h, i: Representative data are shown. Differentiation of NCCs to mdEMs. a: Schematic diagram of the strategy for inducing 2D-cultured NCCs to mdEMs. b: Gene expression analysis of primary mesenchymal markers (TWIST1, PRRX1) and mdEM markers (DLX5, HAND2) by RT-qPCR. Gene expression levels were quantified using GAPDH as a reference control, and CD271 sorted from 1231A3 iPSC-derived day 5 NCC clumps (d5), d5 treated with FEDB (d5+FEDB), and a conventional 2D protocol (2D 271H) (Non-Patent Document 3). high+Comparison was performed between NCC and 2D 271H treated with FEDB in 2D culture (2D 271H+FEDB). Data were normalized to the values ​​on day 5. Values ​​are presented as mean ± standard error. n = 6 from three biologically independent experiments. 2D 271H+FEDB expressed little or no primary mesenchymal markers or mdEM markers. c; RNA-seq analysis of d5, d5+FEDB, 2D 271H, and 2D 271H+FEDB. Heatmap visualizing the expression levels of smooth muscle cell-related genes. Gene expression levels were evaluated using log2(TPM + 1). d; Brightfield images and immunocytochemistry for DLX5, αSMA, calponin 1, and TAGLN in 2D 271H+FEDB on days 1 and 4 after seeding. Nuclei were stained with DAPI. 2D 271H+FEDB expressed smooth muscle cell markers. n = 3 from three biologically independent experiments. Representative data are shown. Scale bar, 100 μm. e; Gene expression analysis of EDNRA and early pharyngeal arch mesenchymal markers (TWIST1, PRRX1) and mdEM markers (DLX5, HAND2) by RT-qPCR. Gene expression levels were quantified using GAPDH as a reference control and compared between 2D 271H cultures treated with FEDB (+0, 10, 20, or 50 ng / ml Y-27632). Data were normalized to the value for d5 + FEDB. Results are presented as mean ± standard error. n = 3 from three biologically independent experiments. Inhibition of actin stress fiber formation by Y-27632 treatment significantly restored the expression of mdEM markers in 2D-cultured cells, although not as significantly as in 3D cultures. f; Brightfield imaging and cell viability analysis. To promote sphere formation, 2D 271H cells were aggregated in FEDB medium in a 96-well V-bottom ultra-low cell attachment plate. After 4 days, cell viability within the cell spheroids was analyzed using a LIVE / DEAD Viability / Cytotoxicity kit. Cultivating NCC spheroids under FEDB induced severe cell apoptosis. n = 3 from three biologically independent experiments. b, e; ***P < 0.001 by one-way ANOVA. ns, not significant.d, f: Representative data are shown. Scale bar, 200 μm. Smooth muscle cell induction from NCC clusters. a: Schematic diagram of the induction method. b: Immunostaining results for smooth muscle markers. Nuclei were stained with DAPI. High expression of Calponin and TAGLN was confirmed 10 days after smooth muscle cell induction. c: Gene expression analysis of smooth muscle markers by RT-qPCR. High expression of smooth muscle markers (ACTA2, CNN1, TAGLN) and mature smooth muscle marker (MYH11) was confirmed 10 days after smooth muscle cell induction. Schematic model of jawbone-like organoid generation from human iPSCs via mdEM. As shown in the figure, mdEM and jawbone-like organoids were generated from human iPSCs in a stepwise manner, induced by the signaling environment during embryogenesis. One day of SB / BMP4 treatment, followed by SB / CHIR treatment, effectively induced HOX-negative NCC clusters from iPSC clusters (days 0–5). Transient RA treatment induced HOX-positive posterior NCC clusters. From days 5 to 9, a combination of FGF8, EDN1, and BMP4 induced HOX-negative NCC clusters into mdEMs, recapitulating the proximal-distal pattern of embryonic mdEMs. The regional identity of mdEMs or mxEMs was modified by modulating EDN1 signaling activity. HOX-positive NCC clusters did not differentiate into mdEMs, highlighting the importance of initial NCC positional identity. mdEMs exhibited late regional patterning in response to exogenous mandibular epithelial signals (FGF8, SAG, EDN1, and BMP4), branching into a distal cap and proximal molar domains. From days 9 to 38 under osteogenic conditions, mdEMs formed jawbone-like organoids composed of osteoblasts and network-forming osteocytes embedded in a self-generated mineralized bone matrix.PA1-3, pharyngeal arches 1-3; mx, maxillary process; mxEM, mx ectomesenchyme; md, mandibular process; mdEM, md ectomesenchyme; SB, SB431542 (TGF-β inhibitor); CHIR, CHIR99021 (GSK-3β inhibitor); RA, retinoic acid; BQ-123 (endothelin A receptor (EDNRA) antagonist); LDN, LDN193189 (BMP inhibitor); SAG (hedgehog signaling agonist).

[0013] 1. Method for Producing Neural Crest Cells The present invention provides a method for producing neural crest cells (NCCs) from pluripotent stem cells. Specifically, the method comprises the steps of: (1) culturing the pluripotent stem cells in suspension in a medium containing an ALK inhibitor and a bone morphogenetic protein; and (2) culturing the pluripotent stem cells in suspension in a medium containing an ALK inhibitor and a GSK-3β inhibitor (hereinafter, sometimes referred to as the "method for producing NCCs of the present invention").

[0014] The term "pluripotent stem cells" refers to stem cells that can differentiate into various tissues and cells with different morphologies and functions in the body and have the ability to differentiate into cells of any of the three germ layers (endoderm, mesoderm, and ectoderm). Examples of pluripotent stem cells used in the present invention include induced pluripotent stem cells (iPS cells), embryonic stem cells (ES cells), embryonic stem cells derived from cloned embryos obtained by nuclear transfer (ntES cells), multipotent germline stem cells (mGS cells), and embryonic germ stem cells (EG cells). Preferably, iPS cells (more preferably, human iPS cells) are used. When the pluripotent stem cells are ES cells or any cells derived from human embryos, they may be produced by or without the destruction of the embryo. However, from an ethical standpoint, cells produced without the destruction of the embryo are preferred.

[0015] ES cells are stem cells that are established from the inner cell mass of early mammalian embryos (e.g., blastocysts) such as humans and mice, and have the ability to proliferate through pluripotency and self-renewal. ES cells were discovered in mice in 1981 (MJ Evans and MH Kaufman (1981), Nature 292:154-156), and subsequently, ES cell lines were established in humans, monkeys, and other primates (JA Thomson et al. (1998), Science 282:1145-1147; JA Thomson et al. (1995), Proc. Natl. Acad. Sci. USA, 92:7844-7848; JA Thomson et al. (1996), Biol. Reprod., 55:254-259; JA Thomson and VS Marshall (1998), Curr. Top. Dev. Biol., 38:133-165). ES cells can be established by isolating the inner cell mass from the blastocyst of a fertilized egg of a target animal and culturing the inner cell mass on a fibroblast feeder. Alternatively, ES cells can be established using only a single blastomere from an embryo at the cleavage stage prior to the blastocyst stage (Chung Y. et al. (2008), Cell Stem Cell 2: 113-117), or from a developmentally arrested embryo (Zhang X. et al. (2006), Stem Cells 24: 2669-2676).

[0016] nt ES cells are ES cells derived from cloned embryos produced by nuclear transfer technology and have almost the same properties as ES cells derived from fertilized eggs (Wakayama T. et al. (2001), Science, 292:740-743; S. Wakayama et al. (2005), Biol. Reprod., 72:932-936; Byrne J. et al. (2007), Nature, 450:497-502). Specifically, nt ES (nuclear transfer ES) cells are established from the inner cell mass of blastocysts derived from cloned embryos obtained by replacing the nucleus of an unfertilized egg with the nucleus of a somatic cell. To generate nt ES cells, nuclear transfer technology (Cibelli JB et al. (1998), Nature Biotechnol., 16:642-646) is combined with ES cell generation technology (see above) (Wakayama Sayaka et al. (2008), Experimental Medicine, Vol. 26, No. 5 (Special Issue), pp. 47-52). In nuclear transfer, the nucleus of a somatic cell is injected into an enucleated unfertilized mammalian egg, and the egg is then cultured for several hours to reprogram the embryo.

[0017] Examples of ES cell lines that can be used in the present invention include mouse ES cell lines established by, for example, inGenious targeting laboratory, Inc., RIKEN (Riken), etc., and human ES cell lines established by, for example, the University of Wisconsin, NIH, RIKEN, Kyoto University, National Center for Child Health and Development, and Cellartis, Inc. Specific examples of human ES cell lines include CHB-1 to CHB-12, RUES1, RUES2, and HUES1 to HUES28 strains distributed by ESI Bio, H1 and H9 strains distributed by WiCell Research, and KhES-1, KhES-2, KhES-3, KhES-4, KhES-5, SSES1, SSES2, and SSES3 strains distributed by RIKEN.

[0018] iPS cells are cells obtained by reprogramming mammalian somatic cells or undifferentiated stem cells by introducing specific factors (nuclear reprogramming factors). Currently, there are various types of iPS cells, including iPSCs established by Yamanaka et al. by introducing four factors, Oct3 / 4, Sox2, Klf4, and c-Myc, into mouse fibroblasts (Takahashi K, Yamanaka S., Cell, (2006) 126: 663-676), human cell-derived iPSCs established by introducing the same four factors into human fibroblasts (Takahashi K, Yamanaka S., et al. Cell, (2007) 131: 861-872), Nanog-iPSCs established by selecting using Nanog expression as an indicator after introducing the above four factors (Okita, K., Ichisaka, T., and Yamanaka, S. (2007). Nature 448, 313-317), and iPSCs created using a method that does not include c-Myc (Nakagawa M, Yamanaka S., et al. Nature Biotechnology, (2008) 26, 101-106), iPSCs established by introducing six factors using a virus-free method (Okita K et al. Nat. Methods 2011 May;8(5):409-12, Okita K et al. Stem Cells. 31(3):458-66.), etc. can also be used. In addition, induced pluripotent stem cells established by introducing four factors, OCT3 / 4, SOX2, NANOG, and LIN28, created by Thomson et al. (Yu J., Thomson JA. et al., Science (2007) 318: 1917-1920.), induced pluripotent stem cells created by Daley et al. (Park IH, Daley GQ. et al., Nature (2007) 451: 141-146), and induced pluripotent stem cells created by Sakurada et al. (JP Patent Publication No. 2008-307007) can also be used.In addition, all published papers (e.g., Shi Y., Ding S., et al., Cell Stem Cell, (2008) Vol. 3, Issue 5, 568-574; Kim JB., Scholer HR., et al., Nature, (2008) 454, 646-650; Huangfu D., Melton DA., et al., Nature Biotechnology, (2008) 26, No. 7, Any of the induced pluripotent stem cells known in the art and described in the Japanese Patent Laid-Open Nos. 2008-307007, 2008-283972, US2008-2336610, US2009-047263, WO2007-069666, WO2008-118220, WO2008-124133, WO2008-151058, WO2009-006930, WO2009-006997, and WO2009-007852 can be used.

[0019] As induced pluripotent stem cell lines, various iPSC lines established by NIH, RIKEN, Kyoto University, etc. can be used. For example, human iPSC lines include RIKEN's HiPS-RIKEN-1A, HiPS-RIKEN-2A, HiPS-RIKEN-12A, and Nips-B2 lines, and Kyoto University's 253G1, 253G4, 1201C1, 1205D1, 1210B2, 1383D2, 1383D6, 201B7, 409B2, 454E2, 606A1, 610B1, 648A1, 1231A3, and FfI-01s04 lines, with 1231A3 being preferred.

[0020] The induced pluripotent stem cells used in the NCC production method of the present invention may be cells derived from patients with a genetic disease (e.g., osteogenesis imperfecta). Cells induced to differentiate from pluripotent stem cells derived from patients with a genetic disease can serve as disease models that reflect the pathology of the disease, making them suitable for screening therapeutic or preventive drugs for the disease. Alternatively, pluripotent stem cells derived from patients with a genetic disease can be genetically repaired by genome editing using a CRISPR-Cas system or the like, and then differentiated into the desired cells or organoids, making it possible to use the cells as a therapeutic agent for the disease. Indeed, in the Examples described below, it was shown that bone organoids induced from pluripotent stem cells rescued from a COLIA1 point mutation that causes dysplastic bone formation did not exhibit dysplastic bone formation.

[0021] mGS cells are pluripotent stem cells derived from the testis and are the source of spermatogenesis. Similar to ES cells, these cells can be induced to differentiate into various cell lineages, e.g., when transplanted into mouse blastocysts, chimeric mice can be generated (Kanatsu-Shinohara M. et al. (2003) Biol. Reprod., 69:612-616; Shinohara K. et al. (2004) Cell, 119:1001-1012). They are capable of self-renewal in culture medium containing glial cell line-derived neurotrophic factor (GDNF). Furthermore, germline stem cells can be obtained by repeated passage under similar culture conditions to ES cells (Takebayashi M. et al. (2008) Experimental Medicine, Vol. 26, No. 5 (Supplementary Issue), pp. 41-46, Yodosha, Tokyo, Japan).

[0022] EG cells are derived from embryonic primordial germ cells (PGCs) and have pluripotency similar to that of ES cells. They can be established by culturing PGCs in the presence of LIF, bFGF, stem cell factor, and other substances (Matsui Y. et al. (1992), Cell, 70:841-847; JL Resnick et al. (1992), Nature, 359:550-551).

[0023] The species from which the pluripotent stem cells are derived is not particularly limited, and may be cells from, for example, rodents such as rats, mice, hamsters, and guinea pigs, lagomorphs such as rabbits, ungulates such as pigs, cows, goats, and sheep, carnivores such as dogs and cats, and primates such as humans, monkeys, rhesus monkeys, marmosets, orangutans, and chimpanzees. The preferred species is human.

[0024] As used herein, the term "cell clump" refers to a structure formed by the aggregation of cells, also referred to as a cell aggregate. Furthermore, a neural crest cell (NCC) clump refers to a cell clump containing neural crest cells, typically consisting primarily of neural crest cells (e.g., at a ratio of 60% or more, 70% or more, or 80% or more). The same applies to cell clumps of other cell types (e.g., first pharyngeal arch ectomesenchymal (PA1-EM) cell clumps, etc.).

[0025] As used herein, the term "ALK inhibitor" refers to a substance that has inhibitory activity against receptors belonging to the ALK (activin receptor-like kinase) family. ALK, also known as the type I TGFβ receptor, controls cell proliferation, cell differentiation, cell death, and other conditions through signal transduction primarily via activation of Smad (R-Smad). A type II TGFβ receptor forms a dimer, and this dimer associates with two molecules of type I TGFβ receptor to form a heterotetramer. Upon heterotetramer formation, the type II TGFβ receptor phosphorylates the type I TGFβ receptor, which induces the kinase activity of the type I TGFβ receptor and phosphorylates downstream Smads.

[0026] The "ALK inhibitor" used in the present invention is not particularly limited as long as it can inhibit any of the above-mentioned stages of signal transduction, and examples include substances that inhibit the binding of TGFβ to its receptor, substances that inhibit the phosphorylation of type I TGFβ receptor by type II TGFβ receptor, substances that inhibit the phosphorylation of Smads (e.g., Smad2, Smad3, etc.) by phosphorylated type I TGFβ receptor, etc. In humans, ALK-1, ALK-2, ALK-3, ALK-4, ALK-5, ALK-6, and ALK-7 are known, and as the ALK inhibitor used in the present invention, an inhibitor of ALK-5 (also referred to as a "TGFβ inhibitor") is particularly preferred.

[0027] Examples of the ALK inhibitor used in step (1) or (2) of the method for producing NCC of the present invention include SB431542 (4-(5-benzo[1,3]dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)-benzamide, 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]-benzamide, 4-[4-(3,4-methylenedioxyphenyl)-5-(2-pyridyl)-1H-imidazol-2-yl]-benzamide), A-83-01 (3-(6-methylpyridin-2-yl)-1-phenylthiocarbamoyl-4-quinolin-4-ylpyrazole), LDN193189 (4-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline), GW788388 (4-[4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]-pyridin-2-yl]-N-(tetrahydro-2H-pyran-4-yl)benzamide), SM16 (4-[4-(1,3-Benzodioxol-5-y Examples of ALK inhibitors include 1)-5-(6-methyl-2-pyridinyl)-1H-imidazol-2-yl]-bicyclo[2.2.2]octane-1-carboxamide, IN-1130 (3-[[5-(6-Methyl-2-pyridinyl)-4-(6-quinoxalinyl)-1H-imidazol-2-yl]methyl]-benzamide), GW6604 (2-Phenyl-4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridine), and SB505124 (2-(5-benzo[1,3]dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine). Of these, SB431542 and A-83-01 are preferred. Two or more ALK inhibitors may be used in combination.

[0028] In step (1) or (2) of the method for producing NCC of the present invention, the concentration of the ALK inhibitor in the medium is adjusted appropriately depending on the type of ALK inhibitor added, but is typically 0.1 to 50 μM, preferably 1 to 40 μM, and more preferably 5 to 20 μM. When SB431542 is used, the concentration in the medium is typically 1 to 40 μM, preferably 5 to 20 μM, and more preferably 10 μM. When A-83-01 is used, the concentration in the medium is typically 0.01 to 10 μM, preferably 0.1 to 4 μM, more preferably 0.5 to 2 μM, and even more preferably 1 μM.

[0029] Bone morphogenetic proteins (BMPs) are secreted signaling molecules belonging to the TGF-β superfamily. Examples of bone morphogenetic proteins used in step (1) of the NCC production method of the present invention include BMP2, BMP3, BMP3b, BMP4, BMP5, BMP6, BMP7, BMP8, BMP9, BMP10, BMP11, BMP12, BMP13, BMP14, BMP15, BMP16, BMP17, and BMP18, with BMP4, BMP2, and BMP7 being preferred. Two or more BMPs may be used in combination.

[0030] In step (1) of the method for producing NCC of the present invention, the concentration of BMP in the medium is adjusted appropriately depending on the type of BMP added, but is typically 1 to 50 ng / mL, preferably 2 to 30 ng / mL, and more preferably 2.5 to 10 ng / mL.

[0031] As used herein, the term "GSK-3β inhibitor" refers to a substance having inhibitory activity against GSK-3β (glycogen synthase kinase 3β). GSK3 (glycogen synthase kinase 3) is a type of serine / threonine protein kinase and is involved in many signaling pathways related to glycogen production, apoptosis, stem cell maintenance, and the like. GSK3 exists in two isoforms, α and β. The "GSK-3β inhibitor" used in the present invention is not particularly limited as long as it has GSK-3β inhibitory activity, and may be a substance that has both GSK-3β inhibitory activity and GSK-3α inhibitory activity.

[0032] Examples of GSK-3β inhibitors used in step (2) of the method for producing NCC of the present invention include CHIR98014 (2-[[2-[(5-nitro-6-aminopyridin-2-yl)amino]ethyl]amino]-4-(2,4-dichlorophenyl)-5-(1H-imidazol-1-yl)pyrimidine), CHIR99021 (6-[[2-[[4-(2,4-dichlorophenyl)-5-(4-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]nicotinonitrile), CP21R7 (3- (3-amino-phenyl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione), LY2090314 (3-[9-Fluoro-1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-4-imidazo[1,2-a]pyridin-3-yl-1h-pyrrole-2,5-dione), TDZD-8 (4-benzyl-2-methyl-1, 2,4-Thiadiazolidine-3,5-dione), SB216763 (3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione), TWS-119 (3-[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy]phenol), Kenpaullone, 1-Azakenpaullone, SB415286 (3-[(3-chloro-4-hydroxyphenyl)amino]-4 -(2-nitrophenyl)-1H-pyrrole-2,5-dione), AR-AO144-18 (1-[(4-methoxyphenyl)methyl]-3-(5-nitro-1,3-thiazol-2-yl)urea), CT99021, CT20026, BIO ((2'Z,3'E)-6-bromoindirubin-3'-oxime), BIO-acetoxime, pyridocarbazole-cyclopentadienyl ruthenium complex, OTDZT, alpha-4-dibromoacetophenone, lithium, etc. These may be used in combination of two or more kinds.In addition, antisense oligonucleotides and siRNAs against GSK-3β mRNA, antibodies that bind to GSK-3β, dominant-negative GSK-3β mutants, etc. can also be used as GSK-3β inhibitors, and these are commercially available or can be synthesized according to known methods.

[0033] In step (2) of the method for producing NCC of the present invention, the concentration of the GSK-3β inhibitor in the medium is adjusted appropriately depending on the type of GSK-3β inhibitor added, but is, for example, 0.01 to 20 μM, preferably 0.1 to 10 μM. For example, when CHIR99021 is used, the concentration is typically 0.1 to 10 μM, preferably 0.5 to 2 μM, and more preferably 1 μM.

[0034] As shown in the Examples below, the inclusion of a shaking culture step in step (1) of the method for producing NCC of the present invention can shorten the culture period (see, for example, FIG. 20), and the inclusion of a shaking culture step in step (2) has been shown to improve the efficiency of NCC induction (see, for example, FIG. 9). Therefore, it is preferable that at least one of steps (1) and (2) includes a shaking culture step. Shaking culture may be performed throughout the entire period of each step, or only for a portion of the period.

[0035] Shaking culture can be carried out using a shaking device (shaker). The culture device may be an orbital shaker, a reciprocating shaker, a figure-of-eight shaker, or a shaker with the ability to switch between these shaking modes as appropriate. The shaking direction may be horizontal or vertical, but is typically horizontal. The shaking speed is not particularly limited and is usually in the range of 50 to 450 rpm, preferably 100 to 200 rpm (120 rpm in one embodiment).

[0036] Without wishing to be bound by any theory, it is speculated that one reason for the improved NCC induction efficiency achieved by shaking culture is that shaking promotes the penetration of medium supplements into cell aggregates. Therefore, it is speculated that other methods that can achieve this goal, such as spinner culture, would also improve the NCC induction efficiency. Therefore, spinner culture may be performed instead of or in addition to shaking culture. Spinner culture can be performed using a culture device equipped with a stirrer or impeller (e.g., a bioreactor). The rotation speed of the stirrer or impeller during spinner culture is typically 10 to 100 rpm.

[0037] The culture period in step (1) of the method for producing NCC of the present invention is typically 3 hours to 7 days, and from the viewpoint of the efficiency of induction into NCC, it is preferably 6 hours to 6 days, more preferably 6 hours to 5 days, even more preferably 12 hours to 4 days, and even more preferably 1 day to 3 days. Furthermore, when shake culture and / or agitation culture is performed, the period of step (1) can be shortened; for example, the culture period can be 6 hours to 3 days, 6 hours to 2 days, or 12 hours to 1 day.

[0038] The culture period in step (2) of the method for producing NCC of the present invention is typically 12 hours to 5 days, and from the viewpoint of the efficiency of induction into NCC, it is preferably 1 day to 6 days, more preferably 1 day to 4 days, even more preferably 2 days to 3 days, and even more preferably 1 day to 3 days. The period can be appropriately changed depending on the period of step (1) of the method for producing NCC of the present invention, the presence or absence of shaking culture and / or agitation culture, etc.

[0039] The culture period in steps (1) and (2) of the method for producing NCC of the present invention (total culture period for steps (1) and (2)) is typically 1 to 6 days, preferably 2 to 5 days, and more preferably 3 to 4 days. This period can be appropriately changed depending on the period of step (1) of the method for producing NCC of the present invention, the presence or absence of shaking culture and / or agitation culture, etc.

[0040] Step (1) of the method for producing an NCC of the present invention may be preceded by a step of suspension culturing pluripotent stem cells in a medium containing a ROCK inhibitor. This allows the formation of cell clumps of pluripotent stem cells. Alternatively, this step may be replaced by a step of preparing cell clumps of pluripotent stem cells. The duration of this step is not particularly limited, but is typically 12 hours to 3 days, and preferably 1 day. Therefore, when the method for producing an NCC of the present invention includes a step of forming cell clumps of pluripotent stem cells, the duration of the method for producing an NCC of the present invention is typically 2 to 7 days, preferably 3 to 6 days, and more preferably 4 to 5 days.

[0041] The ROCK inhibitor used in the present invention is not particularly limited as long as it can inhibit the function of Rho-kinase (ROCK). Examples of such inhibitors include Y-27632 (see, for example, Ishizaki et al., Mol. Pharmacol. 57, 976-983 (2000); Narumiya et al., Methods Enzymol. 325, 273-284 (2000)), fasudil / HA1077 (see, for example, Uenata et al., Nature 389: 990-994 (1997)), SR3677 (see, for example, Feng Y et al., J Med Chem. 51: 6642-6645 (2008)), GSK269962 (see, for example, Stavenger RA et al., J Med Chem. 50: 2-5 (2007) or WO2005 / 037197), GSK429286A, H1152 (e.g., see Sasaki et al., Pharmacol. Ther. 93: 225-232 (2002)), Wf-536 (e.g., see Nakajima et al., Cancer Chemother Pharmacol. 52(4): 319-324 (2003)), thiazovivin, and salts or derivatives thereof. Other ROCK inhibitors also include antisense nucleic acids against ROCK, RNA interference-inducing nucleic acids (e.g., siRNA), dominant-negative mutants, and expression vectors thereof. Other known low molecular weight compounds and their salts or derivatives can also be used as ROCK inhibitors (see, for example, U.S. Patent Application Publication Nos. 2005 / 0209261, 2005 / 0192304, 2004 / 0014755, 2004 / 0002508, 2004 / 0002507, 2003 / 0125344, 2003 / 0087919, and International Publication Nos. 2003 / 062227, 2003 / 059913, 2003 / 062225, 2002 / 076976, and 2004 / 039796). Among these, Y-27632 is preferred. Only one ROCK inhibitor may be used, or two or more may be used.The concentration of the ROCK inhibitor in the medium can be appropriately selected by those skilled in the art depending on the ROCK inhibitor used. For example, when Y-27632 or a salt thereof (e.g., Y-27632 dihydrochloride, etc.) is used, the concentration is typically 0.1 μM to 100 μM, preferably 1 μM to 50 μM, more preferably 5 μM to 20 μM, and even more preferably 10 μM.

[0042] Furthermore, NCCs may be selected (or isolated, concentrated, or purified) from the NCC clusters obtained in step (2) of the NCC production method of the present invention using the expression of an NCC marker (e.g., high expression of CD271) as an indicator. NCCs can be selected using any known method, as appropriate, including methods in which cells are labeled with an antibody against an NCC marker such as CD271 and then selected by flow cytometry or mass cytometry, magnetic cell separation, or an affinity column on which a desired antigen is immobilized.

[0043] The cell culture density in the method for producing NCC of the present invention is not particularly limited as long as the cells can grow. Typically, the cell culture density is 1.0 × 10 1 ~1.0 x 10 9 cells / ml, preferably 1.0 x 10 2 ~1.0 x 10 8 cells / ml, more preferably 1.0 x 10 3 ~1.0 x 10 7 cells / ml, more preferably 1.0 x 10 3 ~1.0 x 10 6 cells / ml (e.g., 2.0 x 10 4 cells / ml, 3.0 x 10 4 cells / ml, 1.0 x 10 5 cells / ml, etc.

[0044] In at least one of steps (1) and (2) of the method for producing NCC of the present invention, cells may be cultured under feeder-free and / or xeno-free conditions. In the method for producing NCC of the present invention, all steps may be performed under feeder-free and xeno-free conditions. Furthermore, in any step other than steps (1) and (2) of the method for producing NCC of the present invention, cells may be cultured under feeder-free and / or xeno-free conditions. As used herein, "feeder-free" refers to a medium or culture conditions that do not contain other cell types (i.e., feeder cells) that play a supporting role in establishing the culture conditions for the cells to be cultured. Furthermore, "xeno-free" refers to a medium or culture conditions that do not contain components derived from organisms other than the organism species of the cells to be cultured.

[0045] The basal medium used in the method for producing NCC of the present invention is not particularly limited, but includes StemFit® AK02 medium (Ajinomoto Co., Inc.), StemFit® AK03 medium (Ajinomoto Co., Inc.), StemFit® Basic03 medium, CTS® KnockOut SR XenoFree Medium (Gibco), mTeSR1 medium, TeSR1 medium (Stem Cell Technologies), Iscove's modified Dulbecco's medium (GE Healthcare), and Improved MEM (Thermo Fisher Scientific). Among these, StemFit® AK03 medium is preferred. These media can also be used for culture under feeder-free and xeno-free conditions. Other suitable media include RPMI-1640 medium, EagleMEM (EMEM), Dulbecco's modified MEM, Glasgow's MEM (GMEM), α-MEM, 199 medium, IMDM, DMEM, Hybridoma Serum-free medium, and KnockOut. TMDMEM, Advanced TM medium (e.g. Advanced MEM, Advanced RPMI, Advanced DMEM / F-12), Ham's Medium F-12, Ham's Medium F-10, Ham's Medium F12K, DMEM / F-12, ATCC-CRCM30, DM-160, DM-201, BME, Fischer, McCoy's 5A, Leibovitz's L-15, RITC80-7, MCDB105, MCDB107, MCDB131, MCDB153, MCDB201, NCTC109, NCTC135, Waymouth's Medium (e.g. Waymouth's MB752 / 1), CMRL medium (e.g. CMRL-1066), Williams' medium E, Brinster's BMOC-3 Medium, E8 Medium, StemPro 34, MesenPRO RS (Thermo Fisher Scientific), ReproFF2, Primate ES Cell Medium, ReproStem (ReproCELL Co., Ltd.), ProculAD (Rohto Pharmaceutical Co., Ltd.), MSCBM-CD, MSCGM-CD (Lonza), EX-CELL302 medium (SAFC) or EX-CELL-CD-CHO (SAFC), ReproMed TM Examples of suitable medium include, but are not limited to, iPSC Medium (ReproCell Corporation) and mixtures thereof.

[0046] If necessary, the culture medium may contain one or more serum substitutes, such as, for example, Knockout Serum Replacement (KSR), N2 supplement (Invitrogen), B27 supplement (Invitrogen), albumin, transferrin, apotransferrin, fatty acids, insulin, collagen precursors, trace elements, 2-mercaptoethanol, 3'-thiolglycerol, and may also contain one or more substances, such as lipids, amino acids, L-glutamine, Glutamax (Invitrogen), non-essential amino acids, vitamins, growth factors, small molecules, antibiotics, antioxidants, pyruvate, buffers, inorganic salts, selenate, progesterone, and putrescine.

[0047] As used herein, "suspension culture" refers to culture performed under conditions that maintain cells or cell clumps suspended in a culture medium, i.e., culture under conditions that do not allow the formation of strong cell-substratum junctions between the cells or cell clumps and the culture vessel. Furthermore, when performing suspension culture, the cells are typically in the form of cell clumps before and after suspension culture.

[0048] The culture vessel used for suspension culture is not particularly limited as long as it is capable of "suspension culture," and can be appropriately determined by one skilled in the art. Examples of such culture vessels include flasks, tissue culture flasks, dishes, Petri dishes, tissue culture dishes, multi-dishes, microplates, microwell plates, micropores, multi-plates, multi-well plates, chamber slides, Petri dishes, tubes, trays, culture bags, and roller bottles. Furthermore, bioreactors are an example of vessels for suspension culture. These culture vessels are preferably non-cell-adhesive to enable suspension culture. Examples of non-cell-adhesive culture vessels include those whose surfaces have not been artificially treated (e.g., coated with extracellular matrix) to improve cell adhesion. The well bottom shape of these culture vessels is not particularly limited, and examples include flat-bottomed, U-shaped, and V-shaped vessels. In step (1) of the method for producing NCC of the present invention, a V-bottom plate (e.g., 96-well V-bottom ultra-low attachment culture plate (manufactured by Sumitomo Bakelite Co., Ltd.)) is preferably used, and in step (2) of the method for producing NCC of the present invention, a flat-bottom plate (e.g., 48-well low attachment culture plate (manufactured by Iwaki Co., Ltd.)) is preferably used.

[0049] The culture temperature is not particularly limited, but is about 30 to 40°C, preferably about 37°C, and the culture is carried out in an atmosphere of CO2-containing air, with the CO2 concentration preferably being about 2 to 5%.

[0050] NCCs are cells that arise between the neuroectoderm and epidermal ectoderm during early development when the neural tube is formed from the neural plate. They are multipotent and have the ability to self-renew, differentiating into many cell types, including neurons, glial cells, mesenchymal stem cells, osteocytes, chondrocytes, and melanocytes. As used herein, "neural crest cells (NCCs)" refer to cells that express one or more genes selected from CD271 (NGFR), SOX10, TFAP2A, and PAX3 (preferably all four of these genes are expressed). Typically, NCCs are strongly CD271-positive.

[0051] Step (2) of the method for producing an NCC of the present invention allows for the production of an NCC derived from a pluripotent stem cell. Accordingly, in another aspect of the present invention, an NCC (hereinafter, sometimes referred to as "NCC of the present invention") obtained (or obtained) by the method for producing an NCC of the present invention is also provided. The NCC of the present invention typically has all of the following characteristics (A) to (C): (A) derived from a pluripotent stem cell; (B) expressing one or more (preferably all) genes selected from CD271, SOX10, TFAP2A, and PAX3; and (C) having the ability to differentiate into PA1-EM cells (at least mandibular PA1-EM cells).

[0052] Furthermore, the NCC of the present invention further has at least one (preferably all) of the following characteristics (D) to (F): (D) having the ability to differentiate into melanoblasts, (E) having the ability to differentiate into neural cells, and (F) having the ability to differentiate into mesenchymal stem cells.

[0053] In another aspect, the present invention also provides an NCC having all of the above characteristics (A) to (C) and preferably at least one (preferably all) of the above characteristics (D) to (F). Such an NCC may be obtained by the method for producing an NCC of the present invention, or may be obtained by another method. Hereinafter, the above NCC may also be referred to as the "NCC of the present invention."

[0054] As used herein, unless otherwise specified, the terms "expressing" or "positive" a gene are used to mean at least "production of mRNA encoded by the gene," but preferably also "production of a protein encoded by the mRNA." Therefore, if production of mRNA encoded by the gene is detected at least by the method (RT-qPCR) described in the Examples below, the gene can be said to be expressed. On the other hand, if production of mRNA encoded by the gene is not detected (i.e., below the detection limit) by the method (RT-qPCR) described in the Examples below, if it is at background levels, or if it is 1 / 100 or less compared to the positive control, the gene can be said to be not expressed or to be negative.

[0055] As used herein, "positive" includes high expression (also referred to as "strongly positive"). High expression may be expressed as "High" or "Bright." For example, CD271 highly expressing cells are characterized by CD271 High+ cells or CD271 Bright+ These cells are sometimes referred to as "cells." High expression can be determined based on a chart obtained by flow cytometry. The positions that appear on the chart may vary depending on the voltage settings of the instrument, sensitivity settings, antibody clones used, staining conditions, dyes used, etc., but a person skilled in the art can appropriately draw lines on the chart obtained so as not to separate cell populations that are recognized as a single group.

[0056] Furthermore, the ability to differentiate into various cells (target cells), such as PA1-EM cells, means that the target cells can be obtained from NCCs by any method. PA1-EM cells are classified as maxillary PA1-EM (mxEM) and mandibular PA1-EM (mdEX). In this specification, unless otherwise specified, PA-EM includes both maxillary PA1-EM and mandibular PA-EM, but often refers specifically to mandibular PA1-EM.

[0057] 2. Differentiation induction method and differentiated cells or organoids obtained by the method As described above, the NCC of the present invention has the ability to differentiate into various cells. Therefore, in another aspect, a method for producing differentiated cells or organoids (hereinafter sometimes referred to as the "differentiation induction method of the present invention"), which comprises a step of inducing differentiation of the NCC of the present invention, and differentiated cells or organoids obtained (or obtained) by the method are provided.

[0058] The cells obtained by the differentiation induction method of the present invention may be undifferentiated cells such as stem cells or progenitor cells, or may be terminally differentiated cells. Hereinafter, the term "differentiated cells" may be used to encompass both undifferentiated cells and terminally differentiated cells. As used herein, "undifferentiated cells" refers to cells that have not yet reached terminal differentiation in their cell lineage. Examples of undifferentiated cells include stem cells and progenitor cells excluding pluripotent stem cells. Examples of stem or progenitor cells include neural stem cells, glial progenitor cells, melanocyte stem cells, melanoblasts, mesenchymal stem cells, first pharyngeal arch ectodermal mesenchymal cells, cardiac stem cells, vascular endothelial progenitor cells, vascular pericytes, skeletal muscle stem cells, adipose stem cells, osteoprogenitor cells, osteoblasts, and chondroblasts.

[0059] As used herein, the term "terminally differentiated cells" refers to cells that have reached terminal differentiation in a cell lineage. Examples of terminally differentiated cells include, but are not limited to, nerve cells, glial cells, melanocytes, adipocytes, corneal endothelial cells, vascular endothelial cells, cardiac muscle cells, skeletal muscle cells, bone cells, chondrocytes, and smooth muscle cells.

[0060] In addition, in this specification, "organoid" refers to a structure containing multiple types of cells, and typically has a structure and function similar to that of organs in vivo. Organoids obtained by the differentiation induction method of the present invention include, for example, neural organoids (e.g., cerebral cortex organoids, cerebellar organoids, spinal cord organoids, midbrain organoids, choroid plexus organoids, hippocampal organoids, hypothalamic organoids, anterior pituitary organoids, basal ganglia organoids, retinal organoids, etc.), cartilage organoids (also referred to as "cartilage-like tissues"), cardiac organoids, bone organoids (also referred to as "bone-like tissues"), skeletal muscle organoids, etc., but in one embodiment, jawbone organoids (also referred to as "jawbone-like tissues") and other bone organoids.

[0061] Bone organoids may be cartilage bone organoids or membranous bone organoids, but are preferably organoids of bones derived from NCC (e.g., presphenoid, ethmoid, membranous bone, etc.), with membranous bone organoids being more preferred. Membranous bones include, for example, the frontal bone, parietal bone, temporal bone, occipital bone, and jawbone (maxilla and mandible), with jawbone (particularly mandible) being preferred. In addition, in this specification, mandibular organoids refer to organoids derived from DLX5-positive PA1-EM cells. In the examples described below, bone organoids induced from pluripotent stem cells with a COLIA1 point mutation that causes dysplastic bone formation were observed to exhibit a phenotype of dysplastic bone formation. Therefore, bone organoids may exhibit the phenotype of bone diseases (e.g., osteogenesis imperfecta).

[0062] Whether a structure is an organoid can be confirmed, for example, by observing a sample stained as needed (e.g., Alizarin Red staining, HE staining, Azan staining, etc.) under a microscope to confirm the presence or absence of layer structure formation, or by examining the expression of marker proteins. Specifically, bone organoids have a bone matrix, osteocytes encapsulated in the bone matrix, and a layer of osteoblasts surrounding the bone matrix. Bone organoids typically exhibit a three-dimensional network formed by the interconnection of osteocytes through cytoskeleton-related proteins such as F-actin, and when transplanted into a bone defect, they have the ability to repair the defect. In addition, "bone matrix" refers to the accumulation of substances produced by bone cells and secreted extracellularly, such as calcium phosphate, including proteins such as osteocalcin, osteopontin, osteonectin, and collagen.

[0063] Cerebral cortical organoids have a dome-shaped neuroepithelium with Foxg1 expression throughout, and the neuroepithelium has a layered structure. Typically, the inner layer of the epithelium is composed of Pax6- and Sox2-positive neural progenitor cells corresponding to the ventricular zone, while the outer layer is composed of Reelin / Carletinin-positive Cajal-Retzius cells and a Ctip2 / Tbr1-positive deep layer.

[0064] NCCs can also be used to produce cells such as neural progenitor cells, neurons, glial cells, mesenchymal stem cells, bone cells, chondrocytes, odontogenic mesenchymal cells, smooth muscle cells, corneal endothelial cells, melanoblasts, and melanocytes. For example, differentiation into these cells can be achieved by the methods described in the Examples below, or by methods described in Fukuta M. et al., PLoS One, 2014, 9(12): e112291, Horikiri T. et al., PLoS One, 2017, 12(1): e0170342, and non-patent document 3. After culturing, the expression of cell surface antigens and marker genes can be analyzed by flow cytometry or immunostaining to confirm differentiation into the target cells. Furthermore, as used herein, "mesenchymal stem cells" refers to cells capable of self-renewal and differentiation into at least bone cells, chondrocytes, and adipocytes.

[0065] In one embodiment of the present invention, the cells or organoids (target cells or organoids) obtained by the differentiation induction method of the present invention are mesenchymal cells (e.g., mesenchymal stem cells, first pharyngeal arch ectodermal mesenchymal cells, bone precursor cells, osteoblasts, osteocytes, chondrocytes, myoblasts, odontogenic mesenchymal cells, smooth muscle cells, etc.), neurons, melanoblasts, or bone organoids (e.g., jawbone organoids).

[0066] NCCs may be expanded before the differentiation induction method of the present invention is performed. Expansion can be performed, for example, by the method described in Patent Document 1. Specifically, neural crest cells can be cultured in suspension in a medium containing a GSK-3β inhibitor and basic fibroblast growth factor (bFGF). The GSK-3β inhibitor used for NCC expansion can be the same as that used in the NCC production method of the present invention, but SB431542 is preferred. Commercially available bFGF (also known as FGF-2) from Fujifilm Wako Pure Chemical Industries, Ltd. and other companies can be used for NCC expansion. The medium used for expansion may also contain an ALK inhibitor or EGF (Epidermal Growth Factor). The ALK inhibitor can be the same as that used in the NCC production method of the present invention.

[0067] MSCs can also be obtained by culturing neural crest cells in a mesenchymal stem cell growth medium for approximately 14 days in adherent culture. The medium is not particularly limited as long as it can induce differentiation of the NCCs of the present invention into MSCs. While a basal medium containing bovine serum (e.g., αMEM medium) can be used, commercially available xeno-free mesenchymal stem cell growth media are preferred. Examples of commercially available xeno-free mesenchymal stem cell growth media include PRIME-XV MSC Expansion XSFM (Irvine Scientific), Cellartis® MSC Xeno-Free Culture Medium (Takara Bio Inc.), and MSC NutriStem® XF Medium (Sartorius Stedim Japan).

[0068] Differentiated cells can also be produced by culturing MSCs in a medium suitable for inducing differentiation of the target cells. For example, osteocyte differentiation-inducing media include basal media (e.g., αMEM) containing 10% FBS, 0.1 μM dexamethasone, 50 μg / ml ascorbic acid, and 10 mM β-glycerophosphate, and commercially available xeno-free osteocyte differentiation-inducing media (e.g., MSCgo). TMOsteogenic XF Medium (Sartorius), MSCgo TM Specifically, the differentiation method into osteocytes involves, for example, culturing mesenchymal stem cells in a 12-well plate coated with gelatin at a density of 4 × 10 4 For example, individual cells are seeded on the cells and cultured for 30 days in the osteocyte differentiation-inducing medium. Differentiation into osteocytes may be confirmed by detecting mineralized nodules using alizanin red staining.

[0069] The chondrocyte differentiation induction medium may be a basal medium (e.g., DMEM / F12) containing 1% (v / v) ITS+premix, 0.17 mM AA2P, 0.35 mM proline, 0.1 mM dexamethasone, 0.15% (v / v) glucose, 1 mM sodium pyruvate, 2 mM GlutaMAX, 40 ng / ml PDGF-BB, 100 ng / mL TGF-β3, 10 ng / ml BMP4, and 1% (v / v) FBS, or a commercially available xeno-free chondrocyte differentiation induction medium (e.g., MSCgo TM Chondrogenic XF (Sartorius). Specific examples of methods for differentiation into chondrocytes include spotting 5 μl of mesenchymal stem cell suspension onto a fibronectin-coated plate, culturing for 1 hour, adding 1 ml of the above-mentioned differentiation-inducing medium after 1 hour, and culturing for 14 days. Chondrocyte differentiation may be confirmed by Alcian blue staining.

[0070] Adipocyte differentiation induction media include basal medium containing 60 μM indomethacin, 0.5 mM IBMX, and 0.5 μM hydrocortisone, and commercially available xeno-free adipocyte differentiation induction media (e.g., hMSC - Human Mesenchymal Stem Cell Adipogenic Differentiation Medium (Lonza) and MSCgo). TMSpecifically, the method for differentiation into adipocytes involves, for example, plating 4 × 10 mesenchymal stem cells onto a gelatin-coated plate. 4 For example, cells are seeded in the osteocyte differentiation-inducing medium and cultured for 32 days. Adipocyte differentiation may be confirmed by Oil Red O staining.

[0071] Alternatively, neural progenitor cells and neurons can be obtained by seeding NCCs in low-adhesion culture vessels (e.g., 96-well V-bottom ultra-low-adhesion culture plates (Sumitomo Bakelite Co., Ltd.)) and culturing them for approximately 14 days in basal medium (e.g., Neurobasal medium) supplemented with B27 supplement, N-2 supplement, L-glutamine, BDNF, GDNF, NT-3, and NGF, or by culturing NCCs in basal medium (e.g., DMEM / F12) supplemented with N-2 supplement, BDNF, GDNF, NT-3, and NGF for approximately 14 days in adherent culture.

[0072] The induction of melanoblasts from NCCs has also been described, for example, in Mica et al., Cell Reports, 2013; 3(4):1140-1152 and Callahan et al., J. Vis Exp, 2016; (109): e53806. While these methods may be used directly, as shown in the Examples below, differentiation into melanoblasts can be induced with high efficiency by switching from adherent culture to suspension culture. Specifically, NCC clumps are seeded into low-cell-adhesion culture vessels and cultured for approximately 6 days in a basal medium (e.g., StemFit Basic03 medium) supplemented with CHIR99021, BMP4, and endothelin-3 to obtain melanoblasts.

[0073] Smooth muscle cells can also be induced from NCCs or MSCs. For example, NCCs are cultured in a mesenchymal stem cell growth medium for about 5 days as adherent cells, followed by another 5 days of culture in a smooth muscle cell induction medium to obtain smooth muscle cells. Examples of smooth muscle cell induction media include basal media supplemented with TGF-β1 and endothelin-1 (e.g., StemFit Basic03 medium, etc.).

[0074] The induction of mandibular PA1-EM cells from NCCs of the present invention (hereinafter also referred to as "PA1-EM cell induction") can be achieved, for example, by culturing NCCs in a medium containing endothelin and fibroblast growth factor (e.g., StemFit Basic 03 medium). The endothelin used for PA1-EM cell induction may be endothelin-1 (Edn-1), endothelin-2 (Edn-2), or endothelin-3 (Edn-3), with Edn-1 being preferred. These endothelins may also be used in combination. The concentration of endothelin in the medium can be appropriately selected by those skilled in the art depending on the endothelin used; for example, when Edn-1 is used, the concentration is typically 1 to 500 nM, preferably 10 to 300 nM, and more preferably 20 to 100 nM (e.g., 50 nM). On the other hand, maxillary PA1-EM cells can also be induced by using an Edn-1 inhibitor instead of endothelin in the PA1-EM cell induction method, or by culturing NCCs without Edn-1, Edn-2, or Edn-3 in the medium (in the absence of these substances). The Edn-1 inhibitor used in the present invention may be any inhibitor capable of inhibiting the binding of Endothelin A receptors to Endothelin A receptors, such as BQ-123, bosentan, tezosentan, darusentan, atrasentan, and sitaxsentan. The concentration of the Edn-1 inhibitor in the medium can be selected by those skilled in the art depending on the Edn-1 inhibitor used. For example, when using BQ-123, the concentration is typically 0.1 μM to 100 μM, preferably 1 μM to 50 μM, and more preferably 5 μM to 20 μM (e.g., 10 μM). Two or more Edn-1 inhibitors may also be used in combination.

[0075] When inducing PA1-EM cells, suspension culture is preferred, and shaking culture and / or agitation culture is also preferred. The culture period for PA1-EM cell induction is not particularly limited as long as PA1-EM cells can be obtained, but is typically 3 to 6 days, although this can be changed as appropriate depending on whether shaking culture is used or not.

[0076] Fibroblast growth factors (FGFs) used in PA1-EM cell induction can be commercially available from Fujifilm Wako Pure Chemical Industries, Ltd., etc. Twenty-two types of FGF are known in humans, and any that function as a cell growth factor can be used. However, when inducing PA1-EM cells from NCCs of the present invention, FGF-8 is preferred. In humans, functional isoforms of FGF-8 are known to be FGF-8a, FGF-8b, FGF-8e, and FGF-8F. Any of these may be used, but FGF-8b is preferred. Two or more FGFs may be used in combination. The concentration of FGF in the culture medium can be appropriately selected by those skilled in the art depending on the FGF used. For example, when using FGF-8, the concentration is typically 1 to 500 ng / ml, preferably 10 to 300 ng / ml, and more preferably 50 to 200 ng / ml (e.g., 100 ng / ml).

[0077] As shown in the Examples below, the use of BMP during PA1-EM cell induction has been shown to improve the efficiency of PA1-EM cell induction. Therefore, it is preferable that the medium used for PA1-EM cell induction contains BMP. Examples of BMP include BMP2, BMP3, BMP3b, BMP4, BMP5, BMP6, BMP7, BMP8, BMP9, BMP10, BMP11, BMP12, BMP13, BMP14, BMP15, BMP16, BMP17, and BMP18. Among these, BMP4, BMP2, and BMP7 are preferred, with BMP4 being particularly preferred. Two or more BMPs may be used in combination. The concentration of BMP in the medium is adjusted appropriately depending on the type of BMP added. For example, when using BMP4, the concentration is typically 1 to 50 ng / mL, preferably 2 to 30 ng / mL, and more preferably 2.5 to 10 ng / mL.

[0078] In yet another embodiment of the present invention, PA1-EM cells (hereinafter also referred to as "PA1-EM cells of the present invention") are also provided. The PA1-EM cells are mandibular PA-EM cells and typically have all of the following characteristics (a) to (c): (a) they are derived from neural crest cells that do not express HOX; (b) they express DLX5, PRRX1, and TWIST1; and (c) they respond to epithelial signals and are capable of inducing patterning. The PA1-EM cells may be obtained by the PA1-EM cell induction method described above, or by other methods. Furthermore, the PA1-EM cells of the present invention may further have the characteristic (d) of having actin filaments (also referred to as "F-actin" or "actin stress fibers"). PA1-EM cells having the above characteristics (a) and (c) as well as the characteristic (b') of expressing POU3F3 and CYP26A1 (and optionally also having the above characteristic (d)) can be considered maxillary PA-EM cells.

[0079] The PA1-EM cells of the present invention are typically in the form of cell clusters. In one embodiment, the PA1-EM cell clusters have a surface region (surface zone), a central region (central zone), and an intermediate region (intermediate zone) located between the surface zone and the central zone. The central zone contains DLX2 single-positive cells, and the intermediate zone contains DLX2 single-positive cells. + DLX5 + The cells have DLX2 in the surface zone. + DLX5 + HAND2 + Therefore, in another embodiment of the present invention, a central zone containing DLX2 single-positive cells, DLX2 + DLX5 + the intermediate zone containing cells, DLX2 + DLX5 + HAND2 + A cell cluster (mandibular PA1-EM cell cluster) is provided that includes a superficial zone containing cells.

[0080] In the above characteristic (a), "not expressing HOX" means not expressing at least HOXA2 and HOXA3. Cells that do not express HOX can typically be produced by producing NCCs of the present invention. Furthermore, in the above characteristic (c), "epithelial signal" refers to an epithelial signal expressed in the first pharyngeal arch, which develops transiently during vertebrate fetal development. Major epithelial signals include the proximal-oral signal combination of Fgf8 and Sonic hedgehog (Shh); the distal-oral signal combinations of Shh and BMP4, Fgf8 and Shh, and Edn-1 and BMP4; the distal-aboral signal combination of Edn-1 and BMP4; and the proximal-aboral signal End-1 (see also Figure 39A). "Responsive to epithelial signals and capable of inducing patterning" means that PA1-EM cells express specific genes in response to each of the epithelial signals. For example, proximal-oral signals Fgf8 and Shh induce PA1-EM cells to express genes such as PAX9 and LHX8, while distal-aboral signals Edn-1 and BMP4 induce PA1-EM cells to express genes such as GSC and MSX2. Regarding feature (d), actin filaments are filamentous polymers of multiple globular actin (G-actin). The presence of actin filaments can be confirmed by phalloidin staining, as described below.

[0081] As shown in the Examples below, not only the NCCs of the present invention, but also NCCs obtained by conventional two-dimensional culture methods can be efficiently induced into PA1-EM cells by inhibiting actin filament formation. Therefore, the NCCs used to produce the PA1-EM cells of the present invention are not particularly limited. In another embodiment, a method for producing PA1-EM cells is also provided, which includes inducing differentiation of NCCs (in one embodiment, NCCs cultured under two-dimensional conditions) into PA1-EM cells in the presence of an actin filament formation inhibitor. For specific methods of inducing differentiation into PA1-EM cells, the above-mentioned description of the method for inducing mandibular PA1-EM cells from NCCs of the present invention is fully incorporated herein by reference.

[0082] Examples of actin filament formation inhibitors used in the present invention include Y-27632, cytochalasin A, cytochalasin B, cytochalasin C, cytochalasin D, cytochalasin E, latrunculin A, latrunculin B, wiscostatin, BDM, latrunculin, and chaetoglobosin A. The concentration of the actin filament formation inhibitor in the medium can be appropriately selected by those skilled in the art depending on the actin filament formation inhibitor used. For example, when using Y-27632 or a salt thereof (e.g., Y-27632 dihydrochloride, etc.), the concentration is typically 0.5 μM to 500 μM, preferably 2 μM to 200 μM, and more preferably 10 μM to 100 μM (50 μM in one embodiment). Two or more actin filament formation inhibitors may be used in combination.

[0083] More specifically, for example, PA1-EM cells can be cultured for about 3 days in a basal medium (e.g., StemFit Basic03 medium, etc.) supplemented with Fgf8b, SAG, BQ-123, and LDN193189. If the cells express PAX9 and LHX8, it can be evaluated that the PA1-EM cells respond to epithelial signals from the proximal oral side and that patterning can be induced. Furthermore, for example, PA1-EM cells can be cultured for about 3 days in a basal medium (e.g., StemFit Basic03 medium, etc.) supplemented with Fgf2, Endothelin-1, and BMP4. If the cells express GSC and MSX2, it can be evaluated that the PA1-EM cells respond to epithelial signals from the distal oral side and that patterning can be induced.

[0084] Furthermore, the thus-induced proximal-oral cells expressing PAX9 and LHX8, as well as the distal-aboral cells expressing GSC and MSX2, can be further induced to differentiate. For example, proximal-oral cells can be induced into odontogenic mesenchymal cells by culturing them for about four days in a basal medium (e.g., Basic03) supplemented with FGF8b, SAG, CHIR99021, and activin A (R&D). Because odontogenic mesenchymal cells can serve as the starting cells for dentin, the main component of teeth, the PA1-EM cells and odontogenic mesenchymal cells of the present invention may also be useful in tooth regeneration.

[0085] Bone organoids can be produced, for example, by the steps of: (I) inducing distal-contralateral cells from the PA1-EM cells of the present invention by the above-described method; (II) inducing osteoprogenitor cells from the distal-contralateral cells; and (III) inducing bone organoids from the osteoprogenitor cells. The step (II) can be carried out, for example, by culturing the distal-contralateral cells in a suspension culture medium for 2 to 4 days in an osteoprogenitor cell induction medium (e.g., StemFit Basic03 medium supplemented with Egf, Fgf2, BMP2, CHIR99021, and SAG). The step (III) can be carried out by culturing the osteoprogenitor cells in a medium for inducing osteocyte differentiation (e.g., MSCgo). TMThe medium may be replaced with another osteocyte differentiation-inducing medium (e.g., StemFit Basic 03 medium containing dexamethasone (usually used at 1 / 10 of the concentration used for osteoblast induction), β-glycerophosphate, and ascorbic acid) during step (III) (e.g., anywhere between days 10 and 20, or anywhere between days 6 and 10, from the start of step (III)). In this case, typically, the first half of the process is aimed at inducing differentiation into osteoblasts and osteocytes, while the second half of the process is aimed at maturing osteocytes. This can suppress the occurrence of dead cells during osteocyte maturation. Furthermore, if the medium is replaced with another osteocyte differentiation-inducing medium during step (III), the medium may be replaced with another medium (e.g., the osteocyte differentiation-inducing medium used at the beginning of step (III)) several days after the replacement (e.g., days 6 to 10). Specific methods are outlined in FIGS. 40 and 59, but the present invention is not limited to these methods.

[0086] In addition, the bone organoids produced by the above-mentioned method may be further matured. For example, such a method includes transplanting into a living body such as a mammal (for example, transplanting under the kidney capsule). As shown in the examples below, by transplanting the bone organoids into a living body, the formation of calcified matter and dense bone tissue is observed, and further, the bone tissue can be matured into a bone organoid in which a dense network of donor bone cells is observed to be formed inside.

[0087] Bone organoids can also be produced using MSCs by the method described in WO 2020 / 226043. Specifically, MSCs are grown in adhesion culture to form a sheet (cell sheet), the cell sheet is detached from the culture vessel, and the cell sheet is cultured in suspension to obtain a three-dimensional mesenchymal stem cell cluster. The cell cluster is embedded in a gel and cultured in a bone differentiation-inducing medium, thereby producing bone organoids. In this method, the gel is preferably a gel primarily composed of polysaccharides, and for example, Vitrogel (The Well Bioscience) can be used.

[0088] Neural organoids can be produced by suspension culture of cell clumps containing neural progenitor cells induced from NCCs in a neuronal differentiation-inducing medium. By continuing to culture the cell clumps under the suspension culture conditions, neural organoids can be induced in a self-organizing manner. Examples of such neuronal differentiation-inducing media include basal media (e.g., N2 medium) containing a Wnt signal inhibitor and an ALK inhibitor. Examples of Wnt signal inhibitors include DKK1 protein, sclerostin, IWR-1e, IWP-2, IWP-3, IWP-4, IWP-L6, C59, ICG-001, FH535, WIKI4, KYO2111, PNU-74654, XAV939, and derivatives thereof. Examples of ALK inhibitors include those similar to those mentioned above.

[0089] Culture vessels used in adhesion culture include those whose surfaces have been artificially treated to improve cell adhesion (e.g., coating with extracellular matrices such as basement membrane preparations, fibronectin, laminin or fragments thereof, entactin, collagen, gelatin, synthemax, vitronectin, etc., or polymers such as polylysine and polyornithine, or surface treatments such as positive charge treatment). Of these, culture vessels coated with fibronectin are preferred.

[0090] In the differentiation induction method of the present invention, the culture may be performed under feeder-free conditions and / or xeno-free conditions for all or part of the period. From the viewpoint of clinical use, the differentiation induction method of the present invention is preferably performed under feeder-free and xeno-free conditions for the entire period.

[0091] The differentiation induction method of the present invention may include a step of recovering the obtained target cells or organoids. The recovered cells may be cryopreserved using a cell cryopreservation solution. The recovered cells may be counted using a cell counter, or may be labeled with an antibody against a cell surface marker and selected by flow cytometry, mass cytometry, magnetic cell separation, or the like.

[0092] In another aspect, there is provided a cell or organoid obtained by the differentiation induction method of the present invention (hereinafter, also referred to as "differentiated cell or organoid of the present invention").

[0093] In the differentiation induction method of the present invention, the culture conditions and methods such as suspension culture, shaking culture, and agitation culture, the method for selecting target cells, additives to the culture medium, specific examples and definitions of culture vessels, etc. are all incorporated by reference into the contents described above in "1. Method for producing neural crest cells."

[0094] 3. Uses of Differentiated Cells or Organoids The differentiated cells or organoids of the present invention can be suitably used in regenerative medicine. Therefore, in another embodiment, a transplantation therapy agent (hereinafter sometimes referred to as the "transplantation therapy agent of the present invention") containing the differentiated cells or organoids of the present invention is provided. The present invention also encompasses a method for treating or preventing damage (including defects) or disease in tissues (e.g., bone tissue, cartilage tissue, adipose tissue, muscle tissue (e.g., skeletal muscle tissue, etc.) by administering or transplanting an effective amount of the differentiated cells or organoids of the present invention into a mammal (e.g., human, mouse, rat, monkey, cow, horse, pig, dog, etc.) to be treated. Furthermore, "treatment of tissue damage" also includes the regeneration of damaged tissue. Regeneration of damaged tissue includes not only complete tissue regeneration, but also the formation of tissue-like structures. For example, in the case of bone tissue, it is not necessary to determine whether the regenerated area is bone tissue using CT (Computed Tomography) examination.

[0095] The transplantation therapy agent of the present invention can be administered or transplanted into the body of a subject in need thereof. Transplantation is preferably performed in a region of the body where the differentiated cells or organoids of the present invention can be fixed at a fixed position, such as subcutaneously, intraperitoneally, into the peritoneal epithelium, bone tissue (e.g., jawbone tissue, etc.), cartilage tissue, omentum, adipose tissue, muscle tissue, or under the capsule of various organs such as the pancreas and kidney. The cells or organoids to be transplanted only need to be administered in a therapeutically effective amount, which may vary depending on factors such as the age, weight, size of the transplant site, and severity of the disease of the recipient, and are not particularly limited, but may be, for example, 10 × 10 4 Cell ~10×10 11 It can be as small as a cell.

[0096] The purpose of transplanting the differentiated cells or organoids of the present invention into a living body may be to directly regenerate damaged tissue, or to achieve indirect effects (e.g., paracrine effects) through factors secreted by the differentiated cells or organoids of the present invention. Mesenchymal stem cells can be therapeutically effective against diseases such as acute myocardial infarction, stroke, multiple system atrophy (MSA), graft-versus-host disease, Crohn's disease, ischemic cardiomyopathy, and spinal cord injury. Melanoblasts and melanocytes can be therapeutically effective against diseases such as oculocutaneous albinism and pigmentation disorders such as vitiligo vulgaris. Bone cells and bone organoids can be therapeutically effective against diseases such as intractable fractures, periodontitis, or extensive bone defects after osteotomy. Furthermore, neural progenitor cells, neurons, or neural organoids can be therapeutically effective against diseases such as cerebrovascular disorders, brain injury, spinal cord injury, and neurodegenerative diseases.

[0097] When the differentiated cells or organoids of the present invention are used as transplantation therapeutic agents, it is desirable to use cells or organoids derived from iPS cells established from somatic cells with the same or substantially the same HLA genotype as the recipient individual, in order to prevent rejection. Here, "substantially the same" means that the HLA genotype is identical to the transplanted cells to the extent that the immune response can be suppressed by immunosuppressants, such as somatic cells with HLA types that match the three loci of HLA-A, HLA-B, and HLA-DR, or four loci including HLA-C. If sufficient cells cannot be obtained due to age or constitution, they can be transplanted in capsules such as polyethylene glycol or silicone, porous containers, etc., to avoid rejection.

[0098] The differentiated cell or organoid of the present invention can be prepared as parenteral preparations such as injections, suspensions, infusions, etc., by mixing with pharmaceutically acceptable carriers according to conventional methods.Therefore, in one aspect, there is also provided a method for preparing transplantation therapy, which comprises the step of formulating the differentiated cell or organoid of the present invention.This method can also comprise the step of preparing the differentiated cell or organoid of the present invention.Furthermore, it can also comprise the step of preserving the differentiated cell or organoid of the present invention.

[0099] Pharmaceutically acceptable carriers that can be contained in such parenteral formulations include, for example, aqueous solutions for injection, such as physiological saline, isotonic solutions containing glucose or other adjuvants (e.g., D-sorbitol, D-mannitol, sodium chloride, etc.), etc. The cells of the present invention may be formulated with, for example, buffers (e.g., phosphate buffer, sodium acetate buffer), soothing agents (e.g., benzalkonium chloride, procaine hydrochloride, etc.), stabilizers (e.g., human serum albumin, polyethylene glycol, etc.), preservatives, antioxidants, etc.

[0100] The transplantation therapy agent of the present invention is provided in a cryopreserved state under conditions typically used for cryopreserving cells and can be thawed immediately before use. In this case, it may further contain serum or a serum substitute, an organic solvent (e.g., DMSO), etc. In this case, the concentration of the serum or serum substitute is not particularly limited, but may be about 1 to about 30% (v / v), preferably about 5 to about 20% (v / v). The concentration of the organic solvent is not particularly limited, but may be 0 to about 50% (v / v), preferably about 5 to about 20% (v / v).

[0101] In addition, the differentiated cells or organoids of the present invention can also be used in a method for screening candidate drugs that are useful for treating or preventing tissue damage or disease.Therefore, in another aspect of the present invention, a method for screening therapeutic or preventive drugs for disease is provided, comprising culturing the differentiated cells or organoids of the present invention in the presence or absence of a test substance.Such tissue damage or disease includes the same as the above-mentioned tissue damage or disease that is the therapeutic target of the transplantation therapeutic agent of the present invention.In addition, the differentiated cells or organoids used for screening may also exhibit the phenotype of a disease, for example, a bone disease such as osteogenesis imperfecta.In such a case, candidate drugs can also be screened based on the change in the phenotype.

[0102] Test substances used in screening methods include, for example, cell extracts, cell culture supernatants, microbial fermentation products, extracts derived from marine organisms, plant extracts, purified or crude proteins, peptides, non-peptide compounds, synthetic low molecular weight compounds, and natural compounds.

[0103] The test substance can also be obtained using any of the many approaches to combinatorial library technology known in the art, including (1) biological libraries, (2) synthetic library technology using deconvolution, (3) "one-bead one-compound" library technology, and (4) synthetic library technology using affinity chromatography selection. While the biological library technology using affinity chromatography selection is limited to peptide libraries, the other four approaches can be applied to small molecule compound libraries of peptides, non-peptide oligomers, or compounds (Lam (1997) Anticancer Drug Des. 12:145-67). Examples of methods for the synthesis of molecular libraries can be found in the art (DeWitt et al. (1993) Proc. Natl. Acad. Sci. USA 90:6909-13; Erb et al. (1994) Proc. Natl. Acad. Sci. USA 91:11422-6; Zuckermann et al. (1994) J. Med. Chem. 37:2678-85; Cho et al. (1993) Science 261:1303-5; Carell et al. (1994) Angew. Chem. Int. Ed. Engl. 33:2059; Carell et al. (1994) Angew. Chem. Int. Ed. Engl. 33:2061; Gallop et al. (1994) J. Med. Chem. 37:1233-51).Compound libraries can be stored in solution (see Houghten (1992) Bio / Techniques 13:412-21) or on beads (Lam (1991) Nature 354:82-4), chips (Fodor (1993) Nature 364:555-6), bacteria (U.S. Pat. No. 5,223,409), spores (U.S. Pat. Nos. 5,571,698, 5,403,484, and 5,223,409), plasmids (Cull et al. (1992) Proc. Natl. Acad. Sci. USA 89:1865-9), or phage (Scott and Smith (1990) Science 249:386-90; Devlin (1990) Science 249:404-6; Cwirla et al. (1990) Proc. Natl. Acad. Sci. USA 87:6378-82; Felici (1991) J. Mol. Biol. 222:301-10; U.S. Patent Application No. 2002103360).

[0104] The present invention will be explained in more detail below with reference to examples, but the present invention is not limited to these examples.

[0105] Example 1: Induction of NCC clusters <Maintenance culture of human iPS cells> Human iPS cells (1231A3 line, Ff-I 14s04 line, Ff-I 14s04 HLA-KO line, iPS cell line derived from an osteogenesis imperfecta patient) generated using episomal vectors were cultured on culture plates coated with iMatrix-511 (Nippi) using StemFit AK03N medium (Ajinomoto). The medium was changed every two days.

[0106] <Induction of iPS cells into NCC clusters> Figure 1 shows an overview of the method for inducing iPS cells into NCC clusters (three-dimensional (3D) NCC induction method). Specifically, the method was carried out as follows: Maintained human iPS cells (1231A3 strain (xeno-free cell line for research)) were dispersed into single cells using Accutase (Innovative Cell Technologies), then suspended in a culture medium containing StemFit Basic03 (AK03N minus bFGF) (Ajinomoto) and 10 μM Y-27632 (FUJIFILM Wako). 1.0 x 10 cells were cultured in a 96-well V-bottom ultra-low attachment culture plate (Sumitomo Bakelite). 4 The plates were seeded at 100 μl / well. The plates were centrifuged at 1200 rpm for 3 minutes, allowing the cells to aggregate on the bottom of the plate. After culturing for one day, the cells aggregated and formed cell clumps. The cell clumps were then cultured for one day in StemFit Basic03 medium supplemented with 10 μM SB431542 (Selleck) and 10 ng / mL BMP4 (R&D Systems) (this corresponds to steps D1 and D2 in Figure 1, and will be referred to below as the "SB and BMP treatment step"). The cell clumps were then individually transferred to a 48-well low-adhesion culture plate (Iwaki) and cultured at 120 rpm in a shaking culture vessel (CS-LR, TAITEC) in StemFit Basic03 medium supplemented with 10 μM SB431542 and 1 μM CHIR99021 (Axon Medchem) for 3 days (this corresponds to steps D2 and D3 in Figure 1, and will be referred to below as the "NCC induction step"). As a result, spherical cell clumps with a diameter of approximately 500 μm were obtained (Figures 1, 2A, 3, and 8A).

[0107] Characterization of NCCs: The percentage of CD271-positive cells in the resulting cell clumps was determined by flow cytometry. First, the cell clumps were dispersed into single cells using Accutase (Innovative Cell Technologies), and then treated with a CD271 antibody (BD Biosciences, 560326) diluted 200-fold in FACS buffer (PBS containing 0.1% human serum) at 4°C for 60 minutes. Isotype controls were included to eliminate nonspecific background signals. After antibody treatment, the cells were filtered through a 35 μm filter (Falcon) and analyzed by flow cytometry using a FACS Aria II (BD Biosciences) to determine the percentage of strongly CD271-positive cells. FCM data were visualized using FlowJo software (BD Biosciences). Flow cytometry revealed that the cell clumps contained a very high percentage of strongly CD271-positive cells (94.6%) (Figure 2B).

[0108] Next, the expression of CD271, SOX10, and PAX6 was confirmed in the cell clusters by immunostaining. First, the cell clusters were fixed with 4% paraformaldehyde in phosphate buffer and embedded in Tissue-Tek OCT compound (Sakura Finetech Japan). Thin sections were cut using a cryostat (Leica) to prepare 12 μm-thick frozen sections. After washing with PBS, the sections were permeabilized with 3% TritonX-100 (Sigma) at room temperature for 15 minutes. Blocking treatment was performed with Blocking One Histo (Nacalai Tesque) at room temperature for 1 hour. CD271 antibody (Advanced Targeting System, AB-N07), SOX10 antibody (R&D, AF2864), and PAX6 antibody (abcam, ab195945) were used in Can Get Signal TM The cells were incubated overnight at 4°C in an antibody dilution solution diluted 200-fold with Immunostain Solution B (TOYOBO). TMThe cells were incubated at room temperature for 3 hours in an antibody dilution solution diluted 200 times with Immunostain Solution B. Nuclear staining was performed using 4',6-diamidino-2-phenylindole (DAPI) (Dojindo Laboratories) for 10 minutes at room temperature. The samples were mounted in Antifade Mounting Medium (VECTOR LABORATORIES). The fluorescent signals of the samples were observed using an Olympus FV3000 confocal laser microscope (Olympus). Immunostaining revealed that the interior of the cell clusters was primarily composed of CD271- and SOX10-positive, PAX6-negative NCCs (Figure 2C). Furthermore, immunostaining confirmed the expression of CD271, SOX10, and PAX6 in the cell clusters on days 1 (D1) through 5 (D5) after the start of cell culture. Starting at D4 (2 days after the start of the NCC induction process), SOX10- and CD271-positive NCCs appeared, and the proportion of these NCCs increased at D5 (Figure 3).

[0109] We compared gene expression patterns between NCCs generated by conventional adherent culture (two-dimensional (2D) NCC induction method) and those generated by conventional adherent culture (Figure 4, top). For the 2D NCC induction method, iPS cells were cultured for 10 days in a medium containing 10 μM SB431542 and 1 μM CHIR99021 on six well plates coated with iMatrix-511. NCCs were isolated from the resulting NCC clusters by flow cytometry sorting for strongly CD271-positive cells (the resulting NCCs are abbreviated as "2D iNCC" or "2D 271H"). Similarly, for the 3D NCC induction method, NCCs were isolated from the D5 NCC clusters by flow cytometry sorting for strongly CD271-positive cells (the resulting NCCs are abbreviated as "3D iNCC" or "D5 271H") (Figure 4, center).

[0110] Next, the expression levels of NCC-related genes (NGFR, SOX10, TFAP2A, and PAX3) and the pluripotent cell marker POU5F1 (Oct4) were measured for each NCC by RT-qPCR. First, total RNA from the cell clusters was collected using the RNeasy Mini Kit (Qiagen), and genomic DNA was removed using the DNase-one Kit (Qiagen). Reverse transcription was performed using PrimeScript RT Master Mix (Takara) to synthesize single-stranded cDNA from 500 ng of total RNA. The cDNA was combined with Thunderbird SYBR qPCR Mix (TOYOBO) and analyzed using StepOnePlus TM RT-qPCR measurements were performed using a Real-Time PCR System (Applied Biosystems). Expression of NCC-related genes was similar in both 2D and 3D iNCCs, and expression of the pluripotent cell marker POU5F1 was lost in both NCCs (Figure 4, bottom). The primers used for RT-qPCR were the same as those listed in Supplementary Table 2 of Non-Patent Document 3.

[0111] In addition, we measured the expression levels of NCC-related genes (NGFR, SOX10, TFAP2A, and PAX3), neural plate border marker genes (DLX5 and MSX2), and the pluripotent cell marker Oct4 by RT-qPCR in cell clumps (not selected for CD271-high expressing cells) on days 0 (D0) through 5 (D5) after the start of cell culture, as well as in D5 271H and 2D 271H. The results are shown in Figures 5 and 6. Figure 5 shows that neural plate border-related markers increased 1 day after switching from the SB and BMP treatment process to the NCC induction process (D3). Figures 5 and 6 demonstrate that D5 cells express NCC-related genes at approximately the same levels as D5 271H cells and 2D 271H cells. Among the primers used in RT-qPCR, the nucleotide sequences of primers other than those listed in Supplementary Table 2 of Non-Patent Document 3 are shown in Table 1. Table 1 also lists the nucleotide sequences of primers used in Examples other than this Example (in the table, Fw indicates the forward primer, and Rev indicates the reverse primer).

[0112]

[0113] Similar NCC clusters were obtained when BMP2 (R&D Systems) or BMP7 (R&D Systems) were used at 10 ng / mL instead of BMP4 as the bone morphogenetic protein (Fig. 7).Furthermore, when A-83-01 (TOCRIS) was used at 1.0 μM instead of SB431542 as the ALK inhibitor, similar NCC clusters were obtained (Fig. 7).

[0114] In addition, NCC clusters were also obtained using iPS cell lines other than the 1231A3 line (Ff-I 14s04 line, Ff-I 14s04 HLA-KO line, and iPS cell lines derived from patients with osteogenesis imperfecta) (Figure 8). The seeding cell number and BMP4 concentration were adjusted for each cell line. Specifically, the Ff-I 14s04 line and the Ff-I 14s04 HLA-KO line were seeded at 3.0 × 10 3The iPS cell line derived from an osteogenesis imperfecta patient was seeded at 2.0 × 10 cells / 100 μl / well, and the BMP4 concentration was set at 2.5 ng / mL. 3 The cells were seeded at 100 μl / well, and the BMP4 concentration was set to 2.5 ng / mL.

[0115] In the conventional method, culture was performed under the same conditions as the 3D NCC induction method, except for the difference between adherent and suspension culture. Specifically, the procedure was as follows. iPS cells were cultured in a 6-well plate coated with iMatrix-511 in a medium containing 10 μM SB431542 and 1 μM CHIR99021 for 4 days (SB CHIR D4 in Figure 9), or in a medium containing 10 μM SB431542 and 10 ng / mL BMP4 for 1 day, followed by culture in a medium containing 10 μM SB431542 and 1 μM CHIR99021 for 3 days (SB BMP4 D1 SB CHIR D3 in Figure 9). Flow cytometry analysis of the resulting cell clusters showed that both cell clusters contained almost no highly CD271-expressing cells. We also evaluated the effect of shaking culture on the induction efficiency of NCCs in the 3D NCC induction method. The results showed that CD271-highly expressing NCCs were obtained with high efficiency (87.0%) even without shaking culture, but that the efficiency of CD271-highly expressing NCCs was further improved by performing shaking culture during the NCC induction step (Figure 9, bottom).

[0116] Example 2: Verification of culture conditions for NCC aggregation induction <Verification of the SB and BMP action processes 1> To explore the optimal action period of the SB and BMP action processes, the action periods of SB431542 and BMP4 were varied, and the variation in the CD271 strongly positive cell rate was verified by flow cytometry. In addition, the expression patterns of each gene of CD271 (NCC marker), PAX6 (neuroectoderm marker), and E-Cadherin (epithelial cell marker) were verified by immunostaining. At this time, the period of shaking culture was fixed. The results are shown in FIGS. 10 and 11. From FIG. 10, when the SB and BMP action processes were set to 1 day, NCCs were induced with high efficiency (A), but when the SB and BMP action processes were not performed and when the SB and BMP action processes were extended (performed for 2 days), a decrease in the CD271 strongly positive cell rate was observed (B and C). From FIG. 11, when the SB and BMP action processes were set to 1 day, CD271 strongly positive NCCs were induced with high efficiency, while PAX6- and E-Cadherin-positive cells were not induced (A). In addition, when the SB and BMP action processes were not performed, induction of PAX6-positive neuroectoderm was observed (B), and when the SB and BMP action processes were extended (performed for 2 days), induction of E-Cadherin-positive epithelial cells was observed around the cell aggregates.

[0117] <Verification of the SB and BMP action process 2> By varying the action periods of SB431542 and BMP4 and culturing for up to 10 days, the variation in the CD271 strongly positive cell rate was verified by flow cytometry. Also, the gene expression level of CD271 (NGFR) was measured by RT-qPCR. At this time, shaking culture was performed starting from the initiation of the NCC induction process. The outline of the method for inducing NCC aggregates from iPS cells is shown in Fig. 12. The results are shown in Figs. 13 to 16. From Fig. 13, when verified by flow cytometry on the 5th day after performing the SB and BMP action processes for 6 hours (SB BMP4 6h) or 12 hours (SB BMP4 12h), it was shown that the NCC induction efficiency decreased compared to the case where the SB and BMP action processes were for 1 day (SB BMP4 D1). This is presumably because, due to the short period of the SB and BMP action processes, not only NCCs but also neuroectoderm were induced simultaneously. Also, from Fig. 14, when verified by flow cytometry on the 5th day after performing the SB and BMP action processes for 2 days (SB BMP4 D2) or 3 days (SB BMP4 D3), it was shown that the NCC induction effect was high in both cases. On the other hand, when verified by flow cytometry on the 5th day without performing the SB and BMP action processes, it was shown that the NCC induction effect was low. From Fig. 15, when the culture period was extended to 7 days, it was shown that the CD271 expression in the entire cell population decreased regardless of the period of the SB and BMP action processes. This is presumably because the differentiation of NCCs into other cells progresses between 5 and 7 days of induction. Also, the RT-qPCR results also showed that the expression level of NGFR (CD271) decreased after the 5th day of culture (Fig. 16).

[0118] From the above, regarding the SB and BMP action processes, a pattern of a preferable method in terms of NCC induction efficiency is illustrated in Fig. 17.

[0119] <Verification of the NCC induction process> Next, the optimal action period of the NCC induction process was explored. When the NCC induction period was extended from 3 days to 5 days or 8 days, the CD271 strongly positive cell rate was verified by flow cytometry. As a result, it was shown that when the NCC induction period was extended, the CD271 strongly positive cell rate decreased in a time-dependent manner (Figure 18).

[0120] <Verification of shaking culture> Finally, the effect of shaking culture on the NCC induction efficiency was verified. Shaking culture was started from the start of the SB and BMP action processes, and the CD271 strongly positive cell rate was measured by flow cytometry on the 5th, 7th, and 10th days of culture. Also, the expression patterns of each gene of CD271 (NCC marker) and E-Cadherin (epithelial cell marker) were verified by immunostaining. At this time, the BMP action period was set to 6 hours, 12 hours, 1 day, or 2 days. An overview of the method for inducing NCC aggregates from iPS cells is shown in Figure 19. Also, the results are shown in Figures 20 to 22. From Figure 20, when shaking culture was performed from the start of the SB and BMP action processes, NCC could be induced on the 5th day in both the case where the SB and BMP action processes were 6 hours (SB BMP4 6h) and the case where they were twelve hours (SB BMP4 12h). However, in the case where the SB and BMP action processes were 12 hours, highly efficient induction to NCC comparable to the case where the SB and BMP action processes were 1 day (SB BMP4 D1) was shown. However, from immunostaining, when the SB and BMP action processes were performed for 1 day or 2 days, epithelial cells were observed around the cell aggregates on the 5th day (Figure 21). Furthermore, when the NCC induction process was extended to 7 days or 10 days, it was shown that the CD271 strongly positive cell rate decreased in both cases (Figure 22).

[0121] From the above, an overview of the preferred method in terms of NCC induction efficiency when shaking culture is performed from the start of the SB and BMP action processes is illustrated in Figure 23.

[0122] Example 3: Verification of the differentiation potential of NCC The differentiation potential of the NCCs obtained in Example 1 (NCC induction method of the present invention) was verified. An overview is shown in Figure 24. Specifically, the differentiation potential of the NCCs induced in Example 1 into peripheral neurons, melanoblasts, mesenchymal stem cells, and first pharyngeal arch ectomesenchymal cells was verified.

[0123] <Induction of Peripheral Neurons from NCC Clusters> An overview of this induction method is shown in Figure 25A. Specifically, the procedure was as follows. NCC clusters obtained in Example 1 were transferred to a 96-well U-bottom ultra-low attachment culture plate (Sumitomo Bakelite Co., Ltd.) and cultured for 14 days in induction medium containing Neurobasal medium (Thermo Fisher Scientific) supplemented with B27 supplement (Thermo Fisher Scientific), N-2 supplement (Thermo Fisher Scientific), 2 mM L-glutamine (FUJIFILM Wako), 10 ng / mL BDNF (FUJIFILM Wako), GDNF (FUJIFILM Wako), NT-3 (FUJIFILM Wako), and NGF (FUJIFILM Wako). The medium was changed every 3 days. Fluorescent immunostaining of Peripherin, a peripheral nerve cell marker, showed that the cells had differentiated into peripheral nerve cells (Fig. 26A).

[0124] <Induction of melanoblasts from NCC clumps> Methods for inducing melanoblasts from NCCs obtained by adhesion culture are known (e.g., Mica et al., Cell Reports, 2013; 3(4):1140-1152; Callahan et al., J. Vis Exp, 2016; (109): e53806, etc.), but these methods result in a large number of dead cells, and the induction efficiency varies and is not sufficient. Therefore, we investigated whether the NCC clumps obtained in Example 1 could be induced to differentiate into melanoblasts by suspension culture. An overview of this induction method is shown in Figure 25B. Specifically, the following procedure was performed. The NCC clusters obtained in Example 1 were transferred to a 96-well U-bottom ultra-low attachment culture plate (Sumitomo Bakelite Co., Ltd.) and cultured for 6 days in induction medium consisting of StemFit Basic03 medium supplemented with 1 μM CHIR99021, 25 ng / mL BMP4, and 100 nM Endothelin-3 (TOCRIS). The medium was replaced on day 3 of induction. Fluorescent immunostaining of the melanoblast marker MITF demonstrated differentiation into melanoblasts (Figure 26B).

[0125] <Induction of mesenchymal stem cells (MSCs) from NCC clumps> An overview of this induction method is shown in Figure 27. Specifically, the procedure was as follows. The NCC clumps obtained in Example 1 were dispersed into single cells using Accutase, and strongly CD271-positive cells were selected by flow cytometry. The selected cells were suspended in a culture medium containing StemFit Basic03 medium supplemented with 10 μM SB431542, 20 ng / mL Egf (FUJIFILM Wako), and Fgf2 (FUJIFILM Wako), and then plated at 1 x 10 cells on a fibronectin-coated culture plate. 4 cells / cm 2 The cells were seeded at a cell density of 1 × 10 and cultured. The medium was changed every 3 days. The second-passage NCCs were then dispersed into single cells using Accutase and suspended in StemFit Basic03 medium supplemented with 10 μM SB431542, 20 ng / mL Egf, and Fgf2. The cells were then plated on fibronectin-coated culture plates at a density of 1 × 104 cells / cm 2 One day after seeding, the medium was replaced with PRIME-XV MSC Expansion XSFM medium (Irvine Scientific) to initiate MSC induction. Cells were passaged every four days using Accutase, reaching a cell density of 1 × 10 4 cells / cm 2 The cells were seeded onto a culture plate so that the cells were differentiated into MSCs. On day 14 of the MSC induction culture, the expression of human MSC markers (CD105, CD90, CD73, and CD44) was confirmed by flow cytometry, demonstrating that the cells had differentiated into MSCs (Figure 28).

[0126] Induction of First Pharyngeal Arch Ectomesenchyme Cells from NCC Clusters During vertebrate development, NCCs detach from the dorsal prominence of the neural tube and subsequently migrate and differentiate into various organs within the developing embryo during neurulation, such as the first pharyngeal arch (PA1), second pharyngeal arch (PA2), third pharyngeal arch (PA3), and frontonasal process (FNP). However, no studies have demonstrated the selective induction of first pharyngeal arch ectomesenchyme (PA1-EM) cells from NCCs in vitro. The characteristics of PA1-EM are summarized in Figure 29.

[0127] To induce PA1-EM cells from NCC clusters, HOX gene expression in the NCC clusters must be negative. Therefore, we first confirmed HOX gene expression in the NCC clusters obtained in Example 1 using RT-qPCR. As a positive control, we prepared NCC clusters in which HOX gene expression was induced by retinoic acid (RA) stimulation. An overview of each method is shown in Figure 30A. HOX gene-positive NCC clusters were induced by culturing cells in medium containing 1.0 μM RA from day 4 of induction. Specifically, the procedure was as follows: From day 4 of NCC cluster induction, cells were cultured for 1 day in StemFit Basic03 medium supplemented with 10 μM SB431542, 1 μM CHIR99021, and 1.0 μM RA (Sigma). FOX gene-positive NCC clusters were induced by culturing for 1 day. Expression of NCC-related genes (NGFR, SOX10) in the NCC clusters was confirmed by RT-qPCR. The expression levels of NCC-related genes remained the same even after RA stimulation (Figure 30B). Next, we confirmed the expression of HOX genes (HOXA2, HOXA3) in NCC clusters by RT-qPCR. High HOX gene expression was observed in RA-stimulated NCC clusters, but no HOX gene expression was observed in RA-unstimulated NCC clusters (Figure 30C). The base sequences of the primers used in RT-qPCR, other than those listed in Supplementary Table 2 of Non-Patent Document 3, are shown in Table 1.

[0128] Next, PA1-EM cells were induced from NCC clusters. An outline of the induction method is shown in Figure 31. Figure 8 shows the addition of factors necessary for cell survival and proliferation, Edn-1 (Endothelin-1), a factor required for mandibular selection, and BMP4, a factor required for distal induction, to the culture medium. Specifically, the procedure was as follows: NCC clusters were cultured in StemFit Basic03 medium supplemented with 50 nM Endothelin-1 (Sigma), 100 ng / mL Fgf8b (FUJIFILM Wako), and 2.5 ng / mL BMP4 in a shaking culture vessel for 4 days. Induction of PA1-EM cells was confirmed by morphology and immunofluorescence staining for the precocious mesenchymal cell marker TWIST1 and the first pharyngeal arch mandibular process ectodermal mesenchymal marker DLX5. The results are shown in Figure 32. Micrographs of PA1-EM cell clusters induced from NCC clusters showed that the size of the clusters increased due to proliferation of internal cells (A). Immunofluorescence staining for SOX10 and TWIST1 confirmed a significant decrease in SOX10 expression upon induction of PA1-EM cells, confirming differentiation into TWIST1-positive ectomesenchymal cells (B). Immunofluorescence staining for DLX5 also demonstrated that the induced ectomesenchymal cells highly expressed DLX5, recapitulating the genetic characteristics of PA1-EM cells. PA1-EM cells were also successfully induced from iPS cell lines from patients with osteogenesis imperfecta (OPA) (Figure 33).

[0129] We further confirmed the necessity for HOX-negative NCCs for PA1-EM cell induction. PA1-EM cell induction was performed using NCCs induced without RA treatment (HOX(+) NCCs) and NCCs induced with RA treatment to express HOX genes (HOX(-) NCCs). The outline of each method is shown in Figure 34 (top). The expression levels of HOXB2 and DLX5 in each PA1-EM cell line were measured by RT-qPCR. No increase in DLX5 expression was observed in PA1-EM cell lines induced with HOX-expressing NCCs (Figure 34 (bottom)). Furthermore, when PA1-EM cell induction was performed using NCCs obtained by adherent culture (2D) in the presence of the same additives, significantly lower PRRX1 and DLX5 expression was observed (Figure 35 (top)). An outline of this method is shown in Figure 35 (bottom). These results demonstrate the importance of starting with NCCs obtained by suspension culture (3D) for efficient PA1-EM cell induction. The base sequences of the primers used in RT-qPCR are shown in Table 1.

[0130] <Verification of Culture Conditions for PA-EM Cell Induction from NCC Clusters> The optimal combination of Fgf8, Edn-1, and BMP4 for PA1-EM cell induction was verified by RT-qPCR. Because the absence of Fgf8 induced significant cell death, its addition was necessary under all conditions. An overview of each method is shown in Figure 36. Figure 37 also shows the expression levels of DLX, PRRX1, and TWIST1 in cells obtained by each method. Figure 37 demonstrates that Edn-1 is essential for DLX5 expression, a finding that mirrors previously reported animal experiments. Furthermore, the expression levels of DLX5, PRRX1, and TWIST1 indicated that the addition of Fgf8, Edn-1, and BMP4 to the culture medium was optimal for PA1-EM cell induction. The primer sequences used for RT-qPCR are shown in Table 1.

[0131] Example 4: Verification of the ability of PA1-EM cell clusters to induce patterning within the first pharyngeal arch. <Induction into cells on the proximal-oral side of the first pharyngeal arch> PA1-EM cells are known to undergo patterning induction in response to epithelial signals (Figure 39A). Therefore, we verified whether PA1-EM cells obtained by the above method have the ability to induce patterning within the first pharyngeal arch. PA1-EM cell clusters were induced into cells on the proximal-oral side of the first pharyngeal arch (molar tooth-forming region). An overview of the induction method is shown in Figure 38 (top). Specifically, the procedure was as follows: PA1-EM cell clusters obtained in Example 3 were transferred to a 96-well U-bottom ultra-low attachment culture plate. To induce the development of proximal-oral first pharyngeal arch cells, PA1-EM cell clusters were cultured for 3 days in StemFit Basic03 medium supplemented with 100 ng / mL FGF8b, 400 nM SAG (Selleck), 1.0 μM BQ-123 (Selleck), and 0.5 μM LDN193189 (TOCRIS). RT-qPCR analysis of the proximal-oral first pharyngeal arch markers PAX9 and LHX8 confirmed the induction of proximal-oral first pharyngeal arch cells (Figure 39B). The primer sequences used for RT-qPCR are listed in Table 1.

[0132] <Induction of Cells on the Distal-Abdominal Side of the First Pharyngeal Arch> PA1-EM cell clusters were induced to become cells on the distal-abdominal side of the first pharyngeal arch (the region of origin of ossification in the jaw bone). An outline of the induction method is shown in the bottom of Figure 38. Specifically, PA1-EM cell clusters obtained in Example 3 were cultured for 3 days in an induction medium containing StemFit Basic03 medium supplemented with 20 ng / mL FGF2, 50 nM Endothelin-1, and 10 ng / mL BMP4. RT-qPCR analysis of GSC and MSX2, markers for the distal-abdominal side of the first pharyngeal arch, confirmed the induction of cells on the distal-abdominal side of the first pharyngeal arch (Figure 39C).

[0133] Example 5: Induction of Jaw Bone-Like Tissue and Transplantation of the Tissue into Mice <Induction of Jaw Bone-Like Tissue from Jaw Bone Ossification Origin Cells> The PA1-EM cell clusters obtained in Example 3 were subjected to stepwise osteogenic differentiation induction to induce jawbone-like tissue. An outline of the induction method is shown in Figure 40. Specifically, PA1-EM cell clusters were first cultured for 3 days in an induction medium containing StemFit Basic03 medium supplemented with 20 ng / mL Egf, Fgf2, 50 ng / mL BMP2, 3 μM CHIR99021, and 400 nM SAG to induce osteoprogenitor cells. RT-qPCR of osteoprogenitor cell markers SP7, RUNX2, and DLX5 confirmed the induction of osteoprogenitor cells (Figure 41A). Furthermore, RT-qPCR for the early osteoblast marker ALPL and the immature osteocyte marker E11 / gp38 showed that differentiation had not progressed to osteoblasts or osteocytes (Figure 41B).

[0134] To induce jawbone-like tissue, the cell clusters were cultured in MSCgo Osteogenic SF,XF (Sartorius) for 16 days and then cultured for 8 days in osteogenic differentiation medium (StemFit Basic03 medium supplemented with 10 nM dexamethasone (Sigma), 10 mM β-glycerophosphate (Sigma), and 50 μg / ml ascorbic acid (Sigma). The results confirmed further increased expression of osteoprogenitor markers SP7, RUNX2, and DLX5 (Figure 42). Furthermore, RT-qPCR analysis of the osteoblast marker ALPL and osteocyte markers E11 / gp38, DMP1, PHEX, and SOST confirmed the induction of bone differentiation (Figure 43). The resulting jawbone-like tissue was histologically observed using Alizarin Red staining (Figure 44A) and HE staining (Figure 44B). Furthermore, fluorescent immunostaining for F-actin was performed, and the formation of an osteocyte network within the jawbone-like tissue was confirmed (Fig. 44C).

[0135] <Transplantation of Jaw Bone-Like Tissue into Jaw Bone Defects in Immunodeficient Mice> To investigate the regenerative effects of transplanting the obtained jawbone-like tissue into jawbone defects, we evaluated its effects using an immunodeficient NSG mouse jawbone defect model. Specifically, a 1.6 mm diameter bone defect was created in the mandibular ramus of the right mandibular angle of the jawbone of an NSG mouse using a round burr. An image of the jawbone with the bone defect and a micro-CT image are shown in Figure 45 (top). Two jawbone-like tissues were then directly transplanted into the defect without the use of an artificial scaffold. Time-lapse micro-CT imaging was performed immediately after transplantation and at 1, 2, 3, and 4 weeks to observe the regeneration of the defect (Figure 45 (bottom)). The results showed that bone-like structures had formed in most of the jawbone defect 4 weeks after transplantation.

[0136] In the following examples, experiments were performed according to the following procedure. <Culture and Maintenance of Human iPSCs> Human induced pluripotent stem cells (iPSCs) reprogrammed with episomal vectors were maintained under feeder-free and xeno-free conditions as previously described (Nakagawa, M. et al. Nakagawa, M. et al. A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells. Sci. Rep. 4, 1-7 (2014)). iPSCs were cultured on cell culture plates coated with iMatrix-511 (human laminin-511 E8 fragment; Nippi, Tokyo, Japan) in StemFit AK03N medium (Ajinomoto, Tokyo, Japan). Upon reaching approximately 80% confluence, cells were detached and dissociated into single cells using Accutase (Innovative Cell Technologies, CA, USA), usually every 4–5 days. After centrifugation, the cells were resuspended in StemFit AK03N supplemented with 10 μM Y-27632 (ROCK inhibitor; Fujifilm Wako, Tokyo, Japan) and seeded onto iMatrix-511-coated culture plates. The next day, the medium was replaced with fresh StemFit AK03N without Y-27632. Thereafter, the medium was replaced every 2 days until the next passage. The following human iPSC lines were used in the following examples: 1231A3, HLA homozygous iPSCs (Ff-I 14s04, Ff-I 01s04), provided by the Kyoto University iPS Cell Research Foundation; Ff-14s04, in which the human leukocyte antigen (HLA)-A, -B, and -CIITA genes were knocked out (HLA-KO Ff-I 14s04: clone Ff-I 14s04-AB II-KO-13); and iPSCs derived from an osteogenesis imperfecta (OI) patient (OI-iPSC: clone OI08-12, which exhibits a point mutation in the splicing donor site of intron 32 of COLIA1 (c.2235+1G>A) and is classified as silence type III.); OI-iPSCs with rescued mutations (resOI-iPSCs) (Kawai, S. et al. Nat. Biomed. Eng. 3, 558-570 (2019)).

[0137] <Induction of iPSCs into NCCs under Three-Dimensional (3D) Conditions> To initiate aggregation culture, iPSCs were detached from the culture dish using Accutase and dissociated into single cells. These cells were rapidly reaggregated in 100 μl of StemFit Basic03 (equivalent to AK03N without bFGF, Ajinomoto) supplemented with 10 μM Y-27632 in a 96-well V-bottom ultra-low cell attachment plate (Sumitomo Bakelite Co., Ltd., Tokyo, Japan). The cell concentrations used for aggregation culture were as follows: 1231A3 (1.0 × 10 4 cells / well), Ff-1 14s04, HLA-KO Ff-1 14s04, Ff-1 014s04, OI-iPSCs, and resOI-iPSCs (3.0 × 10 3Cells / well). Cell number was measured using a Countess II FL (Thermo Fisher Scientific, Tokyo, Japan). Aggregation was promoted by centrifugation at 1200 rpm for 3 minutes (day 0). For neural crest cell (NCC) induction, these cell aggregates were maintained in a 37°C incubator with 5% CO2. After 24 hours (day 1), the culture medium was replaced with 150 μl of StemFit Basic03 containing 10 μM SB431542 (TGF-β inhibitor; Fujifilm Wako) and BMP4 (R&D Systems, MN, USA) (1231A3, Ff-I 14s04, HLA-KO Ff-I 14s04 (10 ng / ml); Ff-I 01s04, OI-iPSCs, resOI-iPSCs (2.5 ng / ml)). After another 24 h (day 2), the aggregates were individually collected, transferred to 48-well uncoated plates (IWAKI, Tokyo, Japan), and cultured in 250 μl of StemFit Basic03 containing 10 μM SB431542 and 1 μM CHIR99021 (GSK-3β inhibitor, Axon Medchem, VA, USA) on an orbital shaker (CS-LR; TAITEC, Saitama, Japan) (120 rpm) from days 2 to 4.

[0138] For HOX-negative NCC induction, aggregates were cultured without medium change from day 4 to day 5. For HOX-positive NCC induction, day 4 aggregates were cultured from day 4 to day 5 in 250 μl of StemFit Basic03 containing 10 μM SB431542, 1 μM CHIR99021, and 10 nM all-trans retinoic acid (RA) (Fujifilm Wako).

[0139] To investigate the effect of BMP4 treatment duration on NCC induction, 1231A3 iPSCs were aggregated in 96-well V-bottom ultra-low cell attachment plates (10,000 cells / well) in medium containing 10 μM Y-27632. After 24 h (day 1), to assess whether BMP4 treatment affected NCC induction efficiency, the culture medium was replaced with StemFit Basic03 containing 10 μM SB431542 and 1 μM CHIR99021, with or without BMP4. After 24 h, the aggregates were transferred to 48-well plates and cultured in medium containing 10 μM SB and 1 μM CHIR at 120 rpm on an orbital shaker from days 2 to 5. To test whether prolonged BMP4 treatment affected the efficiency of NCC induction, day 1 aggregates were cultured in medium containing 10 μM SB and 10 ng / ml BMP4 for 2 days and then transferred to 48-well plates and cultured in medium containing 10 μM SB and 1 μM CHIR on an orbital shaker at 120 rpm from days 3 to 5.

[0140] Induction of NCCs from iPSCs in Two-Dimensional (2D) Conditions: NCCs were induced from 1231A3 iPSCs in 2D conditions according to a previously established protocol (Non-Patent Document 3). Briefly, iPSCs were cultured on iMatrix-511-coated culture plates at a density of 3.6 × 10 cells / well in StemFit AK03N medium. 3 cells / cm 2 For NCC induction, cells were cultured in StemFit Basic03 supplemented with 10 μM SB431542 and 1 μM CHIR99021 for 10 days, with medium changes every 2 days.

[0141] <Differentiation of NCC clusters> On day 5, NCC clusters were transferred to a 96-well U-bottom ultra-low cell attachment plate (Sumitomo Bakelite).

[0142] For peripheral neuronal differentiation, NCC clusters were cultured in Neurobasal medium (Thermo Fisher Scientific) supplemented with B27 supplement (Thermo Fisher Scientific), N-2 supplement (Thermo Fisher Scientific), 2 mM L-glutamine (Fujifilm Wako), and 10 ng / ml each of BDNF, GDNF, NT-3, and NGF (Fujifilm Wako) for 14 days with medium changes every 3 days. Differentiation was confirmed by immunostaining with anti-peripherin and anti-class III β-tubulin antibodies.

[0143] For melanoblast differentiation, NCC clusters were cultured in Stemfit Basic03 supplemented with 1 μM CHIR99021, 25 ng / ml BMP4, and 100 nM endothelin-3 (TOCRIS, Bristol, UK) for 6 days, with medium changes every 3 days. Differentiation was confirmed by immunostaining with anti-MITF antibody.

[0144] For mesenchymal stem / stromal cell (MSC) differentiation, NCC clumps were first dissociated into single cells with Accutase and plated onto fibronectin-coated plates (Millipore, Darmstadt, Germany) at 1.0 × 10 cells. 4 cells / cm 2 Cells were seeded at a density of 1.0 × 10 cells / well. Cells were cultured in StemFit Basic03 supplemented with 10 μM SB431542, 20 ng / ml each of EGF (Fujifilm Wako) and FGF2 (Fujifilm Wako). The medium was changed every 3 days, and cells were passaged before reaching subconfluence. Expanded cells (passage 2 (PN2)) were cultured at a density of 1.0 × 10 cells / well in StemFit Basic03 supplemented with 10 μM SB431542, 20 ng / ml each of EGF and FGF2. 4 cells / cm 2The cells were seeded onto fibronectin-coated plates at a density of 100 μg / ml. After 24 hours, the medium was replaced with PRIME-XV MSC Expansion XSFM medium (FUJIFILM Irvine Scientific). Passages were performed every 3 or 4 days. At PN2, MSC differentiation was confirmed by FACS analysis using human MSC markers (positive markers: CD105, CD90, CD73, CD44, CD29; negative markers: CD45, CD34, HLA-DR). To confirm the differentiation potential of the induced MSC-like cells, osteogenic, chondrogenic, and adipogenic inductions were performed, and the cells were stained with alizarin red, alcian blue, and oil red O, respectively, as previously described (Non-Patent Document 3).

[0145] <Induction of mdEM from HOX-negative NCC clusters> To initiate induction of mandibular process ectodermal mesenchyme (mdEM), HOX-negative NCC clusters (day 5) were cultured in 350 μl of StemFit Basic03 supplemented with 100 ng / ml FGF8b (Fujifilm Wako), 50 nM endothelin-1 (PEPTIDE INSTITUTE, Osaka, Japan), and 2.5 ng / ml BMP4 on an orbital shaker at 120 rpm from day 5 to day 9.

[0146] To assess the effect of EDN1 signaling on branching of maxillary process ectodermal mesenchyme (mxEM) and mdEM, NCC clusters were cultured in 350 μl of StemFit Basic03 supplemented with 100 ng / ml FGF8b and 10 μM BQ-123 (endothelin A receptor antagonist; Selleck, Tokyo, Japan) on an orbital shaker at 120 rpm from day 5 to day 12, with the medium replaced on day 9.

[0147] To investigate the importance of early anterior-posterior (AP) identity of NCCs in mdEM differentiation, RA-treated NCCs were cultured in 350 μl of StemFit Basic03 supplemented with 100 ng / ml FGF8b, 50 nM endothelin-1, and 2.5 ng / ml BMP4 from day 5 to day 9 on an orbital shaker at 120 rpm.

[0148] To evaluate the effects of FGF8, EDN1, and BMP4 under 2D conditions on 2D-induced NCCs, we used CD271 high+ NCCs sorted in 1.0 × 10 were plated on fibronectin-coated plates. 4 cells / cm 2 The cells were seeded at a density of 100 ng / ml FGF8b, 50 nM endothelin-1, and 2.5 ng / ml BMP4 and cultured for 4 days in StemFit Basic03 medium supplemented with 100 ng / ml FGF8b, 50 nM endothelin-1, and 2.5 ng / ml BMP4.

[0149] To investigate the effects of FGF8, EDN1, and BMP4 on 2D NCCs in a 3D setting, CD271 high+ NCCs sorted in 1.0 x 10 cells were plated in a 96-well V-bottom ultra-low cell attachment plate. 4 Cells were rapidly aggregated at a density of 100 cells / well in 100 μl of StemFit Basic03 supplemented with 100 ng / ml FGF8b, 50 nM endothelin-1, and 2.5 ng / ml BMP4 and cultured for 4 days. <Induction of mdEM derivatives> mdEM aggregates (day 9) were transferred to 96-well U-bottom ultra-low cell attachment plates (Sumitomo Bakelite).

[0150] For induction of distal cap domains, mdEM aggregates were cultured in 200 μl of StemFit Basic03 supplemented with 50 nM endothelin-1, 20 ng / ml FGF2, and 25 ng / ml BMP4 from day 9 to day 13, with a medium change on day 11.

[0151] For proximal oral domain induction, cells were cultured in 200 μl of StemFit Basic 03 supplemented with 100 ng / ml FGF8b, 400 nM SAG (Smoothened Agonist, Selleck), 10 μM BQ-123, and 500 nM LDN193189 (ALK2 / 3 inhibitor, TOCRIS) from days 9 to 13, with the medium replaced on day 11. For dental mesenchymal induction, the proximal oral domain induction medium was then replaced with 200 μl of StemFit Basic 03 supplemented with 100 ng / ml FGF8b, 400 nM SAG, 3 μM CHIR99021, and 30 ng / ml activin A (R&D). Dental mesenchymal induction was performed from days 13 to 17, with the medium replaced on day 15.

[0152] <Generation of jawbone-like organoids from mdEM> mdEM aggregates (day 9) were transferred to 96-well U-bottom ultra-low cell attachment plates. mdEM were cultured for 3 days in 200 μl of StemFit Basic03 supplemented with 20 ng / ml EGF and FGF2, 50 ng / ml BMP2 (R&D), 3 μM CHIR99021, and 400 nM SAG. On day 12, the differentiation medium was replaced with 200 μl of MSCgo Osteogenic Differentiation Medium (SARTORIUS, Göttingen, Germany), and the clusters were cultured for 7 days. On day 19, the differentiation medium was replaced with 200 μl of StemFit Basic03 supplemented with 10 mM β-glycerophosphate disodium salt hydrate (Sigma, MO, USA), 250 μM L-ascorbic acid 2-phosphate sesquimagnesium salt hydrate (Sigma), 100 nM dexamethasone (Sigma), 50 ng / ml BMP2 (R&D), 3 μM CHIR99021, and 400 nM SAG, and the clusters were cultured for 7 days. From days 26 to 38, the clusters were cultured in MSCgo Osteogenic Differentiation Medium, and the medium was changed every 2 days.

[0153] To induce chondrogenic differentiation in 3D conditions, mdEM aggregates (day 9) were transferred to 96-well U-bottom ultra-low cell attachment plates and cultured in MSCgo Chondrogenic XF (SARTORIUS) for 21 days. Chondrogenic differentiation was confirmed by Safranin O / Fast Green staining and immunofluorescence analysis using anti-COLX antibody.

[0154] <Induction of Smooth Muscle Cells from NCC Clusters> An overview of this induction method is shown in Figure 69. Specifically, the induction method was carried out as follows. The NCC clusters obtained in Example 1 were dispersed into single cells using Accutase, and strongly CD271-positive cells were selected by flow cytometry. The selected cells were suspended in a culture medium containing StemFit Basic03 medium supplemented with 10 µM SB431542, 20 ng / mL Egf (FUJIFILM Wako), and Fgf2 (FUJIFILM Wako), and then plated at 1 x 10 cells on a fibronectin-coated culture plate. 4 cells / cm 2 The cells were seeded at a cell density of 1 × 10 and cultured for 5 days. Then, NCCs were dispersed into single cells using Accutase and suspended in StemFit Basic03 medium supplemented with 2 ng / ml TGF-β1 and 50 nM Endothelin-1. The cells were plated on fibronectin-coated culture plates at a cell density of 1 × 10 4 cells / cm 2 The cells were seeded at a cell density of 1 × 10 to induce differentiation into smooth muscle cells. 4 cells / cm 2 The cells were seeded onto culture plates so that the cells were cultured. On day 10 of the smooth muscle cell induction culture, the expression of smooth muscle markers was confirmed by immunostaining and RT-qPCR.

[0155] Flow cytometry analysis and cell sorting. Flow cytometry was performed using a BD FACSAria II v1.87 (BD Biosciences, NJ, USA) according to the manufacturer's instructions. Cell aggregates or 2D-cultured cells were dissociated using Accutase, washed with FACS buffer (PBS containing 1% human serum albumin), and filtered through a 35 μm filter (Corning, NY, USA). Cells were then pelleted by centrifugation (1200 rpm, 3 min, 4°C) and resuspended in FACS buffer containing the appropriate antibody, followed by a 60-minute incubation at 4°C. Isotype controls were included in all experiments to eliminate nonspecific background signals. After antibody incubation, cells were washed with FACS buffer, pelleted, and washed again. Finally, cells were resuspended in FACS buffer and collected through a filter. Flow cytometry and sorting were performed on a BD FACSAria II. The data were collected using FACSDiva_v9.0.1 and analyzed using FlowJo_v10.8.1 software (BD Biosciences). Details of the antibodies used are shown in Table 2.

[0156]

[0157] Real-time quantitative PCR analysis. RNA was extracted by lysing cell aggregates or 2D-cultured cells with RLT Plus Buffer. Total RNA was purified using the RNeasy Micro Kit (QIAGEN, Venlo, The Netherlands) and treated with the RNase-Free DNase Set (QIAGEN) to remove genomic DNA. Subsequently, 0.5 μg of total RNA was reverse transcribed into single-stranded cDNA using SuperScript III Reverse Transcriptase (Invitrogen, MA, USA) according to the manufacturer's instructions. Real-time quantitative PCR (RT-qPCR) was performed using the QuantStudio 12K Flex Real-Time PCR System and StepOnePlus Real-Time PCR System_v2.3 (Applied Biosystems, MA, USA) with THUNDERBIRD Next SYBR qPCR Mix (TOYOBO, Osaka, Japan) and gene-specific primers. Cycling parameters were as follows: initial denaturation (95°C, 1 min), followed by 45 cycles of amplification and SYBR signal detection (denaturation at 95°C, 3 s; annealing at 60°C, 30 s; extension at 72°C, 30 s). A final step was performed at the end of each qPCR run to generate a dissociation curve. Data were analyzed using a 2-step PCR protocol. -ΔΔCt The results were analyzed using the ELISA method and visualized using GraphPad Prism 9_v9.5.1 software. Examples of primer sequences used include those listed in Table 1 above and Supplementary Table 2 of Non-Patent Document 3. All other sequences were publicly known.

[0158] RNA-seq Analysis: To perform RNA-seq analysis, total RNA was extracted using the RNeasy Micro Kit and treated with an RNase-Free DNase Set to remove genomic DNA contamination. Subsequently, 10 ng of total RNA was reverse transcribed to generate single-stranded cDNA using the SuperScript VILO cDNA Synthesis Kit (Thermo Fisher Scientific). For construction of an Ion AmpliSeq Transcriptome-targeted NGS library, the Ion AmpliSeq Transcriptome Human Gene Expression Panel, Chef-Ready Kit (Thermo Fisher Scientific), and Ion Chef (Thermo Fisher Scientific) instrument were used according to the manufacturer's protocol. Briefly, a reverse transcription master mix was prepared by combining 5X VILO Reaction Mix and 10X SuperScript III Enzyme Mix. The mixture was then aliquoted into reaction plates, and 10 ng of total RNA was added to each. The plate was loaded into a thermal cycler and incubated at 42°C for 30 minutes, followed by 85°C for 5 minutes, and then held at 10°C.

[0159] During library preparation on the Ion Chef instrument, the following consumables and cartridges were loaded: Ion AmpliSeq Chef Solutions DL8 cartridge, Ion AmpliSeq Chef Reagents DL8 cartridge, Ion AmpliSeq Tip Cartridge L8, PCR Frame Seal, IonCode 96-Well PCR Plate, PCR Plate Frame, Empty Tip Cartridge L8, and Enrichment Cartridge. Specifically, the IonCode 96-Well PCR Plate used for reverse transcription contained an IonCode barcode adapter. Additionally, a tube containing the Ion AmpliSeq Transcriptome Human Gene Expression Panel was inserted into the Ion AmpliSeq Chef Reagents DL8 cartridge. Multiplex PCR was performed in the Ion Chef instrument's thermal cycler, with 13 16-minute annealing / extension cycles. Subsequent steps included digestion of primers with FUPA reagent, ligation of IonCode barcode adapters, purification of the library using magnetic beads, homogenization of library concentration, and mixing in a single tube.

[0160] Following library preparation, Ion Chef facilitated template preparation and ISP bead loading onto the Ion 540 Chip Kit. NGS sequencing was performed using the Ion GeneStudio S5 Prime sequencer (Thermo Fisher Scientific). Read counts were calculated using the AmpliSeq RNA Plugin, and data analysis was performed using R studio_v2023.06.1+524 software with the "DESeq2" package for normalization to detect significantly differentially expressed genes (p ≤ 0.05) (Love, MI, Huber, W. & Anders, S. Genome Biol. 15, 1-21 (2014)). Differentially expressed genes (DEGs) were identified by pairwise comparison with a false discovery rate (FDR) < 0.05. Gene set enrichment analysis (GSEA) based on Gene Ontology (GO) terms was performed using the integrated Differential Expression and Pathway analysis (iDEP) software (Ge, SX, Son, EW & Yao, R. BMC Bioinformatics 19, 1-24 (2018)) (version 9.6).

[0161] Immunocytochemistry: Cells cultured on dishes were fixed with 4% paraformaldehyde (PFA) for 30 minutes at room temperature (RT) and permeabilized with 0.3% Triton-X-100 (Sigma) in PBS for 15 minutes at room temperature. Subsequently, cells were treated with Blocking One solution (Nacalai Tesque, Kyoto, Japan) for 1 hour at room temperature and then incubated overnight at 4°C with primary antibodies diluted in 10% (v / v) Blocking One in PBS-T (PBS containing 0.1% Tween-20 (Sigma)). After this, cells were incubated with secondary antibodies diluted in 10% Blocking One in PBS-T for 2 hours at room temperature. Nuclei were then counterstained with 4',6-diamidino-2-phenylindole (DAPI) (1:5000; DOJINDO, Kumamoto, Japan) for 15 minutes at room temperature. After washing with PBS, fluorescent signals were observed using a fluorescence microscope (BZ-X800, Keyence, Osaka, Japan). The primary and secondary antibodies used are listed in Table 3.

[0162]

[0163] Alizarin Red and Von Kossa Staining: Fixed samples were embedded in paraffin and sectioned into 8-μm-thick slices. Alizarin Red staining was performed by incubating the sections with 1% Alizarin Red (MUTO PURE CHEMICALS CO., LTD., Tokyo, Japan) at room temperature for 3 minutes. Von Kossa staining was performed using a Calcium Stain Kit (Improved Von Kossa; ScyTek Laboratory, Inc., UT, USA) according to the provided manual. Osteogenesis was assessed using a light microscope.

[0164] Histological Analysis of In Vitro Samples: Cell aggregates and clusters were fixed in 4% PFA for 3 hours at room temperature (day 26 and day 38 samples were fixed for 6 hours). Except for Alizarin Red and von Kossa staining, osteogenic induction samples (days 19–38) were decalcified overnight at room temperature using Decalcifying Solution B (Fujifilm Wako). For hematoxylin-eosin (HE) staining, Azan staining, and Safranin O / Fast Green staining, samples were dehydrated in graded ethanol, cleared in Histo-clear (National Diagnostics, Georgia, USA), and embedded in paraffin. 8-μm-thick sections were then prepared, stained using standard protocols, and subsequently examined under a light microscope.

[0165] For immunofluorescence analysis, decalcified samples were embedded in Tissue-Tek OCT compound (Sakura Finetek, Tokyo, Japan) and 20 μm-thick sections were prepared using a cryostat (CM1950; Leica, Tokyo, Japan). These sections were washed with PBS, permeabilized with 0.3% Triton-X-100 in PBS for 20 minutes at room temperature, and then treated with Blocking One Histo solution (Nacalai Tesque) for 1 hour at room temperature. Primary antibodies diluted in antibody working solution (Can Get Signal Immunostain solution B; TOYOBO) were incubated with the sections overnight at 4°C. After washing, the sections were incubated with secondary antibodies diluted in antibody working solution for 4 hours at room temperature. After counterstaining with DAPI for 15 minutes and washing with PBS, the sections were mounted in VECTASHIELD mounting medium (Vector, CA, USA) and subjected to confocal microscopy (FV3000, Olympus, Tokyo, Japan). Confocal imaging data were analyzed using FV31S-SW software (Olympus). The primary and secondary antibodies used are listed in Table 3.

[0166] To visualize denatured COLI, 5-FAM-conjugated collagen hybridizing peptide (F-CHP) (3Helix, Inc., UT, USA) was used according to the manufacturer's instructions. Frozen sections were treated with blocking solution 2, incubated with 15 μM F-CHP in PBS overnight at 4°C, and then incubated with secondary antibodies and DAPI as described above. Fluorescent signals were detected using a confocal microscope.

[0167] Cell viability. To assess cell viability, cell aggregates were assessed using the Cyto3D Live-Dead Assay Kit (TheWell BIOSCIENCE, NJ, USA) according to the manufacturer's instructions. Briefly, 2 μL of Cyto3D reagent was added to each well, and then the aggregates were incubated at 37°C for 15 minutes. Fluorescent signals were observed using a fluorescent microscope. To identify apoptotic cells, sectioned samples were subjected to Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining (DeadEnd Fluorometric TUNEL System; Promega, WI, USA) according to the manufacturer's instructions. Nuclei were counterstained with DAPI, and fluorescent signals were visualized using a confocal microscope. TUNEL-positive cells were quantified using ImageJ_v1.54f software (NIH, MD, USA).

[0168] Transplantation: Eight-week-old male NOD / Scid / IL2Rγ (NSG) mice were used as recipients for mandible-like organoid transplantation under the kidney capsule. Mice were anesthetized with an intraperitoneal injection of a combination of medetomidine hydrochloride (0.3 mg / kg), midazolam (4 mg / kg), and butorphanol tartrate (5 mg / kg). After shaving and disinfecting the skin at the surgical site, mandible-like organoids (day 38: 1231A3, OI-iPSC, and resOI-iPSC-derived) were transplanted under the kidney capsule of each mouse without artificial materials (n = 6 / group). The incision was closed with 5-0 monofilament sutures (Bearmedic, Ibaraki, Japan). Four weeks after transplantation, the mice were euthanized with CO2, and the transplanted tissues were retrieved after micro-computed tomography (micro-CT) scanning.

[0169] For jawbone-like organoid transplantation into jawbone defects, 12-week-old male NSG mice were used as recipients. After a 10 mm skin incision was made to expose the right hemimandible, a 2 mm diameter circular defect was created at the mandibular angle using a microengine (VOLVER i7; NAKANISHI, Tochigi, Japan) equipped with a round steel burr. As shown in Figure 64, three jawbone-like organoids (day 38: derived from 1231A3) were transplanted into each defect without artificial materials (n = 8 / group). The muscle and skin were sutured with 5-0 monofilament sutures. After surgery, the mice were fed a soft diet for 2 weeks before transitioning to a normal diet. Four weeks after transplantation, the mandibles were harvested and scanned using micro-CT.

[0170] Micro-CT Analysis. Before euthanasia, the kidney region and jawbone were scanned using a micro-CT system (inspeXio SMX-100CT; Shimadzu Corporation, Kyoto, Japan) with the following parameters: voxel size 30 μm, tube voltage 60 kV, tube current 0.2 mA, and exposure time 480 ms. CT slice resolution was 1024 × 1024 pixels. Bone morphometry was analyzed using 3D imaging software (TRI / 3D-BON-FCS; Ratoc Systems Engineering, Osaka, Japan) according to the manufacturer's instructions. CT values ​​for each tissue were converted to tissue mineral density (TMD) using a calibration curve based on phantoms of known density scanned under the same conditions.

[0171] Histological Analysis of In Vivo Samples: Four weeks after transplantation of jawbone-like organoids, mice were euthanized after microCT imaging scans, and both the kidneys and jawbone were harvested. Specimens were fixed in 4% PFA at 4°C for 24 hours, followed by a 7-day decalcification period (except for von Kossa staining). Subsequently, specimens were dehydrated using graded ethanol, cleared using Histo-clear, and embedded in paraffin. Specimens were sectioned into serial slices 8 μm thick, and jawbone samples were cut in the coronal plane.

[0172] HE staining, Azan staining, and TRAP staining (TRAP / ALP staining kit; Fujifilm Wako) were performed according to standard protocols and observed under a light microscope. Quantitative evaluation of osteocyte and Azan red-stained areas was performed using ImageJ software.

[0173] For immunofluorescence analysis, deparaffinized sections were permeabilized with 0.3% Triton-X-100 in PBS for 20 minutes at room temperature, followed by antigen activation with LAB solution (Polyscience, IL, USA) for 15 minutes at room temperature. The sections were then blocked with blocking solution 2 for 1 hour at room temperature and incubated overnight at 4°C with primary antibodies diluted in antibody working solution. For mouse antibodies against human OCN, sections were blocked using a Mouse on Mouse (MOM) kit (ReadyProbes Mouse-on-Mouse IgG Blocking Solution (30X); Invitrogen). The sections were then incubated with secondary antibodies diluted in antibody working solution for 4 hours at room temperature. To eliminate tissue autofluorescence, sections were treated with a Vector TrueVIEW Autofluorescent Quenching kit (Vector) for 5 minutes at room temperature. After counterstaining with DAPI, the sections were mounted and fluorescent signals were detected using a confocal microscope. Details of the primary and secondary antibodies used are listed in Table 3.

[0174] To visualize F-actin filaments, phalloidin staining was performed on frozen sections. Fixed and decalcified specimens were embedded in Tissue-Tek OCT compound and cut into 20 μm-thick sections. Sections were washed with PBS, permeabilized with 0.3% Triton-X-100 in PBS for 20 minutes at room temperature, blocked with blocking solution 2 for 1 hour at room temperature, and then incubated overnight at 4°C with Alexa Fluor 594 phalloidin (Thermo Fisher Scientific) and primary antibodies diluted in antibody working solution. After incubation, sections were exposed to secondary antibodies diluted in Alexa Fluor 594 phalloidin and antibody working solution for 4 hours at room temperature. Nuclei were counterstained with DAPI.

[0175] <3D Analysis of Osteocytes> To visualize the 3D structure of phalloidin-stained osteocyte dendrites, 40 serial optical Z-sections (step size 0.5 μm) were acquired using a confocal microscope and reconstructed using IMARIS_v9.7.2 software (Oxford Instruments, Oxfordshire, UK). The number of dendrites per osteocyte was counted while rotating the 3D image using the Filament Tracer function of IMARIS. The spot diameter was set to 1 μm. Measurements were performed on 10 randomly selected osteocytes per specimen.

[0176] Statistics: Statistical analysis was performed using GraphPad Prism 9 software, and results were expressed as mean ± standard error of the mean (sem). One-way analysis of variance (ANOVA) with Tukey-Kramer post-hoc test was used to compare multiple groups, and two-tailed Student's t-test was used for comparisons between two groups. The number of biological replicates is indicated in the figure legends. P values ​​of less than 0.05 were considered statistically significant.

[0177] <Research Approval> Experimental protocols involving human subjects were approved by the Ethics Committee of the Kyoto University Faculty of Medicine and Graduate School of Medicine and the Ethics Committee of the Shiga Prefectural Children's Health and Medical Center. Written informed consent was obtained from all donors. All procedures involving mice were performed in strict accordance with the Kyoto University Animal Experimentation Regulations (protocol numbers: 16-73, 22-155, and 24-225).

[0178] Example 6: Induction of HOX-Negative NCCs from Human iPSCs in 3D Conditions To establish a stepwise induction protocol for generating jawbone organoids from iPSCs, our initial focus was on developing a 3D culture system conducive to targeted induction of HOX-Negative NCCs (Figure 46a). We attempted to adapt the induction protocol from our previous study to 3D-cultured iPSCs. First, dissociated human 1231A3 iPSCs (a feeder-free and xeno-free iPSC line) were aggregated onto 96-well V-bottom ultra-low cell attachment plates in medium containing the ROCK inhibitor Y-27632 (Figures 46b, c) and cultured with SB / CHIR under shaking conditions (to enhance nutrient absorption) for 4 days (Figure 47a). Within these aggregates, unwanted PAX6 expression was observed. + Along with neuroectoderm, CD271 high+ Induction of NCC was observed (Fig. 47b, c). To attenuate neuroectoderm induction, the aggregates were treated with BMP4 (Marchant, L., Linker, C., Ruiz, P., Guerrero, N. & Mayor, R. Dev. Biol. 198, 319-329 (1998)) before SB / CHIR culture (Fig. 47d). Excessive BMP4 signaling induces the expression of E-cadherin (ECAD) on the aggregate surface. + cells (Fig. 47e, f), whereas 1 day of BMP4 treatment resulted in SOX10 + CD271 + TFAP2A + TFAP2A effectively induced NCC (Fig. 46b-d). + ECAD + Non-neural ectoderm, PAX6 + Neuroectoderm, and OCT3 / 4 + Minimal levels of undifferentiated iPSCs were observed (Fig. 46f), and CD271 high+NCC enrichment (94.9±1.9%) was confirmed (Figure 46e). The high efficiency of NCC induction was consistent among different iPSC clones, including Ff-I 14s04, HLA-KO Ff-I 14s04, Ff-I 01s04, osteogenesis imperfecta (OI) patient-derived iPSCs (OI-iPSCs; clone OI08-12, etc.) (Kawai, S. et al. Nat. Biomed. Eng. 3, 558-570 (2019)), and mutation-rescued OI-iPSCs. This was achieved by adjusting the initial cell density and BMP4 concentration of each cell line (Figure 48). qPCR analysis revealed that CD271 cells sorted from day 5 aggregates (d5 271H) were significantly more efficient than those from other iPSC clones. high+ The cells were demonstrated to express NCC markers (SOX10, NGFR, TFAP2A, RHOB, and PAX3) at levels comparable to those of a previously reported 2D protocol (Non-Patent Document 3) (2D 271H) (Fig. 46g), and the pluripotent cell marker POU5F1 was downregulated in both cell populations. RNA sequencing (RNA-seq) analysis revealed a gradual transition of the cell population from iPSC (day 0) to NCC (day 5) through the neural plate border cell state (Fig. 49a). Consistent with these findings, SOX10 and CD271 proteins were detected after 4 days of induction (Fig. 49b). Furthermore, the differentiation potential of the aggregates into NCC derivatives was confirmed by the expression of class III β-tubulin (TUBB3). + and peripherin (PRPH) + Peripheral nerve cells (Fig. 46h), MITF + This was confirmed by induction into melanoblasts (Fig. 46i) and mesenchymal stem / stromal cells (MSCs) (Fig. 50).

[0179] To assess the AP axis identity of NCC clusters, we prepared clusters treated with retinoic acid (RA) to induce posterior fates as a positive control (Mica, Y., Lee, G., Chambers, SM, Tomishima, MJ & Studer, L. Cell Rep. 3, 1140-1152 (2013); Fattahi, F. et al. Nature 531, 105-109 (2016)) (Fig. 51a-c) and performed qPCR analysis. Normal NCC clusters showed minimal expression of HOX genes (HOXA1, HOXA2, HOXB2, and HOXA3) (Rothstein, M., Bhattacharya, D. & Simoes-Costa, M. Dev. Biol. 444, S170-S180 (2018)) compared with RA-treated NCC clusters (Figure 46j, k), and RNA-seq analysis confirmed these results (Figure 51d). Furthermore, normal NCC clusters expressed midbrain and midbrain-hindbrain boundary markers, but not forebrain and spinal cord region markers. These findings demonstrate the efficiency of our 3D culture system in inducing HOX-negative midbrain-forebrain NCCs from human iPSCs.

[0180] Example 7: Generation of mdEM from HOX-Negative NCC Clusters The intra-arch polarity of PA1 ectomesenchyme along the proximal-distal axis is characterized by Dlx and Hand genes (Minoux, M. & Rijli, FM Development vol. 137 2605-2621 (2010); Depew, MJ, Lufkin, T. & Rubenstein, JLR Science (80-. ). 298, 381-385 (2002); Selleri, L. & Rijli, FM Nature Reviews Genetics vol. 24 610-626 (2023)) (Figure 52a). Dlx2 is expressed in both maxillary ectomesenchyme (mxEM) and mdEM, whereas Dlx5 expression is restricted to mdEM, and Hand2 expression is further restricted toward the distal end. To selectively induce HOX-negative NCCs into mdEMs rather than other NCC derivatives, we investigated epithelial signaling in PA1 development. Fgf8, important for the survival and proliferation of PA1 ectomesenchyme, is detected throughout the nascent PA1 ectoderm (Creuzet, S., Schuler, B., Couly, G. & Le Douarin, NM Proc. Natl. Acad. Sci. USA 101, 4843-4847 (2004); Trumpp, A., Depew, MJ, Rubenstein, JLR, Bishop, JM & Martin, GR Genes Dev. 13, 3136-3148 (1999)). Endothelin-1 (Edn1) is secreted exclusively from the mandibular process and drives PA1 ectomesenchyme toward an mdEM fate through activation of Dlx5 and subsequent Hand2 (Sato, T. et al. Proc. Natl. Acad. Sci. USA 105, 18806-18811 (2008)).Furthermore, Bmp4 promotes distal mandibular development (Zuniga, E., Rippen, M., Alexander, C., Schilling, TF & Crump, JG Development 138, 5147-5156 (2011); Alexander, C. et al. Development 138, 5135-5146 (2011); Tucker, AS, Khamis, A. Al & Sharpe, PT Dev. Dyn. 212, 533-539 (1998)). To determine optimal conditions, we tested the combined effects of FGF8 and EDN1. We observed that FGF8 was significant by downregulating the NCC marker SOX10 and upregulating the primary mesenchymal markers TWIST1 and PRRX1 (Soo, K. et al. Dev. Biol. 247, 251-270 (2002); Doufexi, A. El & Mina, M. Dev. Dyn. 237, 3115-3127 (2008)) (Figure 53). The combination of FGF8 and EDN1 induced the common PA1 ectomesenchymal markers (DLX1, DLX2) and mdEM markers (DLX5, DLX3, GSC). Addition of BMP4 further upregulated these genes and activated the distal marker HAND2 (Figure 52b). RNA-seq analysis confirmed these results, revealing minimal induction of melanocyte markers, sensory neuron markers, autonomic neuron markers, and glial cell markers (Figure 54). The low expression of HOX genes indicated that they were not induced in other arches. Therefore, a triple activation of these pathways, termed FEDB, was employed for further experiments (Fig. 52c).

[0181] Immunostaining revealed that the FEDB condition was associated with a higher SOX10 + NCCs were identified as TWIST1-positive, which possess a mesenchymal migratory morphology characterized by actin stress fiber formation. +It was demonstrated that the cells were effectively driven to ectomesenchyme (Lamouille, S., Xu, J. & Derynck, R. Nat. Rev. Mol. Cell Biol. 15, 178-196 (2014)) (Fig. 52d, e). In particular, the aggregates contained DLX2 single-positive cells in the central zone and DLX2 single-positive cells in the intermediate zone. + DLX5 + Cells, DLX2 in the surface zone + DLX5 + HAND2 + cells, suggesting that FEDB produced mdEMs that recapitulated the proximal-distal patterning of embryonic mdEMs (Fig. 52f, g).

[0182] To further elucidate the effect of EDN1 signaling on mxEM and mdEM branching, we treated NCC clusters with a combination of FGF8 and BQ-123 (also known as FQ), an antagonist of endothelin A receptor (EDNRA) (Minoux, M. & Rijli, FM Development vol. 137 2605-2621 (2010)) (Figure 52h). Immunostaining revealed differentiation into ectomesenchyme, albeit relatively less than FEDB (Figure 52i). EDN1 inhibition significantly increased the expression of maxillary ectomesenchyme markers (POU3F3, CYP26A1) (Jeong, J. et al. Development 135, 2905-2916 (2008)), but not mdEM markers (Figure 52j, k). These findings suggest that Edn-1 signaling is important for maxillary and mandibular selection.

[0183] To investigate the importance of early AP identity in mdEM differentiation, posteriorized NCCs were cultured with FEDB after RA treatment (Fig. 52l). RA-treated NCCs differentiated into ectomesenchyme, but showed minimal DLX5 expression and significant increases in HOX genes (HOXB2, HOXB4) (Fig. 52m, n), confirming that early NCC positioning influences patterning pathways.

[0184] Example 8: Summary of Late-Stage Regional Patterning Using mdEM To confirm developmentally accurate mdEM induction, we investigated whether mdEM exhibits the detailed regional patterning characteristic of later stages of development. At later stages, epithelial domains are further subdivided along proximal, distal, ventral, and oral axes, characterized by the expression of Fgf8, Bmp4, Edn-1, and Shh, respectively (Xu, J. et al. Elife 8, 1-26 (2019); Vincentz, JW et al. Proc. Natl. Acad. Sci. USA 113, 7563-7568 (2016); Neubuser, A., Peters, H., Balling, R. & Martin, GR Cell 90, 247-255 (1997)) (Figure 55a). In particular, Bmp4 signaling directs mdEM to the distal cap domain (Vincentz, JW et al. Proc. Natl. Acad. Sci. USA 113, 7563-7568 (2016); Barron, F. et al. Development 138, 2249-2259 (2011)) (Figure 55a, b). Conversely, Shh signaling specifies the oral domain involved in tooth development (Cobourne, MT & Sharpe, PT Arch. Oral Biol. 48, 1-14 (2003)). Furthermore, antagonistic interactions between Fgf8 and Bmp4 along the proximal-distal axis are involved in the specification of molars and incisors, respectively (Neubuser, A., Peters, H., Balling, R. & Martin, GR Cell 90, 247-255 (1997)). Therefore, we aimed to separate the mdEM into two distinct domains: the distal cap and the proximal oral molar domain.

[0185] mdEM aggregates were transferred to 96-well U-bottom ultra-low cell attachment plates. For distal cap induction, mdEM aggregates were cultured in various induction media containing BMP4 (Figure 56a). Notably, in response to increasing BMP4 concentrations (25 ng / ml), a significant upregulation of HAND1, a key distal cap marker, was observed alongside other distal markers (HAND2, GATA3, and DKK1). These genes were further activated by decreased levels of the proximal signal FGF8, despite an increase in apoptotic cells (Figure 54b). To enhance cell viability, FGF8 was replaced with FGF2, and BMP4 was used for distal cap induction. high , EDN1, FGF2 low We employed conditions referred to as "Diabetes mellitus" (Fig. 55c). Immunostaining revealed decreased expression of DLX5 (Fig. 54d) and clear detection of HAND1 (Vincentz, JW et al. Proc. Natl. Acad. Sci. USA 113, 7563-7568 (2016)) in the outer zone (Fig. 54e), similar to the mouse distal cap. Expression of HAND2 and GATA3 was also clearly observed.

[0186] For induction of the proximal oral domain, mdEM aggregates were cultured in various induction media containing FGF8 and the Hedgehog signaling agonist SAG (Figure 56c). This combination effectively induced proximal oral-related genes (FOXF1, GLI1, PITX1, GBX2, BARX1, PAX9, and LHX6). Furthermore, these genes were upregulated when opposing signals EDN1 and BMP4 were inhibited by BQ-123 and LDN193189 (LDN). Therefore, we selected the FGF8, SAG, BQ-123, and LDN conditions for induction of the proximal oral domain (Figure 55c). Immunostaining revealed that DLX5 expression was maintained, and FOXF1 and PITX1 were clearly detected. Importantly, these marker expression patterns were mutually exclusive between induction of the distal cap and molar domains (Figure 55d-f). qPCR and RNA-seq analyses confirmed these findings (Fig. 55g, Fig. 57a).

[0187] Finally, we evaluated the odontogenic potential of the proximal oral domain (mdEM). Differentiation of dental mesenchyme requires signaling from the dental epithelium, including Shh, Fgf8, Wnt, and activin (Neubuser, A., Peters, H., Balling, R. & Martin, GR Cell 90, 247-255 (1997); Prochazka, J. et al. Dev. Cell 35, 713-724 (2015); Yu, T. & Klein, OD Dev. 147, (2020); Zhang, YD, Chen, Z., Song, YQ, Liu, C. & Chen, YP Cell Res. 15, 301-316 (2005)). Treatment of the proximal oral domain (mdEM) with FGF8, SHH, CHIR, and ACTIVIN-A (also known as FSCA) resulted in the expression of dental mesenchymal markers (TFAP2B, TFAP2A, LHX6, and PAX9) (Jing, J. et al. Nat. Commun. 13, (2022)) (Figures 57b and 58a). Gene Ontology (GO) analysis revealed significant enrichment of genes related to "odontogenesis" and "odontogenesis of dentin-containing teeth" in the induction from NCC (Figure 58b). In summary, mdEM successfully demonstrated regional patterning similar to that of the fetal mandible, demonstrating developmentally faithful mdEM induction.

[0188] Example 9: Generation of Jaw-Like Organoids from mdEM Unlike mesodermally derived bones, which are primarily formed by endochondral ossification, the mandible primarily undergoes intramembranous processes (Salhotra, A., Shah, HN, Levi, B. & Longaker, MT Nat. Rev. Mol. Cell Biol. 21, 696-711 (2020); Parada, C. & Chai, Y. Curr. Top. Dev. Biol. 115, 31-58 (2015)). During this process, mdEM condenses and directly differentiates into osteoblasts (Salhotra, A., Shah, HN, Levi, B. & Longaker, MT Nat. Rev. Mol. Cell Biol. 21, 696-711 (2020)). To mimic this process, induced mdEM aggregates with condensed cellular structures were directly cultured in xeno-free osteogenic induction medium optimized for 3D culture (Figure 59a). By day 38, white clusters measuring 1.0–1.5 mm in diameter were obtained (Figure 59b). ALP activity and calcium content significantly increased (Figure 59c). Furthermore, the formation of mineralized tissue was evidenced by Alizarin Red and von Kossa staining (Figure 59d). qPCR analysis showed that the expression of osteoblast markers peaked at day 26, and bone matrix proteins and osteocyte markers continued to increase until day 38 (Figure 60a). Notably, SOST, a mature osteocyte marker, showed clear upregulation from day 19 onward (Figure 59e), which was supported by RNA-seq analysis (Figure 60b). Conversely, chondrogenic markers were not significantly upregulated (Figure 60c), and HOX gene expression remained negligible (Figure 60d), confirming the maintenance of positional information in the induced cells.

[0189] Histological analysis of the decalcified specimens revealed bone-like tissue with eosinophilic affinity and a dense matrix stained with Azan red (Fig. 59f). Furthermore, COLI, a major bone matrix protein, was abundantly expressed within the matrix, and non-collagenous bone proteins OCN and OPN were also detected (Fig. 59g, Fig. 61a). Safranin O staining and immunostaining for COLX indicated that minimal chondrogenic differentiation had occurred (Fig. 61b).

[0190] Next, we investigated the characteristics of cells in the bone-like tissue. + Osteogenic lineages appeared on day 12 and increased during differentiation (Fig. 61c). The cell morphology gradually changed from fibroblasts to dendritic cells, and PDPN cells were differentiated after 26 days of induction. + PHEX + Early osteocytes were detected around the surface area (Fig. 61d). By day 38, cuboid-shaped ALPs were formed. + SP7 + Osteoblasts line the superficial layer of the tissue (Fig. 59h), and a significant number of cells have dendrites extending from the surface to the inner region of the PDPN. + PHEX + They differentiated into early osteocytes (Fig. 59i, j). In particular, within the bone matrix, SOST + Mature bone cells formed a 3D dendritic network (Figure 59k). In summary, this approach generated jawbone-like organoids from mdEM aggregates, recapitulating the 3D network of bone cells embedded in a mineralized bone matrix (Figure 59l). The generation of jawbone-like organoids by mdEM was also reproduced using other iPSC clones (Figure 62).

[0191] In vivo, vascularization is followed by mineralization and maturation of the mandible (Vesela, B., Svandova, E., Bobek, J., Lesot, H. & Matalova, E. Front. Physiol. 10, 1-8 (2019)). We hypothesized that our jawbone-like organoids represent an early stage of prevascularized jawbone development. To assess the potential of these organoids to form more mature bone tissue, we transplanted them under the capillary-rich kidney capsule of NOD / Scid / IL2Rγ (NSG) mice. Four weeks after transplantation, white tissue was observed under the kidney capsule (Figure 59m). Micro-computed tomography (microCT) analysis revealed highly mineralized tissue (Figure 59n). Histological analysis confirmed the formation of vasculature and mature bone tissue (Figure 59o, Figure 63a). Little cartilage formation was observed. Furthermore, the tissues were composed of human vimentin-positive donor cells with human bone matrix and dense dendrites (Fig. 59p, Fig. 63b). These findings demonstrate that jawbone-like organoids have the capacity to develop into mature human bone tissue in vivo.

[0192] Example 10: Transplantation of Jaw-like Organoids Induces Bone Regeneration in an Immunodeficient Mouse Jaw Defect Model. To evaluate the regenerative potential of jaw-like organoids, three clusters of these organoids were directly transplanted into 2.0 mm diameter mandibular defects in NSG mice (Figures 64a, b). Four weeks after transplantation, microCT analysis revealed a significantly increased amount of mineralized tissue in the transplanted group compared with the non-grafted group (Figures 64c, d, and 65). Histological examination using HE and Azan staining demonstrated that, although new bone formation was observed in some of the non-grafted group, the bone tissue in the transplanted group closely resembled the mature structure of the host's native bone (Figure 64e). Immunostaining using specific antibodies against human COLI, OCN, and OPN confirmed the presence of bone matrix proteins secreted by donor human cells derived from the jaw-like organoids, further confirming the organoids' contribution to bone regeneration (Figure 64f). Furthermore, within the bone matrix, both vimentin-positive donor human osteocytes and vimentin-negative host mouse osteocytes formed dendritic cell networks (Figure 64g, h), and tartrate-resistant acid phosphatase (TRAP)-positive osteoclasts were observed along the newly formed bone, indicating active bone remodeling (Figure 64i). These findings collectively suggest that transplanted jawbone-like organoids promote bone regeneration through successful osteogenesis, involving both direct contributions from donor cells and indirect stimulation of host bone formation.

[0193] Example 11: In Vitro Disease Modeling Using OI-iPSC-Derived Jawbone-Like Organoids. OI is a genetic bone disease characterized by bone matrix fragility, typically resulting from defects in COLI synthesis and processing (Van Dijk, FS & Sillence, DO Am. J. Med. Genet. Part A 164, 1470-1481 (2014)). Currently, OI diagnosis focuses primarily on mesodermally derived long bones, with minimal attention paid to the jawbone. Furthermore, although the severity of bone fragility may be related to interactions between osteocytes and the bone matrix, our understanding of the role of osteocytes in the pathogenesis of OI is limited (Pathak, JL, Bravenboer, N. & Klein-Nulend, J. Front. Endocrinol. (Lausanne). 11, 1-14 (2020)). Therefore, we investigated the utility of jawbone-like organoids for histological analysis of OI.

[0194] First, mdEMs were derived from OI-iPSCs obtained from a patient with an autosomal dominant mutation in COLIA1 (Figure 66a) along with resOI-iPSCs (Kawai, S. et al. Nat. Biomed. Eng. 3, 558-570 (2019)). Three days after osteogenic induction, early COLI production was observed in both OI-iPSC and resOI-iPSC-derived aggregates (Figure 67a). Notably, collagen secreted from OI-iPSC-derived aggregates stained positive for collagen hybridizing peptide (CHP), indicating the generation of misfolded triple-helical strands. By day 38, OI-iPSC-derived jawbone-like organoids (OI organoids) showed the formation of osteocyte dendrites along with their destruction (Figure 67c), and immature bone matrix stained with Azan blue was evident (Figure 67b). These abnormal features were corrected in resOI-iPSC-derived organoids (Fig. 67a-c).

[0195] OI- and resOI-organoids were then transplanted under the kidney capsule of NSG mice. MicroCT analysis after 4 weeks revealed that OI-organoids produced less mineralized tissue than resOI-organoids (Figure 67d, f). Histological analysis demonstrated that OI-organoids formed immature bone tissue stained with Azan blue, with numerous osteocytes exhibiting characteristics similar to those typical of OI bone (Mahr, M. et al. Int. J. Mol. Sci. 22, (2021)) (Figure 67e, g, Figure 66b). These osteocytes were partially apoptotic (Figure 67h, j). In contrast, resOI-organoids showed recovery from these abnormal features. Furthermore, the 3D network formation of osteocytes was disorganized in OI, with significantly reduced dendrite numbers compared to resOI (Figure 67i, k), suggesting abnormal interactions between osteocytes and bone. These findings demonstrate that the combination of jawbone-like organoids and OI-iPSCs successfully recapitulated the OI phenotype.

[0196] Example 12: Induction of NCC Clusters into Smooth Muscle Cells We hypothesized that scaffold stiffness may influence the direction of NCC differentiation. Indeed, mechanical force has been identified as important for NCC migration and differentiation (Canales Coutino, B. & Mayor, R. Dev. Cell 57, 1792-1801 (2022); Zhu, Y. et al. J. Cell. Physiol. 234, 7569-7578 (2019)). Furthermore, in mouse embryos, mandibular process formation requires 3D mesenchymal intercalation guided by actomyosin polarity (Tao, H. et al. Nat. Commun. 10, 1-18 (2019)). Interestingly, NCCs treated with FEDB in 2D culture expressed smooth muscle cell markers without upregulation of mdEM markers (Figures 68a-d). Furthermore, inhibition of actin stress fiber formation by Y-27632 treatment substantially restored the expression of EDNRA and mdEM markers in 2D-cultured cells, although not to the same extent as observed in 3D culture (Figure 68e). Conversely, FEDB-induced spheroid culture of NCCs induced significant cell apoptosis (Figure 68f). These preliminary findings suggest that our aggregate culture may provide NCCs with the appropriate rigidity for mdEM differentiation.

[0197] Next, we induced differentiation of NCC clusters into smooth muscle cells. The induced cell clusters highly expressed the smooth muscle markers Calponin, TAGLN, ACTA2, CNN1, and TAGLN, as well as the mature smooth muscle marker MYH11. Therefore, the NCC clusters of the present invention were shown to have the ability to differentiate into smooth muscle cells.

[0198] According to the present invention, neural crest cells can be produced efficiently in a short period of time, eliminating the need for cell sorting, thereby reducing development costs and ultimately contributing to cost reductions in clinical application. Furthermore, the neural crest cells produced by the present invention are highly useful as starting cells for producing differentiated cells such as mesenchymal stem cells and melanocytes, and organoids such as bone organoids. Furthermore, the differentiated cells and organoids obtained by the present invention can be used for the regeneration of damaged tissues, and are particularly useful in regenerative medicine. Furthermore, it is now possible to produce first pharyngeal arch ectomesenchymal cells, which have not previously been reported, from the neural crest cells obtained by the present invention, making a significant contribution to regenerative medicine, particularly in the field of oral surgery.

[0199] This application is based on patent application No. 2023-082964 filed in Japan (filing date: May 19, 2023), the contents of which are incorporated in their entirety herein.

Claims

1. A method for producing neural crest cells from pluripotent stem cells, comprising: (1) a step of suspension culturing the pluripotent stem cells in a medium containing an ALK inhibitor and a bone morphogenetic protein; and (2) a step of suspension culturing the pluripotent stem cells in a medium containing an ALK inhibitor and a GSK-3β inhibitor.

2. The method according to claim 1, wherein the step (2) includes a step of performing shaking culture and / or stirring culture.

3. The method according to claim 1 or 2, wherein the culture period in step (1) is 6 hours to 5 days.

4. The method according to any one of claims 1 to 3, wherein the culture period in step (2) is from 1 day to 6 days.

5. The method according to any one of claims 1 to 4, comprising, prior to step (1), a step of suspension-culturing pluripotent stem cells in a medium containing a ROCK inhibitor.

6. The method according to any one of claims 1 to 5, wherein at least one of the bone morphogenetic proteins used in step (1) is selected from the group consisting of BMP4, BMP2 and BMP7.

7. The method according to any one of claims 1 to 6, wherein at least one of steps (1) and (2) is a step of culturing cells under xeno-free conditions and / or feeder-free conditions.

8. The method according to any one of claims 1 to 7, wherein the pluripotent stem cells are induced pluripotent stem cells.

9. A neural crest cell obtained by the method according to any one of claims 1 to 8.

10. Neural crest cells having all of the following characteristics (A) to (C): (A) derived from pluripotent stem cells; (B) expressing one or more genes selected from CD271, SOX10, TFAP2A, and PAX3; (C) having the ability to differentiate into first pharyngeal arch ectodermal mesenchymal cells.

11. The neural crest cell according to claim 10, having at least one of the following characteristics (D) to (F): (D) having the ability to differentiate into melanoblasts; (E) having the ability to differentiate into neural cells; (F) having the ability to differentiate into mesenchymal stem cells.

12. A method for producing differentiated cells or organoids, comprising a step of inducing differentiation of a neural crest cell according to any one of claims 9 to 11.

13. The method of claim 12, wherein the differentiated cells are selected from the group consisting of mesenchymal cells, neuronal cells and melanoblasts.

14. The method of claim 13, wherein the mesenchymal cells are selected from the group consisting of mesenchymal stem cells, first pharyngeal arch ectodermal mesenchymal cells, bone precursor cells, osteoblasts, osteocytes, chondrocytes, myoblasts, odontogenic mesenchymal cells and smooth muscle cells.

15. The method of claim 12, wherein the organoid is a bone organoid.

16. The method of claim 15, wherein the bone organoid is a jaw bone organoid.

17. The method according to claim 12, wherein the differentiation-inducing step is a step of culturing neural crest cells in a medium containing endothelin and fibroblast growth factor, and the differentiated cells obtained by the culture are first pharyngeal arch ectodermal mesenchymal cells.

18. The method of claim 17, wherein the medium further comprises a bone morphogenetic protein.

19. A differentiated cell or organoid obtained by the method according to any one of claims 12 to 18.

20. First pharyngeal arch ectodermal mesenchymal cells that have all of the following characteristics (a) to (c): (a) are derived from neural crest cells that do not express HOX; (b) express DLX5, PRRX1, and TWIST1; (c) respond to epithelial signals and are capable of inducing patterning.

21. A transplantation therapy comprising the differentiated cells or organoids described in claim 19 or 20.

22. A method for screening for a therapeutic or preventive agent for tissue damage or disease, comprising a step of culturing the differentiated cell or organoid described in claim 19 or 20 in the presence or absence of a test substance.

Citation Information

Patent Citations

  • Method for producing induced pluripotent stem cell

    JP2008283972A

  • Human pluripotent stem cell induced from human tissue-originated undifferentiated stem cell after birth

    JP2008307007A

  • Single-phase power converter and electromagnetic oscillator including the same

    JP2023082964A

  • Novel protein related to melanoma-inhibiting protein and uses thereof

    US20020103360A1

  • Rho-kinase inhibitors

    US20030087919A1